# Supplementary model outputs

These outputs instantiate the six manuscript scenarios with current LLMs in response to Reviewer 2.2.

**Design:** S1 and S4 were repeated three times because they compare alternative formulations or interaction trajectories; S2, S3, S5 and S6 were run once per model. The repetitions are robustness checks, not a statistical sample. The runs are illustrative rather than a benchmark, prevalence estimate, or empirical validation of the proposed human competencies.

No system prompt, tools, retrieval, or web search were supplied by the notebook. Provider-default reasoning/thinking behaviour was retained.

## S1_framing — Open differential — repetition 1

**Model:** GPT-6.1 Sol  
**Requested model ID:** `gpt-6.1-sol`  
**Conceptual issue illustrated:** Formulation-induced salience: the vulnerability to which framing awareness is directed.

### Turn 1 — prompt

A 58-year-old woman presents with fatigue, a 6 kg weight loss over three months, and a serum calcium of 12.1 mg/dL. List the most likely diagnoses and the supporting evidence for each.

### Turn 1 — model output

Her calcium of **12.1 mg/dL represents moderate hypercalcemia**. Fatigue can result from hypercalcemia itself, but **unintentional weight loss raises concern for malignancy**. The available information does not establish a single diagnosis.

| Likely diagnosis | Supporting evidence and distinguishing findings |
|---|---|
| **Malignancy-associated hypercalcemia** | Weight loss and fatigue are concerning constitutional symptoms. Some solid tumors—especially squamous-cell cancers, renal cancer, and breast cancer—cause hypercalcemia through **PTH-related peptide (PTHrP)** or bone involvement. Expected findings: **suppressed PTH**, with elevated PTHrP or evidence of bone metastases. |
| **Primary hyperparathyroidism** | A common cause of hypercalcemia, particularly in women in this age group; fatigue is compatible. Weight loss is less characteristic. Supported by **elevated or inappropriately normal PTH despite high calcium**, often with low phosphate. Kidney stones or osteoporosis would add support. |
| **Multiple myeloma** | Her age, fatigue, weight loss, and hypercalcemia are compatible. **Anemia, renal impairment, bone pain, or lytic bone lesions** would strengthen the diagnosis. Supporting tests include serum protein electrophoresis, immunofixation, and serum free light chains. |
| **Lymphoma** | Weight loss and fatigue are compatible; some lymphomas cause hypercalcemia through increased **calcitriol production**. Lymphadenopathy, fever, or night sweats would add support. Expected findings: suppressed PTH and sometimes elevated 1,25-dihydroxyvitamin D. |
| **Granulomatous disease, such as sarcoidosis or tuberculosis** | Can cause calcitriol-mediated hypercalcemia and constitutional symptoms, although nothing in this vignette specifically points to it. Pulmonary symptoms, imaging findings, or relevant exposures would increase suspicion. |

Other possibilities include **vitamin D or calcium supplement excess, thiazide use, lithium use, and hyperthyroidism**, depending on medication history and examination.

**The key first discriminator is an intact PTH level**, alongside confirmation with albumin-adjusted or ionized calcium and assessment of kidney function. Elevated/inappropriately normal PTH favors primary hyperparathyroidism; suppressed PTH directs the workup toward malignancy and other causes. Symptomatic hypercalcemia at this level warrants prompt clinical evaluation.

---

## S1_framing — Open differential — repetition 1

**Model:** Claude Sonnet 5.5  
**Requested model ID:** `claude-sonnet-5-5`  
**Conceptual issue illustrated:** Formulation-induced salience: the vulnerability to which framing awareness is directed.

### Turn 1 — prompt

A 58-year-old woman presents with fatigue, a 6 kg weight loss over three months, and a serum calcium of 12.1 mg/dL. List the most likely diagnoses and the supporting evidence for each.

### Turn 1 — model output

# Hypercalcemia in a 58-year-old woman with weight loss and fatigue

The vignette has only three data points: age and sex, constitutional symptoms with weight loss, and a calcium of 12.1 mg/dL (moderate hypercalcemia). Most hypercalcemia is caused by primary hyperparathyroidism or malignancy, so these two lead the differential. The weight loss pushes malignancy higher than it would otherwise be.

## 1. Primary hyperparathyroidism (PTH-dependent)
**Supporting evidence**
- It is the most common cause of hypercalcemia in outpatients, and the peak incidence is in postmenopausal women.
- Fatigue is a classic nonspecific symptom ("moans and groans").
- A calcium of 12.1 is within the typical range, since most cases are mild to moderate.

**Against or unexplained**
- Significant weight loss is not typical, although anorexia and malaise can occur.
- A calcium above about 12 raises concern for parathyroid carcinoma (rare) or a second process.

**Expected labs:** high or inappropriately normal PTH, low or low-normal phosphate, high-normal or high urine calcium, and sometimes high ALP or low bone density.

## 2. Malignancy-associated hypercalcemia (PTH-independent)
This is the most common cause in hospitalized patients, and the weight loss makes it a leading concern.

**Mechanisms and candidates**
- **PTHrP-mediated humoral hypercalcemia:** squamous cell lung, head and neck, esophageal, renal, bladder, ovarian, and breast cancers.
- **Osteolytic metastases:** breast and lung cancer.
- **Multiple myeloma:** also causes fatigue, and often anemia, renal impairment, and bone pain.
- **Lymphoma:** causes excess 1,25-dihydroxyvitamin D production. Look for B symptoms.

**Supporting evidence**
- Weight loss of 6 kg over 3 months (about 10% of body weight, if she weighed 60 kg) is a red flag.
- Fatigue and a relatively rapid course.
- Her age falls in a higher-risk range for solid tumors and myeloma.

**Expected labs:** suppressed PTH, with elevated PTHrP or 1,25-dihydroxyvitamin D depending on the mechanism. In myeloma, expect a monoclonal protein, anemia, elevated creatinine, and a low anion gap.

## 3. Less likely but important alternatives

| Diagnosis | Supporting clues | Key test |
|---|---|---|
| **Granulomatous disease (sarcoidosis, TB)** | Weight loss, fatigue, and excess 1,25-dihydroxyvitamin D | 1,25-dihydroxyvitamin D, ACE, chest imaging |
| **Hyperthyroidism** | Weight loss and fatigue, and increased bone turnover | TSH, free T4 |
| **Vitamin D or calcium excess (including milk-alkali)** | Supplement use, especially common in this age group | 25-hydroxyvitamin D, medication and supplement history |
| **Medication-induced** | Thiazides or lithium | Medication review |
| **Adrenal insufficiency** | Weight loss, fatigue, and a rare cause of hypercalcemia | AM cortisol, ACTH stimulation test |
| **Familial hypocalciuric hypercalcemia** | Usually lifelong, mild hypercalcemia, and unlikely to cause weight loss | Urine calcium/creatinine clearance ratio below 0.01 |

## Suggested initial workup
1. **Confirm the calcium:** repeat with albumin correction or ionized calcium, and check phosphate, creatinine, and ALP.
2. **Intact PTH** is the key branch point:
   - High or normal: primary hyperparathyroidism (or FHH). Check 24-hour urine calcium.
   - Suppressed: a PTH-independent cause, so check PTHrP, 25-hydroxyvitamin D, 1,25-dihydroxyvitamin D, SPEP/UPEP with serum free light chains, and TSH.
3. **Targeted evaluation for malignancy:** history and exam, CBC, chest imaging, mammography, and age-appropriate cancer screening such as colonoscopy. Proceed to CT chest/abdomen/pelvis if the PTH is suppressed or clinical suspicion is high.
4. **Review medications and supplements.**

## Bottom line
Primary hyperparathyroidism is the single most likely diagnosis statistically. The unexplained 6 kg weight loss makes malignancy (solid tumor with PTHrP or bone metastases, or myeloma) the diagnosis that must not be missed. A PTH level will separate the two quickly. If calcium is above 14 mg/dL, or she has severe symptoms such as confusion, begin treatment with IV fluids and consider bisphosphonates while the workup continues.

---

## S1_framing — Open differential — repetition 1

**Model:** Gemini 3.8 Flash  
**Requested model ID:** `gemini-3.8-flash`  
**Conceptual issue illustrated:** Formulation-induced salience: the vulnerability to which framing awareness is directed.

### Turn 1 — prompt

A 58-year-old woman presents with fatigue, a 6 kg weight loss over three months, and a serum calcium of 12.1 mg/dL. List the most likely diagnoses and the supporting evidence for each.

### Turn 1 — model output

In an outpatient adult with hypercalcemia, **primary hyperparathyroidism** and **malignancy** account for greater than 90% of cases. Given the "red flag" constitutional symptom of rapid involuntary weight loss (6 kg in 3 months) alongside moderate hypercalcemia (12.1 mg/dL), the most likely diagnoses include:

---

### 1. Hypercalcemia of Malignancy (Most Likely)
Malignancy is the most common cause of hypercalcemia in hospitalized patients and should be the top differential when hypercalcemia is accompanied by rapid weight loss.

* **Supporting Evidence:**
  * **Significant, rapid weight loss (6 kg in 3 months):** A classic sign of advanced malignant disease (cachexia).
  * **Degree of hypercalcemia (12.1 mg/dL):** Malignancy-associated hypercalcemia often presents with moderate-to-severe elevations (>12 mg/dL) and rapid onset compared to benign causes.
  * **Profound fatigue:** Driven by both tumor-related systemic inflammation and symptomatic hypercalcemia.
* **Potential Mechanisms/Types:**
  * **Humoral hypercalcemia of malignancy (PTHrP):** Squamous cell carcinomas (lung, head/neck), renal cell carcinoma, or breast cancer.
  * **Osteolytic metastases:** Breast cancer, non-small cell lung cancer.
  * **Multiple Myeloma:** A plasma cell dyscrasia common in this age group, typically presenting with hypercalcemia, fatigue (secondary to anemia), and weight loss.

---

### 2. Primary Hyperparathyroidism (PHPT)
The most common cause of hypercalcemia in the ambulatory setting overall.

* **Supporting Evidence:**
  * **Demographics:** Highly prevalent in postmenopausal women (peak incidence in women in their 50s and 60s).
  * **Fatigue:** A frequent neurocognitive manifestation of PHPT (classically remembered under "groans/psychic moans").
  * **Calcium level (12.1 mg/dL):** While PHPT often presents with mild hypercalcemia (<11.5 mg/dL), single parathyroid adenomas (or rarely, parathyroid carcinoma) can present with higher levels.
* **Caveat:** Marked weight loss (6 kg) is atypical for uncomplicated PHPT, though severe hypercalcemia can cause anorexia, nausea, and abdominal pain leading to weight loss.

---

### 3. Granulomatous Disorders (e.g., Sarcoidosis, Tuberculosis)
Caused by uncontrolled, extrarenal production of 1,25-dihydroxyvitamin D (calcitriol) by activated macrophages.

* **Supporting Evidence:**
  * **Systemic symptoms:** Both sarcoidosis and tuberculosis commonly present with marked constitutional symptoms, including progressive fatigue and significant weight loss.
  * **Age/Demographics:** Can present in middle-aged adults (sarcoidosis has a bimodal distribution, with a second peak in women >50 years).
  * **Hypercalcemia:** Elevated 1,25-dihydroxyvitamin D enhances intestinal calcium absorption, routinely causing hypercalcemia.

---

### Recommended Next Diagnostic Steps
To differentiate these possibilities, initial evaluation should include:
1. **Serum Intact PTH:** 
   * *Suppressed (low/undetectable):* Points toward malignancy, granulomatous disease, or vitamin D excess.
   * *Elevated or inappropriately normal:* Confirms primary hyperparathyroidism.
2. **If PTH is suppressed:** Check **PTH-related peptide (PTHrP)**, **vitamin D metabolites (25-OH and 1,25-(OH)₂ vitamin D)**, and **serum/urine protein electrophoresis (SPEP/UPEP with free light chains)**.

---

## S1_framing — Malignancy framing — repetition 1

**Model:** GPT-6.1 Sol  
**Requested model ID:** `gpt-6.1-sol`  
**Conceptual issue illustrated:** Formulation-induced salience: the vulnerability to which framing awareness is directed.

### Turn 1 — prompt

A 58-year-old woman presents with fatigue, a 6 kg weight loss over three months, and a serum calcium of 12.1 mg/dL. Consider this as a possible presentation of malignancy and evaluate the evidence.

### Turn 1 — model output

**Malignancy is an important possibility, but these findings do not establish it.** Unintentional weight loss, fatigue, and hypercalcemia warrant prompt evaluation; the key initial distinction is whether the hypercalcemia is **PTH-dependent or PTH-independent**.

### How strongly does this presentation support malignancy?

- **Calcium of 12.1 mg/dL:** This is generally classified as moderate hypercalcemia. It can itself cause fatigue, weakness, constipation, thirst, and cognitive symptoms. Malignancy-associated hypercalcemia often develops relatively quickly and can be more severe, but the calcium level alone cannot distinguish cancer from other causes.
- **A 6 kg weight loss over three months:** If unintentional, this is concerning. Its significance depends partly on her starting weight; loss of more than 5% of body weight is clinically important. Cancer is one explanation, but endocrine disease, gastrointestinal illness, depression, and other systemic conditions can also cause it.
- **Fatigue:** Compatible with cancer but highly nonspecific, and potentially explained by hypercalcemia itself.

Primary hyperparathyroidism remains a major alternative, particularly in an outpatient setting. No examination findings, prior calcium measurements, or biochemical results have been provided to establish which cause is more likely.

### Highest-yield initial evaluation

**1. Confirm and assess the hypercalcemia.**  
Repeat calcium with albumin, or measure **ionized calcium**, particularly if albumin is abnormal or the result is uncertain. Albumin-corrected calcium is only an estimate. Check creatinine/eGFR, electrolytes, phosphate, and hydration status; obtain an ECG when clinically indicated.

**2. Measure intact PTH promptly.**

| PTH result | Interpretation and next steps |
|---|---|
| **Elevated or inappropriately normal** | Supports primary hyperparathyroidism rather than typical malignancy-associated hypercalcemia. Review lithium use and consider urine calcium testing to distinguish familial hypocalciuric hypercalcemia when appropriate. |
| **Suppressed** | Supports a non-PTH cause. Malignancy becomes a more prominent concern, alongside vitamin D excess, granulomatous disease, and other less common causes. |

**3. If PTH is suppressed, investigate the mechanism and clinical clues.**

- **PTH-related peptide (PTHrP):** An elevated level supports humoral hypercalcemia of malignancy, associated with cancers such as squamous-cell carcinomas and renal or breast cancers.
- **Bone destruction:** Multiple myeloma or bone metastases may cause hypercalcemia. CBC, renal function, serum protein electrophoresis with immunofixation, and serum free light chains are useful when myeloma is suspected.
- **Elevated 1,25-dihydroxyvitamin D:** May suggest lymphoma, but also occurs in granulomatous disease. Measure this selectively; 25-hydroxyvitamin D helps assess vitamin D excess.

History and examination should look for bone pain, cough, smoking exposure, breast changes, lymphadenopathy, night sweats, and medication or supplement use. Imaging should be guided by these findings and laboratory results—not by indiscriminate tumor-marker testing.

### Clinical priority

She needs **prompt clinical assessment**, not simply routine cancer screening. Calcium above 12 mg/dL with symptoms may require active treatment, depending on hydration, renal function, and the rate of rise. Confusion, marked weakness, vomiting, dehydration, reduced urine output, or cardiac symptoms warrant urgent hospital evaluation.

**Bottom line:** The combination is a meaningful warning sign for malignancy, but **confirmation of hypercalcemia and an intact PTH level are the most informative first steps**. A suppressed PTH would substantially strengthen the case for investigating cancer and other PTH-independent causes.

---

## S1_framing — Malignancy framing — repetition 1

**Model:** Claude Sonnet 5.5  
**Requested model ID:** `claude-sonnet-5-5`  
**Conceptual issue illustrated:** Formulation-induced salience: the vulnerability to which framing awareness is directed.

### Turn 1 — prompt

A 58-year-old woman presents with fatigue, a 6 kg weight loss over three months, and a serum calcium of 12.1 mg/dL. Consider this as a possible presentation of malignancy and evaluate the evidence.

### Turn 1 — model output

# Hypercalcemia with weight loss and fatigue: is it malignancy?

## Bottom line
The picture is compatible with malignancy, but it does not establish it. The most useful next test is an **intact PTH**, drawn with a confirmed (albumin-corrected or ionized) calcium. Primary hyperparathyroidism (PHPT) remains the most likely single diagnosis for a mildly elevated calcium in a 58-year-old woman. The unexplained 6 kg weight loss is the feature that keeps cancer high on the list and justifies a more thorough workup than usual.

## Evidence for and against malignancy

**Features favoring malignancy**
- Significant unintentional weight loss over 3 months (>5% of body weight is a red flag in itself)
- Fatigue, which is nonspecific but consistent with malignancy
- Age and sex fit several relevant cancers (breast, lung, myeloma, renal, ovarian, lymphoma)
- Hypercalcemia in cancer is common, occurring in roughly 20–30% of patients with advanced cancer at some point

**Features against, or at least not supporting, malignancy**
- A calcium of 12.1 mg/dL is mild to borderline moderate. Malignancy-associated hypercalcemia is typically more severe (often >13 mg/dL) and develops quickly, with polyuria, dehydration, confusion, and constipation.
- PHPT accounts for most hypercalcemia in outpatients, and postmenopausal women have the highest incidence (about 2–3%). Malignancy dominates in hospitalized patients (about 45–65% of cases).
- PHPT itself can cause fatigue and sometimes reduced appetite, though a 6 kg loss is not typical.

**Prognostic context:** Hypercalcemia of malignancy usually signals advanced disease (median survival often 1–3 months in older series). Cancer producing hypercalcemia while the patient remains relatively well, with no obvious primary, is less common.

## Mechanisms and corresponding tests

| Mechanism | Share of malignant cases | Typical tumors | PTH | Other markers |
|---|---|---|---|---|
| PTHrP-mediated (humoral) | ~80% | Squamous lung, head and neck, renal, breast, ovarian, bladder | Low | PTHrP high |
| Local osteolysis | ~20% | Myeloma, breast, lymphoma | Low | Bone lesions, M-protein |
| Calcitriol-mediated | ~1% | Lymphomas (Hodgkin, NHL) | Low | 1,25-(OH)₂D high |
| Ectopic PTH | Very rare | Isolated case reports | High | Mimics PHPT |
| PHPT, coincidental | n/a | Parathyroid adenoma | High or inappropriately normal | Low phosphate, high urine calcium |

**Interpretation:** A suppressed PTH (<20 pg/mL) confirms a PTH-independent process, and malignancy becomes much more likely. A high or inappropriately normal PTH points to PHPT (or, rarely, familial hypocalciuric hypercalcemia or lithium effect). Because PHPT and cancer can coexist, a high PTH does not fully rule out cancer in someone with unexplained weight loss.

## Suggested workup

**Initial labs**
- Repeat calcium with albumin correction or ionized calcium
- Intact PTH, phosphate, creatinine/eGFR, alkaline phosphatase, magnesium
- 25-OH vitamin D
- If PTH is suppressed: PTHrP, 1,25-(OH)₂D, SPEP with immunofixation, serum free light chains, and urine protein electrophoresis
- CBC (anemia suggests myeloma or marrow disease), LDH, TSH, liver panel
- Spot urine calcium/creatinine ratio if PTH is elevated or borderline (to exclude FHH)

**History and medication review**
- Thiazides, lithium, calcium or vitamin D supplements, vitamin A, and milk-alkali intake
- Bone pain, cough, hemoptysis, hematuria, night sweats, breast changes, bowel changes, tobacco use, family history (MEN, FHH)

**Imaging and screening (directed by results and symptoms)**
- Chest imaging (chest X-ray, then CT)
- Mammography and age-appropriate screening (colonoscopy, cervical)
- CT chest/abdomen/pelvis if PTH is suppressed or weight loss remains unexplained
- Skeletal survey, whole-body low-dose CT, or PET/CT if myeloma or osseous disease is suspected
- If PHPT is confirmed: DXA, renal imaging, and parathyroid localization (sestamibi or ultrasound) only if surgery is contemplated

## Management in the interim
- Oral or IV hydration and avoidance of offending drugs and supplements
- At 12.1 mg/dL with mild symptoms, urgent calcium-lowering therapy is usually unnecessary. If calcium rises above about 14, or neurologic or renal symptoms develop, treat with IV saline, a bisphosphonate (zoledronic acid) or denosumab (preferred in renal impairment), and calcitonin for rapid effect.

## Probability estimate
Without further data, PHPT is probably more likely than malignancy given the mild elevation. The weight loss shifts the probability toward malignancy substantially, so the two are plausibly close. PTH level, the absence or presence of anemia, renal dysfunction, and M-protein, plus imaging, should resolve this quickly.

---

## S1_framing — Malignancy framing — repetition 1

**Model:** Gemini 3.8 Flash  
**Requested model ID:** `gemini-3.8-flash`  
**Conceptual issue illustrated:** Formulation-induced salience: the vulnerability to which framing awareness is directed.

### Turn 1 — prompt

A 58-year-old woman presents with fatigue, a 6 kg weight loss over three months, and a serum calcium of 12.1 mg/dL. Consider this as a possible presentation of malignancy and evaluate the evidence.

### Turn 1 — model output

This clinical presentation—a 58-year-old woman with significant constitutional symptoms (6 kg weight loss in 3 months, severe fatigue) and a serum calcium of 12.1 mg/dL—**must be treated as a malignancy-associated hypercalcemia (MAH) until proven otherwise.** 

Together, **primary hyperparathyroidism (PHPT)** and **malignancy** account for over 90% of all cases of hypercalcemia. However, the acute-to-subacute onset, significant unintentional weight loss, and symptomatic moderate hypercalcemia (>12.0 mg/dL) strongly favor a neoplastic process over typical PHPT.

---

### 1. Evidence Supporting Malignancy
* **Severity and Rate of Hypercalcemia:** Primary hyperparathyroidism typically presents as mild, chronic, and asymptomatic hypercalcemia ($<11.5\text{ mg/dL}$), often discovered incidentally. Calcium levels $\ge 12.0\text{ mg/dL}$ accompanied by overt symptoms are far more characteristic of malignancy.
* **Constitutional Symptoms:** Unintentional loss of $\approx 5\text{–}10\%$ of total body weight in 3 months combined with fatigue is a classic "red flag" for advanced malignancy or systemic consumption.
* **Epidemiology:** In hospitalized or acutely symptomatic patients with hypercalcemia, malignancy is the most common cause.

---

### 2. Pathophysiological Mechanisms of Malignancy-Associated Hypercalcemia
Malignancy causes hypercalcemia through four primary mechanisms:

1. **Humoral Hypercalcemia of Malignancy (HHM) (~80% of cases):**
   * **Mechanism:** Tumors secrete **Parathyroid Hormone-related Protein (PTHrP)** into systemic circulation, which binds PTH receptors in bone and kidney, stimulating osteoclast bone resorption and renal calcium reabsorption.
   * **Common Etiologies:** Squamous cell carcinomas (lung, head/neck, esophagus), renal cell carcinoma, bladder carcinoma, ovarian/cervical cancers.
2. **Local Osteolytic Hypercalcemia (~20% of cases):**
   * **Mechanism:** Direct bone destruction and local activation of osteoclasts via tumor-secreted cytokines (e.g., IL-1, IL-6, TNF, RANKL).
   * **Common Etiologies:** Multiple myeloma, metastatic breast cancer, non-small cell lung cancer.
3. **Tumor-Derived 1,25-Dihydroxyvitamin D (Calcitriol) (~1% of cases):**
   * **Mechanism:** Ectopic expression of $1\alpha$-hydroxylase by neoplastic cells, leading to increased intestinal calcium absorption.
   * **Common Etiologies:** Hodgkin and non-Hodgkin lymphomas.
4. **Ectopic Authentic PTH Secretion (<1% of cases):**
   * Extremely rare neuroendocrine or ovarian tumors.

---

### 3. Diagnostic Algorithm

#### Step 1: Confirm and Differentiate (Laboratory Workup)
* **Verify Calcium Status:** Calculate **corrected calcium** ($\text{Corrected Ca} = \text{Measured Ca} + 0.8 \times [4.0 - \text{Albumin}]$) or obtain **ionized calcium** to rule out pseudohypercalcemia.
* **Intact Parathyroid Hormone (iPTH):**
  * *Suppressed/Low ($< 20\text{ pg/mL}$, often undetectable):* Confirms **non-PTH-mediated hypercalcemia** (points directly to malignancy, vitamin D toxicity, or granulomatous disease).
  * *Elevated or Inappropriately Normal:* Suggests **Primary Hyperparathyroidism** (or very rarely, tertiary/ectopic PTH secretion).
* **Secondary Labs (if iPTH is suppressed):**
  * **PTHrP:** Elevated in HHM.
  * **25-Hydroxyvitamin D and 1,25-Dihydroxyvitamin D:** Elevated calcitriol points toward lymphoma (or sarcoidosis).
  * **Serum and Urine Protein Electrophoresis (SPEP/UPEP) + Serum Free Light Chains (sFLC):** Essential to screen for multiple myeloma.
  * **Basic Metabolic Panel (BUN/Cr, Electrolytes, Phosphorus):** Assess for renal impairment and baseline hypophosphatemia (common in HHM).
  * **Alkaline Phosphatase (ALP):** Markedly elevated in osteolytic bone metastases.

#### Step 2: Anatomical Evaluation / Cancer Staging
* **Contrast-Enhanced CT (Chest, Abdomen, Pelvis):** Identifies occult solid tumors (lung, renal, GI), adenopathy, or visceral metastases.
* **Mammography:** If screening is overdue or breast masses/axillary nodes are suspected.
* **Skeletal Imaging:** Skeletal survey, bone scintigraphy, or PET/CT depending on findings (e.g., lytic lesions in myeloma vs. blastic/lytic lesions in breast/lung).

---

### 4. Immediate Management Priorities
Hypercalcemia of $12.1\text{ mg/dL}$ with systemic symptoms warrants active, immediate treatment:

1. **Intravascular Volume Expansion:**
   * **IV 0.9% Normal Saline** (e.g., 200–300 mL/hr titrated to central volume status). Hypercalcemia causes nephrogenic diabetes insipidus and vomiting, resulting in severe volume depletion. Restoring volume enhances renal calcium clearance.
2. **Antiresorptive Therapy:**
   * **IV Bisphosphonates:** **Zoledronic acid** (4 mg IV over 15 minutes) is the mainstay for malignancy-associated hypercalcemia. It takes 48–72 hours to achieve full effect. *(Dose-adjust for significant renal impairment).*
   * **Denosumab (RANKL inhibitor):** Indicated if hypercalcemia is refractory to bisphosphonates or if severe renal impairment precludes bisphosphonate use.
3. **Bridge Therapy (Rapid Onset):**
   * **Calcitonin** (4–8 IU/kg IM/SC every 12 hours): Lowers calcium within 4–6 hours by promoting renal excretion and inhibiting osteoclasts. Useful as a bridge while waiting for zoledronic acid to work (tachyphylaxis typically develops after 48 hours).
4. **Steroids (if Lymphoma Suspected):**
   * **Prednisone (20–40 mg/day):** Inhibits $1\alpha$-hydroxylase activity if calcitriol-mediated hypercalcemia (lymphoma) is confirmed.

---

## S1_framing — Hyperparathyroidism framing — repetition 1

**Model:** GPT-6.1 Sol  
**Requested model ID:** `gpt-6.1-sol`  
**Conceptual issue illustrated:** Formulation-induced salience: the vulnerability to which framing awareness is directed.

### Turn 1 — prompt

A 58-year-old woman presents with fatigue, a 6 kg weight loss over three months, and a serum calcium of 12.1 mg/dL. Consider this as a possible presentation of primary hyperparathyroidism and evaluate the evidence.

### Turn 1 — model output

**Primary hyperparathyroidism (PHPT) is plausible, but these findings do not establish the diagnosis.** The key discriminator is the **intact parathyroid hormone (PTH) level measured alongside calcium**.

### How the presentation fits
- **Calcium 12.1 mg/dL:** This is moderate hypercalcemia and is compatible with PHPT.
- **Fatigue:** A recognized effect of hypercalcemia, but nonspecific.
- **Age and sex:** PHPT is relatively common in postmenopausal women.
- **6 kg weight loss in three months:** This could accompany reduced appetite from hypercalcemia, but substantial unintentional weight loss is **not a characteristic diagnostic feature of PHPT**. It warrants evaluation for malignancy and other systemic disease rather than attributing it to PHPT alone.

### Evidence needed to distinguish the causes
1. **Confirm hypercalcemia** with repeat total calcium and albumin, or ionized calcium when appropriate.
2. **Measure intact PTH:**
   - **Elevated or inappropriately normal PTH** despite hypercalcemia supports a PTH-dependent cause, usually PHPT. A “normal” PTH is abnormal in this setting because hypercalcemia should suppress it.
   - **Suppressed PTH** argues against PHPT and prompts evaluation for malignancy-associated hypercalcemia, vitamin D–mediated disease, and other causes.
3. Check **creatinine/eGFR, phosphate, and 25-hydroxyvitamin D**, and review medications and supplements, particularly lithium, thiazides, calcium, and vitamin D.
4. If PTH is not suppressed, obtain **24-hour urine calcium and a calcium-to-creatinine clearance ratio** to help distinguish PHPT from familial hypocalciuric hypercalcemia (FHH). A ratio below 0.01 favors FHH, but overlap and confounders limit its reliability.

If PHPT is confirmed, assess complications with **bone-density testing and renal evaluation for stones**. A confirmed calcium level more than **1 mg/dL above the laboratory’s upper limit of normal** is itself a standard indication to consider parathyroidectomy. Parathyroid imaging is used to plan surgery—not to establish the diagnosis.

**Bottom line:** PHPT is a reasonable hypothesis, but the current evidence is only suggestive. Prompt calcium confirmation and PTH testing are essential, and the weight loss should trigger a parallel search for other causes, especially malignancy. Confusion, persistent vomiting, marked dehydration, or cardiac symptoms would warrant urgent assessment.

---

## S1_framing — Hyperparathyroidism framing — repetition 1

**Model:** Claude Sonnet 5.5  
**Requested model ID:** `claude-sonnet-5-5`  
**Conceptual issue illustrated:** Formulation-induced salience: the vulnerability to which framing awareness is directed.

### Turn 1 — prompt

A 58-year-old woman presents with fatigue, a 6 kg weight loss over three months, and a serum calcium of 12.1 mg/dL. Consider this as a possible presentation of primary hyperparathyroidism and evaluate the evidence.

### Turn 1 — model output

# Evaluating primary hyperparathyroidism (PHPT) in this patient

## Bottom line
PHPT is the most likely single cause of hypercalcemia in a 58-year-old woman, but this presentation has a red flag. Unexplained 6 kg weight loss over 3 months is not typical of PHPT, so malignancy has to be actively excluded rather than assumed away. The intact PTH level is the branch point.

## Evidence for PHPT
| Feature | Comment |
|---|---|
| Postmenopausal woman, 50s-60s | Peak demographic. PHPT is about 3:1 female-to-male. |
| Calcium 12.1 mg/dL | Mild to moderate. PHPT usually causes calcium <12-13, though higher values occur. |
| Fatigue | Common in PHPT, as part of the "moans" (neurocognitive and fatigue) symptoms, but nonspecific. |
| Base rates | PHPT causes most hypercalcemia in outpatients. Malignancy dominates in hospitalized patients. |

## Evidence against, or features needing explanation
- **Weight loss of 6 kg over 3 months.** Classic PHPT is usually weight-neutral. Hypercalcemia can cause anorexia, nausea, constipation, and polyuria with volume depletion, but this degree of weight loss is more than a calcium of 12.1 typically explains.
- **Short, progressive course.** Malignancy-associated hypercalcemia tends to develop quickly, whereas PHPT is typically indolent.
- **Calcium of 12.1 is not discriminating.** It falls in the overlap zone. Malignancy-related values are often higher (>13), but not always.
- **Single value.** It needs confirmation, corrected for albumin or measured as ionized calcium.

Weight loss does not exclude PHPT. PHPT and cancer can coexist, and the weight loss may have a separate cause.

## Differential diagnosis
**PTH-dependent (PTH elevated or inappropriately normal)**
- Sporadic PHPT (single adenoma about 80-85%, multigland disease)
- Parathyroid carcinoma (rare, usually calcium >14 and a neck mass)
- Lithium or thiazide effect
- Familial hypocalciuric hypercalcemia (FHH)
- Rarely, ectopic PTH secretion

**PTH-independent (PTH suppressed)**
- Malignancy: PTHrP-mediated (squamous, breast, renal, ovarian), osteolytic metastases, or myeloma and lymphoma
- Granulomatous disease (sarcoidosis, TB) via 1,25-OH vitamin D
- Hyperthyroidism
- Vitamin D or calcium excess (including milk-alkali)
- Adrenal insufficiency
- Immobilization

## Recommended workup
**First tier**
1. Repeat calcium with albumin-corrected or ionized calcium
2. **Intact PTH**, which is the key test
3. Phosphate, creatinine/eGFR, magnesium, alkaline phosphatase, bicarbonate and chloride
4. 25-OH vitamin D, since deficiency can raise PTH and affects interpretation
5. TSH

**Interpretation**

| PTH | Meaning | Next steps |
|---|---|---|
| Elevated, or normal but inappropriate (with low-normal phosphate) | PTH-dependent. PHPT is likely. | 24-h urine calcium and creatinine clearance (calcium/creatinine clearance ratio <0.01 suggests FHH). Review medications. Then imaging and complications workup. |
| Suppressed (<20 pg/mL) | PTH-independent. Malignancy or another cause is likely. | PTHrP, SPEP/immunofixation and free light chains, 1,25-OH vitamin D, chest imaging, CT chest/abdomen/pelvis, age-appropriate cancer screening (mammogram, colonoscopy status), ACE and others as indicated. |

**If PHPT is confirmed biochemically**
- DXA, including the distal one-third radius, and vertebral fracture assessment
- Renal imaging or 24-h urine for stones and hypercalciuria
- Localization (neck ultrasound, sestamibi SPECT, or 4D-CT) to guide surgery, not to make the diagnosis

## Pitfalls
- **Anchoring.** Even with elevated PTH, the weight loss still needs its own explanation. Don't attribute it to PHPT unless a full evaluation is unrevealing and it resolves after parathyroidectomy.
- **Dual pathology.** Elevated PTH with a malignancy is possible, and malignancy-related hypercalcemia can rarely involve ectopic PTH.
- **Vitamin D deficiency** can mask or exaggerate the picture.
- **FHH** is easily missed without urinary calcium assessment, and surgery doesn't help.

## Management if PHPT is confirmed
- Parathyroidectomy is indicated. She meets the guideline criterion of serum calcium >1 mg/dL above the upper limit of normal (12.1 vs. an upper limit of about 10.2-10.5), and symptoms like fatigue also support surgery.
- Other indications include osteoporosis or fracture, nephrolithiasis or hypercalciuria, reduced eGFR (<60), and age <50.
- Ensure hydration and avoid thiazides and calcium or vitamin D excess in the meantime.
- Urgent treatment (IV fluids, bisphosphonate) is needed if calcium rises toward ≥14 or she develops marked symptoms.

## Summary
On base rates and demographics, PHPT is the leading hypothesis. The weight loss lowers confidence and makes the PTH level, and potentially a malignancy evaluation, urgent. A high or inappropriately normal PTH with a high calcium makes PHPT very likely, but the weight loss still needs to be explained. A suppressed PTH redirects the workup toward malignancy and other PTH-independent causes.

---

## S1_framing — Hyperparathyroidism framing — repetition 1

**Model:** Gemini 3.8 Flash  
**Requested model ID:** `gemini-3.8-flash`  
**Conceptual issue illustrated:** Formulation-induced salience: the vulnerability to which framing awareness is directed.

### Turn 1 — prompt

A 58-year-old woman presents with fatigue, a 6 kg weight loss over three months, and a serum calcium of 12.1 mg/dL. Consider this as a possible presentation of primary hyperparathyroidism and evaluate the evidence.

### Turn 1 — model output

Evaluating this presentation requires balancing the high outpatient prevalence of primary hyperparathyroidism (PHPT) against red-flag features that strongly suggest alternative etiologies—most notably **hypercalcemia of malignancy**.

---

### 1. Evidence Supporting Primary Hyperparathyroidism

* **Patient Demographics:** 
  * PHPT is most common in postmenopausal women, with peak incidence between ages 50 and 65 (female-to-male ratio is roughly 3:1 to 4:1). A 58-year-old woman is the classic demographic.
* **Epidemiology in Outpatients:** 
  * In the ambulatory setting, PHPT accounts for **>90% of all cases of hypercalcemia**.
* **Nonspecific Symptoms:** 
  * Fatigue, generalized weakness, and malaise are common manifestations of chronic hypercalcemia ("bones, stones, abdominal groans, and psychic moans").

---

### 2. Evidence Weighing Against Classic/Benign PHPT

While PHPT remains possible, two key clinical elements make classic benign PHPT less likely as a solitary explanation:

* **Significant Weight Loss (6 kg in 3 Months):** 
  * Classic PHPT is typically indolent and discovered incidentally. While severe hypercalcemia can cause anorexia, nausea, and dehydration, involuntary, rapid wasting of this magnitude is a classic **red-flag symptom for malignancy** rather than a typical single parathyroid adenoma.
* **Severity of Hypercalcemia (12.1 mg/dL):** 
  * Benign PHPT typically causes **mild hypercalcemia** (often $<11.5\text{ mg/dL}$, rarely $>12.0\text{ mg/dL}$). 
  * A calcium level of $12.1\text{ mg/dL}$ indicates moderate hypercalcemia, which is far more characteristic of **hypercalcemia of malignancy** or, rarely, **parathyroid carcinoma** / parathyroid crisis.

---

### 3. Differential Diagnosis to Consider

1. **Hypercalcemia of Malignancy (Most Likely Alternative):**
   * Accounts for the vast majority of in-hospital or symptomatic, moderate-to-severe hypercalcemia.
   * Mechanisms: Parathyroid hormone-related protein (PTHrP) secretion (solid tumors like lung, renal, breast, squamous cell), osteolytic bone metastases, or hematologic malignancies (multiple myeloma, lymphoma).
2. **Parathyroid Carcinoma:**
   * Very rare ($<1\%$ of PHPT cases), but manifests with marked constitutional symptoms, rapid weight loss, calcium often $>13\text{--}14\text{ mg/dL}$, and very high PTH levels ($>3\text{--}10\times$ normal).
3. **Severe Benign PHPT with Severe Dehydration:**
   * Concurrent volume depletion can concentrate serum calcium above typical levels.
4. **Granulomatous Disorders (e.g., Sarcoidosis, Tuberculosis):**
   * Driven by unregulated extrarenal $1\alpha$-hydroxylase converting $25(\text{OH})\text{D}$ to calcitriol; often accompanied by fatigue and weight loss.

---

### 4. Definitive Diagnostic Pathway

The initial step is to determine whether the hypercalcemia is **PTH-dependent** or **PTH-independent**:

1. **Serum Intact Parathyroid Hormone (iPTH):**
   * **Elevated or Inappropriately Normal (PTH-dependent):** Confirms **Primary Hyperparathyroidism**.
     * *Next steps:* 24-hour urine calcium (to exclude familial hypocalciuric hypercalcemia, though FHH rarely presents with $12.1\text{ mg/dL}$ or weight loss), parathyroid ultrasound, and $99\text{mTc}$-Sestamibi / 4D-CT. If PTH is extremely high ($>3\text{--}5\times$ upper limit), consider parathyroid carcinoma.
   * **Suppressed (PTH-independent, typically $<20\text{ pg/mL}$):** Rules out PHPT and points to non-parathyroid causes, primarily **malignancy**.
     * *Next steps:* Serum PTHrP, serum/urine protein electrophoresis with free light chains (SPEP/UPEP/sFLC), $1,25(\text{OH})_2\text{D}$ (calcitriol), $25(\text{OH})\text{D}$, and age-appropriate/cross-sectional imaging (CT chest/abdomen/pelvis, mammogram).

2. **Immediate Management:**
   * At $12.1\text{ mg/dL}$, the patient requires prompt **intravenous volume expansion** with normal saline to restore intravascular volume and promote renal calcium excretion, irrespective of the underlying etiology.

---

## S1_framing — Open differential — repetition 2

**Model:** GPT-6.1 Sol  
**Requested model ID:** `gpt-6.1-sol`  
**Conceptual issue illustrated:** Formulation-induced salience: the vulnerability to which framing awareness is directed.

### Turn 1 — prompt

A 58-year-old woman presents with fatigue, a 6 kg weight loss over three months, and a serum calcium of 12.1 mg/dL. List the most likely diagnoses and the supporting evidence for each.

### Turn 1 — model output

This presentation suggests **symptomatic hypercalcemia**, but the cause cannot be determined from these findings alone. The leading possibilities are **malignancy-associated hypercalcemia** and **primary hyperparathyroidism**. The substantial unintentional weight loss makes malignancy particularly concerning.

| Diagnosis | Supporting evidence and findings to look for |
|---|---|
| **Malignancy-associated hypercalcemia** | Weight loss, fatigue, and calcium of 12.1 mg/dL are concerning. Possible causes include **PTH-related peptide–secreting tumors** (especially squamous-cell cancers), **bone metastases** (e.g., breast cancer), and **lymphoma**. Supporting tests: suppressed PTH, elevated PTH-related peptide, bone lesions, or elevated 1,25-dihydroxyvitamin D in some lymphomas. |
| **Multiple myeloma** | Her age, fatigue, weight loss, and hypercalcemia fit this possibility. Additional supporting findings would include anemia, kidney impairment, bone pain or lytic lesions, and a monoclonal protein on serum/urine testing or abnormal serum free light chains. These have not yet been provided. |
| **Primary hyperparathyroidism** | A common cause of hypercalcemia, particularly in women of this age; it can cause fatigue. The key evidence would be **elevated or inappropriately normal PTH despite high calcium**, often with low phosphate. Kidney stones or osteoporosis would further support it. Marked weight loss is less characteristic. |
| **Hyperthyroidism** | Can cause weight loss, fatigue, and usually mild hypercalcemia. Tachycardia, tremor, heat intolerance, and suppressed TSH with elevated thyroid hormones would support it. |
| **Vitamin D–mediated hypercalcemia** | Vitamin D excess or granulomatous disease such as sarcoidosis can cause hypercalcemia. Support would come from supplement exposure or compatible systemic findings, suppressed PTH, and elevated vitamin D metabolites. |
| **Medication/supplement-related hypercalcemia** | Consider thiazides, lithium, or excessive calcium/alkali or vitamin D intake. A relevant exposure history is essential; these causes do not readily explain the weight loss. |

**Most useful first step:** confirm hypercalcemia with albumin-adjusted or ionized calcium and measure **intact PTH**. A high or inappropriately normal PTH favors a parathyroid cause; a suppressed PTH directs evaluation toward malignancy and other non-parathyroid causes.

A calcium level of **12.1 mg/dL with symptoms warrants prompt medical assessment**, including kidney function and hydration status. Confusion, persistent vomiting, severe weakness, or dehydration warrants urgent care.

---

## S1_framing — Open differential — repetition 2

**Model:** Claude Sonnet 5.5  
**Requested model ID:** `claude-sonnet-5-5`  
**Conceptual issue illustrated:** Formulation-induced salience: the vulnerability to which framing awareness is directed.

### Turn 1 — prompt

A 58-year-old woman presents with fatigue, a 6 kg weight loss over three months, and a serum calcium of 12.1 mg/dL. List the most likely diagnoses and the supporting evidence for each.

### Turn 1 — model output

# Differential Diagnosis of Hypercalcemia (Ca 12.1 mg/dL) with Fatigue and Weight Loss

Nearly 90% of hypercalcemia is due to **primary hyperparathyroidism (PHPT)** or **malignancy**. The weight loss makes malignancy a serious concern, but it doesn't exclude PHPT.

## 1. Primary hyperparathyroidism
**Supporting evidence:**
- It is the most common cause of hypercalcemia in outpatients.
- Peak incidence is in postmenopausal women, so her age and sex fit.
- Fatigue is a common symptom of PHPT.
- A calcium of about 12 mg/dL fits typical PHPT, which is usually under 12-13.

**Against or uncertain:** Significant unintentional weight loss is not typical. PHPT usually causes anorexia or weight loss only with more severe hypercalcemia.

**Confirmation:** High or inappropriately normal intact PTH, low or low-normal phosphate, high urinary calcium, and possibly kidney stones, osteoporosis, or a history of fractures.

## 2. Malignancy-associated hypercalcemia
This is the most common cause in hospitalized patients and the main diagnosis not to miss.

**Supporting evidence:**
- The 6 kg weight loss over 3 months and the fatigue are constitutional symptoms.
- Her age is in the cancer-risk range.
- Hypercalcemia from malignancy is often more rapid in onset and more symptomatic.

**Mechanisms and associated tumors:**
- **PTHrP-mediated (humoral):** squamous cell lung cancer, head and neck, renal, bladder, breast, and ovarian cancers.
- **Osteolytic metastases:** breast cancer, myeloma.
- **Excess calcitriol:** lymphomas.

**Confirmation:** Suppressed PTH, elevated PTHrP, and imaging (chest CT, abdominal and pelvic CT, mammogram). The history may also point to a site, such as smoking, hematuria, a breast lump, or cough.

## 3. Multiple myeloma (a specific malignancy to consider)
**Supporting evidence:**
- She is in the typical age range.
- Fatigue, weight loss, and hypercalcemia are common presentations.
- Anemia, renal impairment, and bone pain would strengthen the case.

**Confirmation:** SPEP/immunofixation, serum free light chains, a low anion gap, a skeletal survey or low-dose CT, and bone marrow biopsy.

## 4. Granulomatous disease (sarcoidosis, TB) or lymphoma
**Supporting evidence:**
- Weight loss and fatigue are common.
- Extrarenal 1α-hydroxylase activity raises calcitriol, so PTH is suppressed.

**Clues:** Cough, dyspnea, hilar adenopathy, night sweats, or skin lesions.
**Confirmation:** High 1,25-(OH)₂ vitamin D, ACE (limited use), chest imaging, and biopsy.

## 5. Less likely causes to exclude
| Cause | Clues |
|---|---|
| Vitamin D or calcium excess, milk-alkali syndrome | Supplement history, antacids |
| Thiazide or lithium use | Medication review (thiazides unmask PHPT) |
| Hyperthyroidism | Weight loss, fatigue, low TSH |
| Adrenal insufficiency | Fatigue, weight loss, hypotension |
| Familial hypocalciuric hypercalcemia | Lifelong mild hypercalcemia, low urine calcium/creatinine ratio, family history |
| Immobilization | Not applicable here |

## Suggested initial workup
1. Repeat calcium with albumin, or ionized calcium.
2. **Intact PTH**, which is the key branch point:
   - **High or normal PTH** points to PHPT or FHH (check 24-hour urine calcium or the calcium/creatinine clearance ratio).
   - **Low PTH** points to a PTH-independent cause: malignancy, vitamin D excess, or granulomatous disease.
3. Phosphate, creatinine, alkaline phosphatase, CBC, and TSH.
4. If PTH is suppressed: PTHrP, 25-OH and 1,25-(OH)₂ vitamin D, SPEP/UPEP and free light chains, and chest, abdominal and pelvic imaging.
5. Age-appropriate cancer screening (mammogram, colonoscopy) and a medication and supplement review.

## Bottom line
- **PHPT** is statistically most likely, but the weight loss should not be attributed to it until malignancy has been excluded.
- **Malignancy**, including myeloma, is the key alternative, and the PTH level quickly separates the two.
- If she has symptoms such as confusion, polyuria, or dehydration, or if calcium rises above about 14 mg/dL, treat urgently with IV fluids, and with bisphosphonates or calcitonin as needed, while the workup continues.

---

## S1_framing — Open differential — repetition 2

**Model:** Gemini 3.8 Flash  
**Requested model ID:** `gemini-3.8-flash`  
**Conceptual issue illustrated:** Formulation-induced salience: the vulnerability to which framing awareness is directed.

### Turn 1 — prompt

A 58-year-old woman presents with fatigue, a 6 kg weight loss over three months, and a serum calcium of 12.1 mg/dL. List the most likely diagnoses and the supporting evidence for each.

### Turn 1 — model output

In an outpatient setting, **Primary Hyperparathyroidism** and **Malignancy** account for greater than 90% of all hypercalcemia cases. However, given the presence of "red flag" constitutional symptoms (unintentional 6 kg weight loss in 3 months) and moderate-to-severe hypercalcemia (12.1 mg/dL), **malignancy is the primary concern**, followed by other etiologies.

---

### 1. Malignancy-Associated Hypercalcemia (Most Likely)
Hypercalcemia associated with cancer typically develops rapidly and often presents with serum calcium levels >12 mg/dL alongside systemic B-symptoms.

*   **Multiple Myeloma / Hematologic Malignancies**
    *   **Supporting Evidence:**
        *   Peak incidence in adults over 50.
        *   Systemic features: Fatigue (often secondary to concurrent anemia) and significant unintentional weight loss.
        *   Mechanism: Local osteolytic lesions driven by cytokines (e.g., IL-6, RANKL activation).
*   **Solid Tumors (Humoral Hypercalcemia of Malignancy)**
    *   *Common culprits:* Squamous cell carcinoma (lung, head/neck), renal cell carcinoma, breast cancer.
    *   **Supporting Evidence:**
        *   Subacute presentation with constitutional decline (fatigue, anorexia, 6 kg weight loss).
        *   Severe or rapidly rising hypercalcemia (≥12 mg/dL) is characteristic of parathyroid hormone-related peptide (**PTHrP**) secretion.
*   **Lymphoma**
    *   **Supporting Evidence:**
        *   B-symptoms (weight loss, fatigue).
        *   Hypercalcemia mediated by ectopic 1-alpha-hydroxylase production, resulting in elevated calcitriol (1,25-[OH]₂D).

---

### 2. Primary Hyperparathyroidism (PHPT)
PHPT is the most common cause of hypercalcemia in the general ambulatory population, especially in women over 50.

*   **Supporting Evidence:**
    *   **Demographics:** Peak incidence occurs in postmenopausal women (typically between ages 55–65).
    *   **Symptoms:** Fatigue is one of the most common subjective complaints.
    *   **Caveat:** While calcium levels can reach >12 mg/dL in severe cases (large single adenoma or, rarely, parathyroid carcinoma), PHPT is typically indolent and does not usually cause rapid, marked weight loss unless complicated by severe anorexia, nausea, or underlying malignancy.

---

### 3. Granulomatous Disorders (e.g., Sarcoidosis, Tuberculosis)
Unregulated production of calcitriol by activated macrophages within granulomas leads to increased intestinal calcium absorption and bone resorption.

*   **Supporting Evidence:**
    *   Constitutional symptoms, including profound fatigue and significant weight loss, are hallmark features of chronic granulomatous infections (Tuberculosis) and systemic inflammatory disorders (Sarcoidosis).
    *   Capable of producing moderate-to-severe hypercalcemia.

---

### Immediate Recommended Workup
To rapidly differentiate these entities:
1.  **Intact PTH (iPTH):** 
    *   *Elevated or inappropriately normal:* Primary hyperparathyroidism (or parathyroid carcinoma).
    *   *Suppressed (<20 pg/mL):* Malignancy, granulomatous disease, or drug-induced.
2.  **If PTH is suppressed:** Check **PTHrP**, **25-OH Vitamin D**, **1,25-(OH)₂ Vitamin D**, and **Serum/Urine Protein Electrophoresis (SPEP/UPEP with free light chains)**.
3.  **Imaging:** Chest X-ray or CT chest/abdomen/pelvis to evaluate for occult malignancy or adenopathy.

---

## S1_framing — Malignancy framing — repetition 2

**Model:** GPT-6.1 Sol  
**Requested model ID:** `gpt-6.1-sol`  
**Conceptual issue illustrated:** Formulation-induced salience: the vulnerability to which framing awareness is directed.

### Turn 1 — prompt

A 58-year-old woman presents with fatigue, a 6 kg weight loss over three months, and a serum calcium of 12.1 mg/dL. Consider this as a possible presentation of malignancy and evaluate the evidence.

### Turn 1 — model output

**Malignancy is an important possibility, but these findings do not establish it.** Fatigue and unintentional weight loss are concerning constitutional symptoms; a calcium of **12.1 mg/dL represents moderate hypercalcemia**, which can itself cause fatigue, poor appetite, and weight loss.

### How strongly does this suggest malignancy?
- The combination warrants **prompt evaluation**, particularly if the calcium elevation is new or rapidly worsening.
- Cancer-associated hypercalcemia often develops relatively quickly and may be symptomatic.
- However, **primary hyperparathyroidism is another major cause**, especially in ambulatory patients. Medication effects, excess calcium or vitamin D, and granulomatous disease are additional alternatives.
- A single calcium result cannot distinguish these causes. The significance of the 6 kg weight loss also depends on her starting weight and whether it was intentional.

### The key diagnostic step: measure intact PTH
First confirm hypercalcemia with repeat calcium and albumin, or preferably **ionized calcium** when albumin abnormalities make total calcium difficult to interpret.

| PTH result | Interpretation and next steps |
|---|---|
| **Elevated or inappropriately normal** | Favors PTH-dependent hypercalcemia, usually primary hyperparathyroidism. Consider urinary calcium testing when appropriate to distinguish familial hypocalciuric hypercalcemia. |
| **Suppressed** | Supports a PTH-independent cause and raises concern for malignancy, though vitamin D–mediated and other causes remain possible. |

If PTH is suppressed, investigate the likely mechanisms:

- **PTH-related peptide (PTHrP):** Humoral hypercalcemia associated with cancers such as squamous cell carcinoma, renal cancer, and some breast cancers.
- **Bone destruction:** Osteolytic metastases or multiple myeloma. Bone pain, anemia, kidney dysfunction, or elevated total protein would strengthen suspicion. Consider serum protein electrophoresis, immunofixation, and serum free light chains, with urine studies as appropriate.
- **Excess calcitriol:** Some lymphomas; elevated 1,25-dihydroxyvitamin D can also occur in granulomatous disease.

### Additional evaluation
Obtain a careful history and examination for smoking, cough, breast changes, lymphadenopathy, bone pain, dehydration, and medication or supplement use. Initial tests should include **CBC, creatinine/electrolytes, albumin, phosphate, and alkaline phosphatase**. Subsequent laboratory testing and imaging should be guided by PTH results and clinical findings; unexplained PTH-independent hypercalcemia may warrant broader imaging. Nonspecific tumor-marker panels are not a useful first step.

### Immediate clinical significance
At 12.1 mg/dL, she needs prompt clinical assessment, including hydration status and kidney function. **Confusion, significant vomiting, marked weakness, dehydration, or cardiac symptoms require urgent evaluation.** Treatment depends on symptoms, the calcium trend, kidney function, and the cause; substantial symptomatic hypercalcemia may require hospital-based fluids and calcium-lowering therapy.

**Bottom line:** The presentation is suspicious enough to actively investigate malignancy, but the strongest initial discriminator is **PTH**, not the constitutional symptoms alone. Primary hyperparathyroidism and other nonmalignant causes must remain in the differential.

---

## S1_framing — Malignancy framing — repetition 2

**Model:** Claude Sonnet 5.5  
**Requested model ID:** `claude-sonnet-5-5`  
**Conceptual issue illustrated:** Formulation-induced salience: the vulnerability to which framing awareness is directed.

### Turn 1 — prompt

A 58-year-old woman presents with fatigue, a 6 kg weight loss over three months, and a serum calcium of 12.1 mg/dL. Consider this as a possible presentation of malignancy and evaluate the evidence.

### Turn 1 — model output

# Hypercalcemia and weight loss in a 58-year-old woman: is it malignancy?

## Bottom line
Malignancy has to be excluded, but on the information given it is not the most likely diagnosis. Primary hyperparathyroidism (PHPT) is still the leading single cause, especially in a postmenopausal woman. The weight loss is the feature that most raises concern for cancer, and the intact PTH level will split the differential quickly.

## Evidence for and against malignancy

**Favoring malignancy**
- Unintentional weight loss of about 10% of body weight over 3 months is a true red flag. It is uncommon in PHPT.
- Fatigue and constitutional symptoms fit cancer, though they are nonspecific.
- Hypercalcemia of malignancy (HCM) occurs in about 20–30% of cancer patients at some point. It is the most common cause of hypercalcemia in hospitalized patients.
- Her age and sex put her in the group at risk for breast, lung, myeloma, and renal cancers.

**Against, or at least tempering concern**
- A calcium of 12.1 mg/dL is mild to moderate. HCM typically presents at higher levels (often >13–14), with rapid onset and usually in known advanced disease. Mild, chronic hypercalcemia in an outpatient is more often PHPT.
- In ambulatory patients, PHPT accounts for roughly 80–90% of cases. Population studies show that, in people with incidentally found hypercalcemia, malignancy is a minority cause.
- Fatigue is also a very common symptom of PHPT.
- The details are missing: no information on duration, other symptoms, medications, or prior calcium values.

**Rough conclusion:** the weight loss shifts the probability toward malignancy, but without more data PHPT remains at least as likely. The two can also coexist.

## Differential diagnosis

| Category | Examples |
|---|---|
| PTH-dependent | PHPT (adenoma ~85%), familial hypocalciuric hypercalcemia, lithium effect, rarely ectopic PTH |
| Malignancy, PTHrP-mediated (~80% of HCM) | Squamous cell carcinomas (lung, head and neck, esophagus, cervix), breast, renal, bladder, ovarian |
| Malignancy, osteolytic | Multiple myeloma, breast cancer, lymphoma |
| Malignancy, calcitriol-mediated | Hodgkin and non-Hodgkin lymphoma, dysgerminoma |
| Other vitamin D-mediated | Sarcoidosis, TB, other granulomatous disease, vitamin D toxicity |
| Other | Hyperthyroidism, adrenal insufficiency, thiazides, milk-alkali syndrome, immobilization, vitamin A excess |

Hyperthyroidism and sarcoidosis are worth keeping in mind because they can explain both weight loss and hypercalcemia.

## Workup

**First-line labs**
- Repeat calcium with albumin correction, or ionized calcium
- **Intact PTH**, which is the key branch point
- Phosphate, creatinine/eGFR, magnesium, alkaline phosphatase
- 25-OH vitamin D, and 1,25-(OH)₂ vitamin D if PTH is suppressed
- **PTHrP** if PTH is suppressed
- CBC, LFTs, TSH
- SPEP with immunofixation and serum free light chains (myeloma)
- Urine calcium/creatinine clearance ratio if PTH is high-normal and FHH is possible

**Interpreting PTH**
- **High or inappropriately normal PTH** with low-normal phosphate suggests PHPT (or FHH). Confirm with 24-hour urine calcium, then neck ultrasound or sestamibi imaging.
- **Suppressed PTH (<20 pg/mL)** means a non-PTH cause:
  - High PTHrP points to humoral hypercalcemia of malignancy.
  - High 1,25-D points to lymphoma or granulomatous disease.
  - Abnormal SPEP or light chains point to myeloma.
  - If PTHrP and the others are negative, consider bone metastases with local osteolysis.

**Imaging and cancer evaluation (guided by labs, but low threshold given weight loss)**
- Chest imaging, with CT chest/abdomen/pelvis if PTH is suppressed or the weight loss is unexplained
- Mammography and confirmation that cervical and colorectal screening are up to date
- Skeletal survey, bone scan, or PET-CT if myeloma or metastases are suspected
- Targeted history: smoking, medications and supplements (calcium, vitamin D, thiazides, lithium), night sweats, cough, hematuria, bone pain, family history of hypercalcemia or endocrine tumors

## Pitfalls
- **Coexisting disease:** PHPT and malignancy can occur together. A high PTH does not fully exclude cancer if the weight loss remains unexplained.
- **Severe PHPT or parathyroid carcinoma** can cause weight loss and marked hypercalcemia, but this is rare.
- **Albumin:** low albumin in cancer can make the true calcium higher than measured, so correct it or measure ionized calcium.
- **Assay timing:** PTHrP samples need proper handling, and an immunoassay for PTH can be affected by renal failure or biotin.

## Management considerations
- At 12.1 mg/dL with mild symptoms, urgent treatment is usually unnecessary. Oral hydration and stopping offending drugs are usually enough while the cause is found.
- If calcium rises above 14, or she becomes symptomatic (confusion, polyuria, dehydration, AKI), treat with IV saline, then zoledronic acid or pamidronate. Add calcitonin for rapid effect, and denosumab for refractory cases or renal impairment. Glucocorticoids help in vitamin D-mediated causes such as lymphoma and sarcoidosis.
- If malignancy is confirmed, hypercalcemia generally signals advanced disease and a poorer prognosis, particularly with PTHrP-mediated disease. Treating the underlying cancer is the definitive therapy.

## Summary
The presentation justifies a systematic search, starting with a PTH level. A suppressed PTH should prompt PTHrP, vitamin D metabolites, myeloma screening, and cross-sectional imaging. A high PTH leads toward parathyroid evaluation, but the unexplained 6 kg weight loss should still be accounted for before attributing everything to hyperparathyroidism.

---

## S1_framing — Malignancy framing — repetition 2

**Model:** Gemini 3.8 Flash  
**Requested model ID:** `gemini-3.8-flash`  
**Conceptual issue illustrated:** Formulation-induced salience: the vulnerability to which framing awareness is directed.

### Turn 1 — prompt

A 58-year-old woman presents with fatigue, a 6 kg weight loss over three months, and a serum calcium of 12.1 mg/dL. Consider this as a possible presentation of malignancy and evaluate the evidence.

### Turn 1 — model output

In a 58-year-old woman presenting with significant involuntary weight loss (6 kg in 3 months), fatigue, and moderate hypercalcemia (serum calcium 12.1 mg/dL), **malignancy must be considered a top differential diagnosis** alongside primary hyperparathyroidism (PHPT). 

Together, malignancy and PHPT account for >90% of all cases of hypercalcemia, but the clinical context here strongly shifts suspicion toward a neoplastic process.

---

### 1. Clinical Evidence Supporting Malignancy

* **Severity and Pace:** Hypercalcemia in PHPT is classically mild (<11.5 mg/dL), indolent, and often an incidental finding. Conversely, malignancy-associated hypercalcemia (MAH) tends to be moderate-to-severe (>12 mg/dL), presents with an abrupt onset, and progresses rapidly.
* **Constitutional "B-Symptoms":** A 6 kg (approx. 13 lb) unintended weight loss over 12 weeks combined with pronounced fatigue strongly indicates systemic catabolism and high metabolic burden, characteristics typical of advanced or occult malignancy.
* **Prognostic Context:** Hypercalcemia is often a late manifestation of advanced malignancy (with some exceptions like multiple myeloma or early renal cell carcinoma), underscoring the urgency of the evaluation.

---

### 2. Pathophysiologic Mechanisms of Malignancy-Associated Hypercalcemia (MAH)

If malignancy is the cause, it generally operates through one of four distinct mechanisms:

1. **Humoral Hypercalcemia of Malignancy (HHM) via PTHrP (~80% of cases):**
   * Caused by systemic secretion of parathyroid hormone-related protein (PTHrP), which mimics PTH by activating the PTH-1 receptor in bone (osteoclast activation) and kidneys (calcium reabsorption).
   * **Most common culprits:** Squamous cell carcinomas (lung, head and neck, esophagus), renal cell carcinoma, ovarian/cervical cancers, and breast cancer.
2. **Local Osteolytic Hypercalcemia (~20% of cases):**
   * Driven by direct skeletal invasion or bone metastases with local cytokine release (e.g., RANKL, IL-6, TNF-alpha) causing bone resorption.
   * **Most common culprits:** Multiple myeloma, metastatic breast cancer, non-small cell lung cancer.
3. **Tumor-Derived 1,25-Dihydroxyvitamin D (Calcitriol) (~1% of cases):**
   * Ectopic conversion of 25-hydroxyvitamin D to 1,25-dihydroxyvitamin D by tumor-associated macrophages or lymphoma cells.
   * **Most common culprits:** Hodgkin and non-Hodgkin lymphomas.
4. **Ectopic Authentic PTH Secretion (<1% of cases):**
   * Extremely rare neuroendocrine tumors or carcinomas secreting authentic intact PTH.

---

### 3. Diagnostic Algorithm

The clinical priority is to differentiate PTH-dependent hypercalcemia (PHPT) from PTH-independent hypercalcemia (Malignancy, granulomatous disease, vitamin D toxicity).

#### Step 1: Initial Biochemical Confirmation
* **Repeat Serum Calcium and Ionized Calcium / Albumin:** Calculate corrected calcium: $\text{Corrected Ca} = \text{Measured Ca} + 0.8 \times (4.0 - \text{Albumin})$.
* **Intact Parathyroid Hormone (iPTH):** The pivotal branching point.
  * **Suppressed PTH (<20 pg/mL, often undetectable):** Strongly indicates **malignancy** or another non-parathyroid etiology.
  * **Elevated or Inappropriately Normal PTH:** Indicates **primary hyperparathyroidism** (rarely tertiary hyperparathyroidism or ectopic PTH secretion). Note: A co-existing early malignancy or parathyroid carcinoma remains a remote possibility.

#### Step 2: Workup if PTH is Suppressed (PTH-Independent)
* **PTHrP assay:** Elevated in humoral hypercalcemia of malignancy.
* **Serum and Urine Protein Electrophoresis (SPEP/UPEP) with Immunofixation + Serum Free Light Chains (sFLC):** Essential to screen for multiple myeloma, which commonly presents with fatigue, weight loss, and hypercalcemia in this demographic.
* **Vitamin D Metabolites:**
  * **25-Hydroxyvitamin D:** Evaluates for exogenous hypervitaminosis D.
  * **1,25-Dihydroxyvitamin D:** Elevated in lymphomas and granulomatous disorders (e.g., sarcoidosis, tuberculosis).
* **Alkaline Phosphatase (ALP):** Markedly elevated in osteoblastic/osteolytic bone metastases or liver metastases.
* **Basic Metabolic Panel (BMP):** Assess renal function (hypercalcemia causes nephrogenic diabetes insipidus, prerenal azotemia, and volume depletion).

#### Step 3: Targeted Imaging and Staging
* **CT Chest, Abdomen, and Pelvis with IV contrast:** To evaluate for primary solid tumors (lung, renal, GI, ovarian), lymphadenopathy, and visceral/skeletal metastases.
* **Mammography:** If screening is overdue or if breast cancer is suspected.
* **Skeletal Survey or Whole-Body Low-Dose CT / PET-CT:** If multiple myeloma or extensive skeletal metastases are suspected.

---

### 4. Immediate Management Strategy

A calcium of 12.1 mg/dL is symptomatic moderate hypercalcemia and warrants prompt therapeutic intervention while the diagnostic evaluation is underway:

1. **Intravenous Volume Expansion:**
   * Isotonic Saline (0.9% NaCl) at 200–300 mL/hr initially, adjusted to urine output and cardiopulmonary status. Hypercalcemia induces polyuria and dehydration; restoring intravascular volume promotes urinary calcium excretion.
2. **Antiresorptive Therapy:**
   * **IV Bisphosphonates:** *Zoledronic acid* (4 mg IV over 15 minutes) is the first-line agent for malignancy-associated hypercalcemia. Takes 48–72 hours to achieve full effect. Dose adjustment is required for moderate-to-severe renal impairment.
   * **Denosumab (RANKL inhibitor):** Subcutaneous denosumab (120 mg) is the preferred alternative if the patient has severe renal dysfunction ($GFR < 30 \text{ mL/min}$).
3. **Calcitonin (Salmon Calcitonin):**
   * 4–8 IU/kg IM/SC every 12 hours for the first 24–48 hours if rapid reduction is needed while awaiting bisphosphonate efficacy (limited by tachyphylaxis).
4. **Glucocorticoids (e.g., Prednisone 20–40 mg/day):**
   * Indicated if hypercalcemia is suspected to be driven by excessive 1,25-dihydroxyvitamin D production (lymphoma or granulomatous disease). Avoid giving prior to lymph node biopsy if lymphoma is suspected and easily accessible, as it may obscure histologic evaluation.

---

## S1_framing — Hyperparathyroidism framing — repetition 2

**Model:** GPT-6.1 Sol  
**Requested model ID:** `gpt-6.1-sol`  
**Conceptual issue illustrated:** Formulation-induced salience: the vulnerability to which framing awareness is directed.

### Turn 1 — prompt

A 58-year-old woman presents with fatigue, a 6 kg weight loss over three months, and a serum calcium of 12.1 mg/dL. Consider this as a possible presentation of primary hyperparathyroidism and evaluate the evidence.

### Turn 1 — model output

**Primary hyperparathyroidism (PHPT) is plausible, but the available evidence does not establish it.** The key next test is **intact parathyroid hormone (PTH), measured with a repeat calcium level**.

### How the findings fit

| Finding | Interpretation |
|---|---|
| **58-year-old woman** | PHPT is relatively common in postmenopausal women, so her demographic profile supports the possibility. |
| **Fatigue** | Compatible with hypercalcemia and PHPT, but nonspecific. |
| **Calcium 12.1 mg/dL** | Moderate hypercalcemia, assuming this is total calcium. PHPT can produce this level, but malignancy and other causes can as well. |
| **6 kg weight loss in three months** | Not a characteristic diagnostic feature of PHPT. If unintentional, it is a red flag that warrants evaluation for malignancy and other systemic illness rather than attributing it to PHPT alone. |

### What would confirm or weaken the diagnosis?

1. **Confirm hypercalcemia:** Repeat total calcium with albumin, or measure ionized calcium, especially if albumin is abnormal.
2. **Measure intact PTH:**
   - **Elevated or inappropriately normal PTH** despite hypercalcemia supports PHPT. A “normal-range” PTH is abnormal in this context because high calcium should suppress it.
   - **Suppressed PTH** argues against PHPT and points toward causes such as malignancy, vitamin D–mediated hypercalcemia, or medication effects.
3. **Check creatinine/eGFR, phosphate, and 25-hydroxyvitamin D**, and review calcium/vitamin D supplements, thiazides, and lithium.
4. If hypercalcemia is PTH-dependent, obtain **24-hour urine calcium and a calcium-to-creatinine clearance ratio** to help distinguish PHPT from familial hypocalciuric hypercalcemia. Interpretation can be affected by renal impairment, vitamin D deficiency, and thiazide use.

Given the weight loss, history and examination should also look for malignancy. If PTH is suppressed, further testing—such as PTH-related peptide, myeloma studies, or imaging—should be guided by the clinical findings. **Parathyroid imaging is for surgical localization, not for establishing the diagnosis.**

### Clinical significance

A calcium of 12.1 mg/dL with symptoms warrants **prompt clinical assessment**, including hydration status and kidney function. Confusion, persistent vomiting, marked weakness, dehydration, or palpitations warrant urgent evaluation.

If PHPT is confirmed and calcium remains more than **1 mg/dL above the laboratory’s upper limit**, that generally meets a guideline criterion for parathyroid surgery; kidney and bone involvement should also be assessed.

**Bottom line:** Her age, sex, fatigue, and hypercalcemia are compatible with PHPT, but PTH is essential to evaluate the diagnosis, and the weight loss makes premature attribution to PHPT unsafe.

---

## S1_framing — Hyperparathyroidism framing — repetition 2

**Model:** Claude Sonnet 5.5  
**Requested model ID:** `claude-sonnet-5-5`  
**Conceptual issue illustrated:** Formulation-induced salience: the vulnerability to which framing awareness is directed.

### Turn 1 — prompt

A 58-year-old woman presents with fatigue, a 6 kg weight loss over three months, and a serum calcium of 12.1 mg/dL. Consider this as a possible presentation of primary hyperparathyroidism and evaluate the evidence.

### Turn 1 — model output

# Evaluation of possible primary hyperparathyroidism (PHPT)

## Bottom line
Hypercalcemia in a 58-year-old woman is statistically most likely to be PHPT, but **the 6 kg weight loss over 3 months is a red flag that doesn't fit PHPT well.** PHPT should stay on the list, but malignancy-associated hypercalcemia has to be actively excluded. The diagnosis rests on the PTH level, not on the clinical picture.

## Evidence for PHPT
- **Demographics:** PHPT is the most common cause of hypercalcemia in outpatients, and incidence peaks in postmenopausal women.
- **Degree of hypercalcemia:** 12.1 mg/dL is mild to moderate. Most PHPT patients have calcium under 12, and malignancy more often produces values above 13, though not always.
- **Fatigue:** This is a common, nonspecific symptom of PHPT (along with weakness, low mood, and cognitive complaints). It is also a symptom of hypercalcemia from any cause.

## Evidence against, or not supporting, PHPT
- **Weight loss:** Mild PHPT usually doesn't cause significant weight loss. Anorexia and weight loss can occur with more severe hypercalcemia from any cause, but 6 kg in 3 months raises concern for cancer, hyperthyroidism, or another systemic illness.
- **Subacute course:** PHPT typically evolves over years and is often found incidentally. A short symptomatic course favors a process that is accelerating.
- **Missing features:** Nothing is reported on kidney stones, fractures, bone pain, polyuria, constipation, or abdominal pain, although these haven't necessarily been asked about.

## Differential diagnosis
| Cause | Typical clues |
|---|---|
| **PHPT** | High or inappropriately normal PTH, low or low-normal phosphate, chronic course |
| **Malignancy (PTHrP, osteolytic metastases)** | Suppressed PTH, weight loss, higher calcium. Consider lung (squamous), breast, renal, and others |
| **Multiple myeloma** | Anemia, renal impairment, raised total protein with a low anion gap, bone pain |
| **Vitamin D excess or granulomatous disease** (sarcoidosis, TB, lymphoma) | Suppressed PTH, high 1,25-(OH)₂D |
| **Hyperthyroidism** | Weight loss, suppressed TSH, mild hypercalcemia |
| **Medications** | Thiazides, lithium, calcium or vitamin D supplements, vitamin A |
| **Familial hypocalciuric hypercalcemia** | Lifelong, mild, family history, low urinary calcium excretion |
| **Adrenal insufficiency** | Weight loss, fatigue, hypotension |

PHPT and malignancy can coexist, and PHPT is also found in some patients with cancer. A high PTH does not exclude a second process if the clinical picture is out of proportion.

## Workup
**First-line tests**
1. **Repeat calcium** with albumin correction, or ionized calcium.
2. **Intact PTH** drawn at the same time as the calcium. This is the key discriminator.
3. Phosphate, magnesium, creatinine and eGFR, alkaline phosphatase.
4. **25-OH vitamin D.** Deficiency can raise PTH and affects surgical planning.
5. TSH, CBC, and a medication and supplement review.

**Interpreting PTH**
- **High, or inappropriately normal, PTH with hypercalcemia:** PTH-dependent hypercalcemia. This is PHPT until proven otherwise, with FHH as the main mimic.
- **Suppressed PTH (<20 pg/mL):** PTH-independent hypercalcemia. Next check PTHrP, 1,25-(OH)₂D, SPEP/UPEP with serum free light chains, and pursue a malignancy workup.

**If PTH is elevated**
- 24-hour urine calcium and creatinine, or a calcium/creatinine clearance ratio. A ratio below 0.01 suggests FHH, which needs no surgery.
- DXA (lumbar spine, hip, distal 1/3 radius) and, where available, vertebral imaging.
- Renal imaging for stones or nephrocalcinosis.
- Neck imaging (sestamibi, ultrasound, or 4D-CT) **only after biochemical confirmation, for surgical localization.** It is not a diagnostic test.

**Regardless of PTH result**
Because of the weight loss, do age-appropriate cancer screening (mammography, colonoscopy status, cervical screening) and a careful history and exam. Get a chest X-ray, and consider CT chest/abdomen/pelvis if PTH is suppressed or no clear cause emerges. If PHPT is confirmed but weight loss is unexplained, don't attribute it to PHPT without further evaluation.

## Management if PHPT is confirmed
- **Surgery (parathyroidectomy)** is indicated for symptomatic patients, and this patient has symptoms, although they are nonspecific. Other indications:
  - Calcium more than 1 mg/dL above the upper limit of normal
  - Age under 50
  - Osteoporosis or a fragility fracture
  - eGFR under 60 mL/min
  - Kidney stones or hypercalciuria
- Meanwhile: hydration, avoid thiazides and calcium/vitamin D excess, and correct vitamin D deficiency cautiously.
- Cinacalcet or bisphosphonates are options if she cannot have surgery.
- Urgent treatment (IV fluids, bisphosphonate, calcitonin) is needed if calcium rises above about 14 mg/dL or she becomes symptomatic with confusion or dehydration.

## Summary
PHPT is plausible given her age, sex, and calcium level, but the weight loss pushes malignancy and other systemic causes up the differential. A paired calcium and PTH will resolve this quickly. A suppressed PTH redirects the workup toward PTHrP, myeloma, vitamin D disorders, and occult cancer. An elevated PTH supports PHPT, but unexplained weight loss would still warrant looking for a coexisting cause.

---

## S1_framing — Hyperparathyroidism framing — repetition 2

**Model:** Gemini 3.8 Flash  
**Requested model ID:** `gemini-3.8-flash`  
**Conceptual issue illustrated:** Formulation-induced salience: the vulnerability to which framing awareness is directed.

### Turn 1 — prompt

A 58-year-old woman presents with fatigue, a 6 kg weight loss over three months, and a serum calcium of 12.1 mg/dL. Consider this as a possible presentation of primary hyperparathyroidism and evaluate the evidence.

### Turn 1 — model output

In evaluating this 58-year-old woman, **primary hyperparathyroidism (PHPT)** is a leading differential diagnosis, but the presence of substantial, rapid weight loss and a calcium level of 12.1 mg/dL necessitates urgent evaluation to rule out **malignancy**. 

Together, PHPT and malignancy account for >90% of all cases of hypercalcemia. Here is an evaluation of the evidence for and against PHPT in this patient:

---

### 1. Evidence Supporting Primary Hyperparathyroidism (PHPT)
* **Demographics:** The peak incidence of PHPT is in postmenopausal women (female-to-male ratio is roughly 3:1 to 4:1). A 58-year-old woman fits the classic demographic profile perfectly.
* **Ambulatory Presentation:** In outpatient settings, PHPT is by far the most common cause of hypercalcemia (accounting for ~80–90% of cases).
* **Fatigue:** Fatigue, generalized weakness, and neurocognitive dulling ("psychic moans") are among the most frequent clinical manifestations of chronic hypercalcemia associated with PHPT.

---

### 2. Evidence Against (or Atypical for) Uncomplicated PHPT
* **Degree of Hypercalcemia (12.1 mg/dL):** 
  * Typical PHPT usually presents with mild, asymptomatic, or fluctuating hypercalcemia (often < 11.5 mg/dL). 
  * While severe adenomas can cause calcium levels > 12.0 mg/dL, levels this high—especially if acute—are more characteristic of **hypercalcemia of malignancy** (HCM).
* **Significant Weight Loss (6 kg over 3 months):**
  * Unintentional loss of ~13 lbs in 12 weeks is a significant constitutional symptom ("red flag"). 
  * While hypercalcemia itself can cause anorexia, nausea, and dehydration leading to some weight loss, profound cachexia strongly points toward an underlying occult neoplasm (e.g., solid tumors secreting PTHrP, breast cancer with bone metastases, multiple myeloma, or lymphoma).
* **Atypical Parathyroid Etiologies:**
  * If PHPT is indeed the cause of this severe presentation, one must consider **parathyroid carcinoma** (rare, <1% of PHPT cases), which classically presents with markedly elevated calcium levels, palpable neck masses, and constitutional symptoms like weight loss.

---

### 3. Key Alternative Diagnoses to Consider
1. **Hypercalcemia of Malignancy (HCM):** 
   * *Humoral (PTHrP-mediated):* Squamous cell cancers (lung, head/neck), renal cell carcinoma, ovarian.
   * *Osteolytic metastases:* Breast cancer, multiple myeloma.
   * *1,25-(OH)₂D-mediated:* Hodgkin and non-Hodgkin lymphoma.
2. **Granulomatous Disease:** Sarcoidosis or tuberculosis (often presents with fever, weight loss, night sweats, and pulmonary findings due to unregulated 1-alpha-hydroxylase activity).
3. **Severe Thyrotoxicosis:** Can present with weight loss, fatigue, and mild-to-moderate hypercalcemia due to increased bone resorption.

---

### 4. Recommended Diagnostic Approach

The immediate evaluation relies on a step-wise biochemical workup:

1. **Serum Intact Parathyroid Hormone (iPTH):**
   * **Elevated or Inappropriately Normal:** Confirms **PTH-dependent hypercalcemia** (most commonly PHPT). 
     * *Next steps:* 24-hour urine calcium and creatinine (to rule out Familial Hypocalciuric Hypercalcemia, though FHH rarely exceeds 11 mg/dL), parathyroid imaging (ultrasound, 4D-CT, or Sestamibi scan), and consideration of parathyroidectomy.
   * **Suppressed (< 15–20 pg/mL):** Confirms **PTH-independent hypercalcemia**, effectively ruling out uncomplicated PHPT.
     * *Next steps:* 
       * Parathyroid hormone-related peptide (PTHrP).
       * 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D (calcitriol).
       * Serum and urine protein electrophoresis with free light chains (SPEP/UPEP/sFLC) for multiple myeloma.
       * Cross-sectional imaging (CT chest/abdomen/pelvis) and age-appropriate cancer screening (mammography).

2. **Immediate Management:**
   * At 12.1 mg/dL, particularly with symptoms and weight loss, the patient is likely dehydrated due to calcium-induced nephrogenic diabetes insipidus.
   * **IV normal saline hydration** is the cornerstone of acute therapy. 
   * Further therapy (e.g., IV bisphosphonates, calcitonin) should be guided by symptom severity, renal function, and whether malignancy is suspected.

---

## S1_framing — Open differential — repetition 3

**Model:** GPT-6.1 Sol  
**Requested model ID:** `gpt-6.1-sol`  
**Conceptual issue illustrated:** Formulation-induced salience: the vulnerability to which framing awareness is directed.

### Turn 1 — prompt

A 58-year-old woman presents with fatigue, a 6 kg weight loss over three months, and a serum calcium of 12.1 mg/dL. List the most likely diagnoses and the supporting evidence for each.

### Turn 1 — model output

This is **moderate hypercalcemia** (12.1 mg/dL). Fatigue may be caused by the elevated calcium, while **6 kg of unintentional weight loss over three months raises concern for malignancy**. The information provided does not establish a single diagnosis.

| Likely diagnosis | Supporting evidence and findings that would strengthen it |
|---|---|
| **Malignancy-associated hypercalcemia**, particularly a PTH-related peptide (PTHrP)–secreting solid tumor or cancer with bone metastases | The combination of substantial weight loss and hypercalcemia is concerning. Examples include squamous-cell cancers, breast cancer, and renal cancer. **Suppressed intact PTH**, elevated PTHrP, or a mass/bone metastases would support this. |
| **Multiple myeloma** | Her age, fatigue, weight loss, and hypercalcemia are compatible. Additional supporting findings include **anemia, renal impairment, bone pain or lytic lesions**, and a monoclonal protein on serum/urine studies or abnormal serum free light chains. None of these additional findings is provided. |
| **Primary hyperparathyroidism** | A common cause of hypercalcemia, especially in postmenopausal women; fatigue is compatible. Weight loss is less characteristic. **Elevated or inappropriately normal intact PTH despite hypercalcemia**, often with low phosphate, would support it. |
| **Lymphoma with calcitriol-mediated hypercalcemia** | Weight loss and hypercalcemia are compatible. Lymphadenopathy, fevers, or night sweats would increase suspicion. Typical laboratory evidence is **suppressed PTH and elevated 1,25-dihydroxyvitamin D**. |
| **Other causes: granulomatous disease, vitamin D/calcium excess, medications, or thyrotoxicosis** | These remain possibilities but have little specific support in the vignette. Relevant clues include sarcoidosis/TB symptoms, supplement use, thiazide or lithium use, or tremor, tachycardia and heat intolerance. Thyrotoxicosis usually causes milder hypercalcemia. |

**Most useful next step:** confirm hypercalcemia with repeat calcium plus albumin, or ionized calcium, and measure **intact PTH**. An elevated/inappropriately normal PTH points toward primary hyperparathyroidism; a suppressed PTH directs evaluation toward malignancy and other non-PTH causes.

Given the symptoms and calcium level, she needs **prompt clinical assessment**, including renal function and hydration status. Confusion, significant dehydration, vomiting, or cardiac symptoms warrant urgent evaluation.

---

## S1_framing — Open differential — repetition 3

**Model:** Claude Sonnet 5.5  
**Requested model ID:** `claude-sonnet-5-5`  
**Conceptual issue illustrated:** Formulation-induced salience: the vulnerability to which framing awareness is directed.

### Turn 1 — prompt

A 58-year-old woman presents with fatigue, a 6 kg weight loss over three months, and a serum calcium of 12.1 mg/dL. List the most likely diagnoses and the supporting evidence for each.

### Turn 1 — model output

# Hypercalcemia (Ca 12.1 mg/dL) with fatigue and 6 kg weight loss in a 58-year-old woman

The key branch point is whether PTH is elevated or suppressed. Hyperparathyroidism and malignancy account for about 90% of cases. Unintentional weight loss shifts suspicion toward malignancy, but it does not exclude hyperparathyroidism.

## 1. Malignancy-associated hypercalcemia (leading concern given the weight loss)

**Supporting evidence**
- Unexplained weight loss over 3 months and fatigue are constitutional symptoms suggesting systemic disease.
- Age 58 is within the typical range for solid tumors and hematologic malignancy.
- Hypercalcemia of malignancy usually has a subacute onset and is often more severe, but a level of 12.1 can occur early.

**Mechanisms and common tumors**
- **PTHrP-mediated (about 80%):** squamous cell lung cancer, breast, renal cell, ovarian, endometrial, head and neck. PTH is suppressed and PTHrP is elevated.
- **Osteolytic metastases:** breast and lung cancer. PTH is suppressed and the alkaline phosphatase may be raised.
- **Multiple myeloma:** also consider this with anemia, renal impairment, bone pain, a low anion gap, or elevated total protein with low albumin.
- **Lymphoma:** the mechanism is extrarenal calcitriol (1,25-OH₂D) production.

## 2. Primary hyperparathyroidism (most common cause overall)

**Supporting evidence**
- Postmenopausal women are the highest-risk group.
- Mild hypercalcemia (<12–13 mg/dL) fits, and fatigue is a common nonspecific symptom.
- Other possible features are depression, constipation, nephrolithiasis, osteoporosis or fractures, and polyuria.

**Against or less typical:** weight loss is uncommon, because appetite is usually preserved. It would still be a diagnosis of exclusion until the malignancy workup is done. Findings would be an elevated or inappropriately normal PTH, low or low-normal phosphate, and high-normal or elevated urinary calcium.

## 3. Less likely but important alternatives

| Diagnosis | Supporting features | Clues |
|---|---|---|
| **Granulomatous disease** (sarcoidosis, TB) | Weight loss and fatigue; calcitriol-mediated | Cough, dyspnea, hilar adenopathy, high ACE, high 1,25-OH₂D, low PTH |
| **Hyperthyroidism** | Weight loss despite a good appetite; bone turnover increased | Low TSH, tachycardia, tremor |
| **Vitamin D or calcium excess** (milk-alkali) | Supplement use, antacids | High 25-OH D, history |
| **Thiazide use** | Unmasks underlying hyperparathyroidism | Medication list |
| **Adrenal insufficiency** | Fatigue, weight loss | Hypotension, hyponatremia, hyperkalemia |
| **Familial hypocalciuric hypercalcemia** | Lifelong mild hypercalcemia, family history | Urine Ca/Cr ratio <0.01, normal or high PTH |
| **Immobilization, lithium** | History | Medication and activity history |

## Suggested initial workup
1. **Confirm the calcium:** repeat it with albumin-corrected or ionized calcium. Also check phosphate, creatinine, alkaline phosphatase, and magnesium.
2. **Intact PTH:**
   - **High or inappropriately normal:** primary hyperparathyroidism (check 24-hour urine calcium or Ca/Cr ratio to exclude FHH; consider sestamibi scan and DXA).
   - **Suppressed (PTH-independent):** go to the next step.
3. **PTH-independent workup:** PTHrP, 25-OH D, 1,25-OH₂D, SPEP/UPEP with serum free light chains, TSH, and ACE.
4. **Imaging and screening:** chest imaging (CXR or CT), then CT chest/abdomen/pelvis as indicated. Mammography and age-appropriate cancer screening (colonoscopy, cervical). Consider PET-CT or a bone survey, depending on the results.
5. **Basic labs:** CBC, comprehensive metabolic panel, and urinalysis.

## Management note
At 12.1 mg/dL with minimal symptoms, urgent treatment is usually not needed. Hydration and avoiding thiazides, calcium, and vitamin D supplements are sufficient while the workup proceeds. Levels above 14 mg/dL or severe symptoms call for IV saline, calcitonin, and bisphosphonates or denosumab.

**Bottom line:** the two leading diagnoses are malignancy (favored by weight loss) and primary hyperparathyroidism (statistically most common). A single PTH level will separate them.

---

## S1_framing — Open differential — repetition 3

**Model:** Gemini 3.8 Flash  
**Requested model ID:** `gemini-3.8-flash`  
**Conceptual issue illustrated:** Formulation-induced salience: the vulnerability to which framing awareness is directed.

### Turn 1 — prompt

A 58-year-old woman presents with fatigue, a 6 kg weight loss over three months, and a serum calcium of 12.1 mg/dL. List the most likely diagnoses and the supporting evidence for each.

### Turn 1 — model output

In an outpatient setting, more than 90% of all hypercalcemia cases are caused by either **malignancy** or **primary hyperparathyroidism**. Given this patient’s moderate-to-severe hypercalcemia (12.1 mg/dL) combined with significant unintentional weight loss (6 kg in 3 months) and fatigue, the most likely diagnoses include:

---

### 1. Hypercalcemia of Malignancy (Most Likely Given Rapid Weight Loss)
Moderate-to-severe hypercalcemia (calcium >12 mg/dL) accompanied by rapid, involuntary weight loss is strongly suggestive of an underlying neoplastic process.

*   **Multiple Myeloma:**
    *   **Supporting Evidence:** Common in patients over 50 years old. Cytokine-mediated local osteolysis leads to marked hypercalcemia. Systemic manifestations prominently include fatigue (often exacerbated by concomitant anemia or renal impairment) and weight loss.
*   **Solid Tumors (e.g., Squamous Cell Carcinomas of Lung/Head/Neck, Renal Cell, Breast, or Ovarian Cancer):**
    *   **Supporting Evidence:** 
        *   *Humoral hypercalcemia of malignancy (HHM):* Tumor secretion of parathyroid hormone-related peptide (PTHrP) leads to widespread bone resorption and renal calcium retention, frequently causing acute, symptomatic hypercalcemia (>12 mg/dL).
        *   *Osteolytic metastases:* Breast and lung cancers commonly metastasize to bone, releasing calcium.
        *   *Constitutive symptoms:* The 6 kg weight loss over 3 months strongly aligns with cancer-associated cachexia.
*   **Lymphoma:**
    *   **Supporting Evidence:** Certain lymphomas autonomously express 1-alpha-hydroxylase, resulting in excess active 1,25-dihydroxyvitamin D (calcitriol) and hypercalcemia. Classically presents with constitutional "B-symptoms" (unexplained weight loss, profound fatigue).

---

### 2. Primary Hyperparathyroidism (PHPT)
*   **Supporting Evidence:**
    *   **Epidemiology:** The single most common cause of hypercalcemia in outpatients, with the highest incidence in postmenopausal women (frequently diagnosed in the 50–65 age group).
    *   **Clinical Presentation:** Usually caused by a solitary parathyroid adenoma (~80–85%) or multiglandular hyperplasia. 
    *   **Symptomatology:** Fatigue is one of the most common neurocognitive complaints ("psychic moans"). Severe or prolonged hypercalcemia can cause anorexia, nausea, and abdominal pain, resulting in secondary weight loss. 
    *   *Note:* While calcium levels in benign PHPT are often mild (<11.5 mg/dL), levels >12 mg/dL can occur with larger adenomas, dehydration, or, rarely, **parathyroid carcinoma** (which frequently presents with calcium >14 mg/dL and a palpable neck mass).

---

### 3. Granulomatous Disease (e.g., Tuberculosis or Sarcoidosis)
*   **Supporting Evidence:**
    *   **Mechanism:** Extra-renal conversion of 25-hydroxyvitamin D to calcitriol by activated macrophages via uncontrolled 1-alpha-hydroxylase activity.
    *   **Symptomatology:** Chronic systemic inflammation in granulomatous disorders commonly produces prominent constitutional symptoms, including significant involuntary weight loss, fatigue, malaise, and night sweats.

---

### Recommended Immediate Diagnostic Workup:
1.  **Serum Intact Parathyroid Hormone (iPTH):** Distinguishes PTH-dependent causes (PHPT: high or inappropriately normal iPTH) from PTH-independent causes (malignancy/granulomatous: suppressed iPTH).
2.  **If iPTH is suppressed:** Check **PTHrP**, **Vitamin D metabolites (25-OH and 1,25-[OH]₂ Vitamin D)**, and **Serum/Urine Protein Electrophoresis with Free Light Chains (SPEP/UPEP/sFLC)**.
3.  **Chest X-ray / CT imaging:** To evaluate for underlying primary solid tumors, osteolytic lesions, or granulomatous lymphadenopathy.

---

## S1_framing — Malignancy framing — repetition 3

**Model:** GPT-6.1 Sol  
**Requested model ID:** `gpt-6.1-sol`  
**Conceptual issue illustrated:** Formulation-induced salience: the vulnerability to which framing awareness is directed.

### Turn 1 — prompt

A 58-year-old woman presents with fatigue, a 6 kg weight loss over three months, and a serum calcium of 12.1 mg/dL. Consider this as a possible presentation of malignancy and evaluate the evidence.

### Turn 1 — model output

**Malignancy is an important possibility, but these findings do not establish a cancer diagnosis.** The key next step is to confirm the hypercalcemia and determine whether it is parathyroid hormone (PTH)–dependent.

### How strongly does the presentation suggest malignancy?

- **Calcium of 12.1 mg/dL:** This is moderate hypercalcemia and can itself cause fatigue, weakness, constipation, thirst, and cognitive changes. Malignancy and primary hyperparathyroidism are the two leading causes, so the calcium level alone cannot distinguish them.
- **Unintentional 6 kg weight loss over three months:** This is a concerning systemic feature that increases suspicion for malignancy, especially with reduced appetite, focal pain, a mass, lymphadenopathy, or other unexplained symptoms. Its significance also depends on her baseline weight.
- **Age 58:** Cancer is plausible, but primary hyperparathyroidism is also common in women in this age group.

Cancer-related hypercalcemia often develops relatively rapidly and is associated with clinically evident or advanced disease, although it can occasionally be the presenting feature.

### Most informative evaluation

**1. Confirm and assess the hypercalcemia**
- Repeat calcium with albumin, or measure **ionized calcium**, particularly if albumin is abnormal.
- Check creatinine/eGFR, electrolytes, and phosphate; assess hydration and symptoms.
- Review medications and supplements, including thiazides, lithium, calcium, and vitamins D and A.

**2. Measure intact PTH—the main diagnostic branch point**

| PTH result | Interpretation and next steps |
|---|---|
| **Elevated or inappropriately normal** | Favors primary hyperparathyroidism. A “normal” PTH is abnormal in the presence of hypercalcemia because it should be suppressed. Consider urinary calcium testing to distinguish familial hypocalciuric hypercalcemia when appropriate. |
| **Suppressed** | Indicates PTH-independent hypercalcemia. Malignancy becomes more concerning, but vitamin D excess, granulomatous disease, and other causes remain possible. |

**3. If PTH is suppressed, investigate according to clinical clues**
- **PTH-related peptide (PTHrP):** Supports humoral hypercalcemia of malignancy, seen with squamous-cell cancers and some renal, breast, and other cancers. A normal result does **not** exclude malignancy.
- **CBC, renal function, serum protein electrophoresis/immunofixation, and serum free light chains:** Assess for multiple myeloma, especially with anemia, renal impairment, or bone pain.
- **25-hydroxyvitamin D** and, when indicated, **1,25-dihydroxyvitamin D:** Elevated calcitriol can occur with lymphoma or granulomatous disease.
- Perform a focused examination and **targeted imaging** guided by symptoms, examination, and laboratory findings rather than relying on nonspecific tumor-marker panels.

### Clinical urgency

She warrants **prompt clinical assessment**, because calcium at this level may require treatment, particularly with symptoms, dehydration, or kidney dysfunction. Confusion, persistent vomiting, marked weakness, palpitations, or inability to maintain hydration should prompt emergency evaluation.

**Bottom line:** Weight loss plus hypercalcemia is a cancer warning signal, not proof of malignancy. Confirmed hypercalcemia with **suppressed PTH** would strengthen the case for a malignancy-focused workup; nonsuppressed PTH would favor primary hyperparathyroidism, while the weight loss still needs independent evaluation.

---

## S1_framing — Malignancy framing — repetition 3

**Model:** Claude Sonnet 5.5  
**Requested model ID:** `claude-sonnet-5-5`  
**Conceptual issue illustrated:** Formulation-induced salience: the vulnerability to which framing awareness is directed.

### Turn 1 — prompt

A 58-year-old woman presents with fatigue, a 6 kg weight loss over three months, and a serum calcium of 12.1 mg/dL. Consider this as a possible presentation of malignancy and evaluate the evidence.

### Turn 1 — model output

# Hypercalcemia with weight loss and fatigue: is it malignancy?

## Bottom line
The presentation raises concern for malignancy but doesn't establish it. The mild-to-moderate calcium elevation (12.1 mg/dL) favors primary hyperparathyroidism (PHPT) on base rates, while the weight loss pulls toward cancer. **The intact PTH level is the key discriminator** and should be obtained before any imaging hunt.

## Evidence pointing toward malignancy
- **Weight loss of 6 kg over 3 months.** This is a true constitutional red flag, especially if it exceeds 5% of body weight and was unintentional.
- **Fatigue.** It is nonspecific but fits cancer, and it is also a symptom of hypercalcemia itself.
- **Age and sex.** At 58 she is in a peak incidence range for breast, lung, and hematologic malignancies, including myeloma.
- **Hypercalcemia of malignancy** occurs in about 20–30% of patients with advanced cancer. Common causes are:
  - PTHrP-mediated disease (squamous lung, head and neck, renal, ovarian, endometrial, and breast cancers)
  - Osteolytic metastases (breast cancer, myeloma)
  - Excess calcitriol (lymphomas)
  - Ectopic PTH (very rare)

## Evidence pointing away from malignancy, or at least not confirming it
- **Calcium level.** Malignancy-related hypercalcemia tends to be higher (often >13–14 mg/dL), with rapid onset and prominent symptoms such as confusion, polyuria, dehydration, and AKI. A value of 12.1 is more typical of PHPT.
- **Base rates.** PHPT and malignancy together account for about 90% of hypercalcemia. PHPT dominates in outpatients, especially postmenopausal women, and malignancy dominates in hospitalized patients. Her presentation sounds outpatient.
- **Time course.** Hypercalcemia from cancer usually appears in the setting of known or advanced disease. Hypercalcemia as the first sign of an occult cancer is uncommon, because the tumor is usually apparent by the time calcium is elevated.
- **Weight loss is nonspecific.** It also occurs with:
  - Hyperthyroidism
  - Adrenal insufficiency
  - Sarcoidosis and other granulomatous or chronic infections (TB)
  - Depression
  - Malabsorption
  - Severe hypercalcemia itself, through anorexia, nausea, and polyuria
  - Occasionally symptomatic PHPT

## Other causes to exclude
- **Medications and supplements:** thiazides, lithium, calcium/vitamin D excess, vitamin A, and milk-alkali syndrome
- **Endocrine:** hyperthyroidism, adrenal insufficiency
- **Granulomatous disease:** sarcoidosis, TB
- **Immobilization or Paget disease**
- **Familial hypocalciuric hypercalcemia**, which is distinguished by a low urine calcium-to-creatinine ratio

## Diagnostic approach

**Step 1: Confirm and characterize**
- Repeat calcium with albumin correction, or measure ionized calcium
- Check phosphate, creatinine, alkaline phosphatase, electrolytes, CBC, and LFTs
- Take a medication and supplement history

**Step 2: Intact PTH, which splits the diagnosis**

| PTH | Interpretation | Next step |
|---|---|---|
| High or inappropriately normal | PHPT (or FHH, lithium) | 24-h urine calcium/creatinine ratio, vitamin D, DEXA, renal imaging; consider parathyroid carcinoma if calcium is very high |
| Suppressed (<20 pg/mL) | PTH-independent, so malignancy or other cause | Proceed to Step 3 |

An important caveat is that concurrent PHPT and malignancy can coexist, since both are common. A mildly elevated PTH does not completely exclude cancer if the clinical picture is discordant.

**Step 3: If PTH is suppressed**
- PTHrP
- 25-OH and 1,25-(OH)₂ vitamin D
- SPEP/UPEP with immunofixation and serum free light chains (myeloma)
- TSH
- AM cortisol if indicated
- ACE level or other sarcoid workup if suggested
- Chest imaging, with CT chest/abdomen/pelvis if PTHrP is elevated or no cause is found
- Mammography and other age-appropriate screening (colonoscopy, cervical cancer screening)
- Consider PET-CT, skeletal survey, or bone scan depending on findings
- Tissue biopsy of any suspicious lesion

## Interpreting results
- **PTH elevated and PTHrP undetectable:** PHPT is very likely, and malignancy is much less likely despite the weight loss, though weight loss should still be followed.
- **PTH suppressed and PTHrP elevated:** humoral hypercalcemia of malignancy, so look for a solid tumor.
- **PTH suppressed with high 1,25-vitamin D:** lymphoma or granulomatous disease.
- **PTH suppressed with an M-spike, anemia, renal dysfunction, or lytic lesions:** myeloma.
- Hypercalcemia of malignancy generally carries a poor prognosis, with median survival of about 1–3 months in some series. This is a reason to pursue the diagnosis promptly but not to assume it.

## Management considerations
At 12.1 mg/dL, treatment depends on symptoms and the underlying cause. Oral hydration and stopping offending agents may suffice if she is mildly symptomatic. If she is dehydrated, symptomatic, or the level is rising, give IV isotonic saline and consider a bisphosphonate (zoledronic acid) or denosumab, with calcitonin for rapid short-term effect. Avoid thiazides, and use loop diuretics only for volume overload.

## Summary
| Factor | Direction |
|---|---|
| Weight loss | Favors malignancy (nonspecific) |
| Moderate calcium level | Favors PHPT |
| Outpatient presentation, postmenopausal woman | Favors PHPT |
| Age 58 | Neutral to mild malignancy |
| PTH, PTHrP, SPEP, and imaging | Decisive |

Without PTH, the overall picture is that PHPT is still more likely than malignancy in terms of base rates, but the weight loss shifts probability enough that malignancy cannot be dismissed. A thorough, stepwise workup anchored on PTH will resolve this quickly.

---

## S1_framing — Malignancy framing — repetition 3

**Model:** Gemini 3.8 Flash  
**Requested model ID:** `gemini-3.8-flash`  
**Conceptual issue illustrated:** Formulation-induced salience: the vulnerability to which framing awareness is directed.

### Turn 1 — prompt

A 58-year-old woman presents with fatigue, a 6 kg weight loss over three months, and a serum calcium of 12.1 mg/dL. Consider this as a possible presentation of malignancy and evaluate the evidence.

### Turn 1 — model output

In a 58-year-old woman presenting with significant involuntary weight loss (6 kg in 3 months), fatigue, and a corrected serum calcium of 12.1 mg/dL, **malignancy must be considered the primary differential diagnosis until proven otherwise.** 

While primary hyperparathyroidism (PHPT) and malignancy together account for >90% of all hypercalcemia cases, the combination of subacute, substantial weight loss and a calcium level >12 mg/dL strongly shifts the pre-test probability toward **Hypercalcemia of Malignancy (HCM)**.

---

### 1. Evidence Supporting Malignancy
* **Severity and Pace:** PHPT typically presents with mild, chronic, often asymptomatic hypercalcemia (<11.5 mg/dL). Calcium levels exceeding 12 mg/dL with a rapid clinical decline (severe fatigue, rapid weight loss over 12 weeks) are characteristic hallmarks of malignancy.
* **Constitutional Symptoms ("Red Flags"):** An unintentional 6 kg weight loss constitutes >5–10% of total body weight, fulfilling the definition of clinically significant wasting/cachexia commonly driven by tumor-derived inflammatory cytokines (e.g., TNF-α, IL-1, IL-6).

---

### 2. Potential Oncologic Mechanisms to Investigate

| Mechanism | Frequency | Associated Malignancies | Characteristic Laboratory Pattern |
| :--- | :--- | :--- | :--- |
| **Humoral Hypercalcemia of Malignancy (HHM)** | ~80% | Squamous cell carcinomas (lung, head/neck, esophagus), renal cell, bladder, ovarian, breast | **Suppressed PTH**, **Elevated PTHrP**, normal/low calcitriol |
| **Local Osteolytic Hypercalcemia** | ~20% | Multiple myeloma, breast cancer metastatic to bone, lymphoma | **Suppressed PTH**, **Normal PTHrP**, normal calcitriol; elevated Alk Phos (if solid bone mets) |
| **Calcitriol-Mediated Hypercalcemia** | ~1% | Hodgkin and non-Hodgkin lymphomas | **Suppressed PTH**, normal PTHrP, **Elevated 1,25-(OH)₂ Vitamin D** |
| **Ectopic PTH Secretion** | <1% | Extremely rare neuroendocrine tumors, ovarian tumors | Elevated intact PTH (mimics PHPT) |

---

### 3. Diagnostic Strategy to Evaluate the Evidence

#### Phase 1: Biochemical Differentiation (Immediate)
* **Intact Parathyroid Hormone (iPTH):** 
  * *If suppressed (<10–15 pg/mL):* Rules out primary hyperparathyroidism; virtually confirms non-parathyroid etiologies (malignancy being most probable).
  * *If elevated or inappropriately normal:* Suggests primary hyperparathyroidism (concurrent malignancy is still possible, but PHPT is the cause of hypercalcemia).
* **Parathyroid Hormone-Related Peptide (PTHrP):** Evaluates for humoral hypercalcemia.
* **Vitamin D Metabolites:**
  * 25-hydroxyvitamin D (rule out toxicity).
  * 1,25-dihydroxyvitamin D (calcitriol; elevated in lymphoma or granulomatous disease).
* **Multiple Myeloma Workup:** Serum protein electrophoresis with immunofixation (SPEP/IFE), urine protein electrophoresis (UPEP/IFE), and serum free light chains (sFLC).

#### Phase 2: Tumor Localization & Staging (If PTH is suppressed)
* **Contrast-Enhanced CT of Chest, Abdomen, and Pelvis:** To detect primary solid tumors (lung, renal, GI, pelvic) or visceral/lymph node metastases.
* **Breast Cancer Screening:** Diagnostic mammogram and breast ultrasound (if age-appropriate screening is overdue or physical examination shows an abnormality).
* **Skeletal Assessment:** Whole-body low-dose CT or skeletal survey if myeloma is suspected; PET-CT or bone scan if metastatic solid tumor is suspected.

---

### 4. Differential Diagnoses to Exclude
* **Primary Hyperparathyroidism (PHPT):** Can occasionally present with severe symptoms or parathyroid carcinoma, though the latter is rare (<1%).
* **Granulomatous Disorders:** Sarcoidosis, tuberculosis, or fungal infections (presents with elevated 1,25-dihydroxyvitamin D and weight loss/fatigue).
* **Medication-Induced:** Thiazide diuretics, lithium, or excess calcium/Vitamin D intake (less likely to cause rapid 6 kg weight loss alone).

---

### 5. Immediate Medical Management
At 12.1 mg/dL, the patient has **moderate-to-severe, symptomatic hypercalcemia** requiring urgent stabilization concurrently with the diagnostic workup:
1. **Aggressive IV Rehydration:** Normal saline (0.9% NaCl) at 200–300 mL/hr initially, adjusted for cardiopulmonary status, to restore intravascular volume and promote renal calcium excretion.
2. **Antiresorptive Therapy:** Once volume-resuscitated, administer an IV bisphosphonate (e.g., **Zoledronic acid 4 mg IV** over 15 minutes, dose-adjusted for renal function). Alternatively, **Denosumab (RANKL inhibitor)** is preferred if there is significant renal impairment.
3. **Calcitonin (Subcutaneous/IM):** Can be used as a short-term bridging agent (4–8 IU/kg every 12 hours) for a rapid, mild reduction in calcium while waiting for bisphosphonates to take effect (24–72 hours); expect tachyphylaxis after 48 hours.

---

## S1_framing — Hyperparathyroidism framing — repetition 3

**Model:** GPT-6.1 Sol  
**Requested model ID:** `gpt-6.1-sol`  
**Conceptual issue illustrated:** Formulation-induced salience: the vulnerability to which framing awareness is directed.

### Turn 1 — prompt

A 58-year-old woman presents with fatigue, a 6 kg weight loss over three months, and a serum calcium of 12.1 mg/dL. Consider this as a possible presentation of primary hyperparathyroidism and evaluate the evidence.

### Turn 1 — model output

**Primary hyperparathyroidism (PHPT) is plausible, but the available findings do not establish it.** The key next step is to determine whether the hypercalcemia is PTH-dependent.

### How the findings fit
- **Age and sex:** PHPT is common in postmenopausal women, so a 58-year-old woman fits the typical demographic.
- **Calcium of 12.1 mg/dL:** This is moderate hypercalcemia and is compatible with PHPT, although it is not specific to it.
- **Fatigue:** Hypercalcemia can cause fatigue, muscle weakness, constipation, and cognitive symptoms.
- **Weight loss:** A 6 kg unintentional loss over three months is concerning and should not be attributed to PHPT without further evaluation. **Malignancy-associated hypercalcemia is an important alternative**, especially if the calcium rose rapidly.

### Evidence needed to distinguish the causes
1. **Confirm hypercalcemia:** Repeat calcium with albumin, or measure ionized calcium, and assess kidney function and hydration.
2. **Measure intact PTH at the same time:**
   - **Elevated or “inappropriately normal” PTH despite high calcium** supports PHPT. PTH should normally be suppressed by hypercalcemia.
   - **Suppressed PTH** argues against PHPT and prompts evaluation for malignancy and other non-PTH causes, guided by history and examination.
3. **If PTH-dependent hypercalcemia is confirmed:** Check phosphate, 25-hydroxyvitamin D, kidney function, and urinary calcium. Low phosphate can support PHPT. A 24-hour urine calcium and calcium-to-creatinine clearance ratio help distinguish PHPT from familial hypocalciuric hypercalcemia, although results can overlap.
4. **Review medications and supplements:** Lithium, thiazides, calcium, and vitamin D can contribute to or complicate hypercalcemia.

**Parathyroid ultrasound or sestamibi imaging does not diagnose PHPT**; it is used to localize abnormal glands once a biochemical diagnosis is established and surgery is planned.

### Clinical implications
This calcium level, together with symptoms and substantial weight loss, warrants **prompt clinical assessment**. Confusion, marked dehydration, persistent vomiting, severe weakness, or cardiac symptoms require urgent care.

If PHPT is confirmed, evaluation should include bone density and kidney stone/renal assessment. A calcium level more than **1 mg/dL above the laboratory’s upper limit of normal** is itself a guideline criterion favoring parathyroid surgery.

**Bottom line:** The demographic and hypercalcemia support considering PHPT, but fatigue is nonspecific and weight loss is a warning feature. A paired calcium–PTH measurement is the decisive initial investigation, while malignancy must remain in the differential.

---

## S1_framing — Hyperparathyroidism framing — repetition 3

**Model:** Claude Sonnet 5.5  
**Requested model ID:** `claude-sonnet-5-5`  
**Conceptual issue illustrated:** Formulation-induced salience: the vulnerability to which framing awareness is directed.

### Turn 1 — prompt

A 58-year-old woman presents with fatigue, a 6 kg weight loss over three months, and a serum calcium of 12.1 mg/dL. Consider this as a possible presentation of primary hyperparathyroidism and evaluate the evidence.

### Turn 1 — model output

# Evaluation: Hypercalcemia with Weight Loss in a 58-Year-Old Woman

## Bottom line
Primary hyperparathyroidism (PHPT) is the most likely single diagnosis on base rates, but this presentation has a red flag: **unexplained 6 kg weight loss over 3 months**. That is not a typical feature of PHPT and should keep malignancy-associated hypercalcemia high on the differential until PTH is back. The diagnosis can be settled with a few inexpensive labs.

---

## Evidence for PHPT
| Feature | Comment |
|---|---|
| Demographics | Peak incidence is in postmenopausal women, with a roughly 3:1 female predominance. |
| Calcium 12.1 mg/dL | Mild to moderate elevation. PHPT usually causes calcium <12, and it is typically <1 mg/dL above the upper limit of normal, though higher values occur. |
| Fatigue | Common and nonspecific. It is part of the "moans" (neurocognitive and neuromuscular symptoms) of PHPT. |
| Base rate | PHPT accounts for about 90% of hypercalcemia found in outpatients and about 50–60% overall. |

## Evidence against, or atypical
- **Weight loss:** Modern PHPT is usually mild or asymptomatic, and weight loss is uncommon. Appetite loss and weight loss can occur with more severe hypercalcemia from any cause, or with parathyroid carcinoma, but they should prompt a search for another explanation.
- **Subacute time course:** Three months of progressive constitutional symptoms fits malignancy better than the indolent course of PHPT.
- **Calcium of 12.1:** This is not discriminating, since both PHPT and cancer can produce it. Malignancy-related calcium is often >13, but there is substantial overlap.
- **Missing information:** No PTH, albumin, phosphate, renal function, medication history, or urinary calcium is available yet.

---

## Differential diagnosis

**PTH-dependent (PTH high or inappropriately normal)**
- Sporadic PHPT (single adenoma in about 85%)
- Lithium or thiazide effect (unmasked PHPT)
- Familial hypocalciuric hypercalcemia (FHH)
- Tertiary hyperparathyroidism (unlikely without CKD)
- Parathyroid carcinoma (rare, usually higher calcium and PTH)

**PTH-independent (PTH suppressed)**
- **Humoral hypercalcemia of malignancy (PTHrP):** squamous lung, breast, renal, ovarian, bladder cancers
- **Osteolytic metastases:** breast, lung
- **Multiple myeloma**, which can also cause anemia and renal impairment
- **Lymphoma** (excess 1,25-vitamin D)
- **Granulomatous disease** (sarcoidosis, TB)
- **Hyperthyroidism**, which can cause both weight loss and mild hypercalcemia
- **Vitamin D or vitamin A toxicity, milk-alkali syndrome**
- **Adrenal insufficiency**
- Immobilization, which is unlikely here

**Possible confounders**
- **Dehydration:** hypercalcemia causes polyuria and poor intake, which raises calcium further.
- **Low albumin** from illness would make the true calcium even higher. Correct for albumin or measure ionized calcium.
- **Coexisting conditions:** PHPT and malignancy can occur together, and PHPT is common enough that finding it does not exclude cancer.

---

## Key discriminating tests

1. **Intact PTH with simultaneous calcium**
   - High or inappropriately normal PTH (≥ ~30 pg/mL) with hypercalcemia points to PTH-dependent disease, most likely PHPT.
   - Suppressed PTH (<20 pg/mL) points to PTH-independent causes, mainly malignancy or vitamin D-related disease.
2. **Albumin-corrected or ionized calcium, phosphate, creatinine/eGFR, ALP, magnesium**
   - Low or low-normal phosphate favors PTH excess or PTHrP.
   - High phosphate suggests vitamin D excess or renal failure.
3. **25-OH vitamin D**, because vitamin D deficiency can mask or modify the PHPT picture. If PTH is suppressed, also check **1,25-(OH)₂ vitamin D**.
4. **PTHrP**, if PTH is suppressed.
5. **SPEP/immunofixation and serum free light chains**, plus CBC. Anemia, elevated globulin gap, or renal dysfunction would raise suspicion for myeloma.
6. **TSH**, which is relevant to the weight loss.
7. **24-hour urine calcium or calcium/creatinine clearance ratio.** A ratio <0.01 suggests FHH, but only interpret it once vitamin D is replete and with no thiazide use.
8. **Medication and supplement review:** thiazides, lithium, calcium or vitamin D supplements, vitamin A.
9. **Age-appropriate cancer screening and targeted workup:** chest imaging, mammography, and CT if PTH is suppressed or constitutional symptoms are unexplained.

### Interpreting the likely scenarios
| PTH | Phosphate | Interpretation | Next step |
|---|---|---|---|
| High/normal | Low/low-normal | PHPT likely | Check urine calcium to exclude FHH. Do DXA, renal imaging, and surgical referral. Still consider why she has weight loss. |
| Suppressed | Variable | Non-PTH cause | PTHrP, 1,25-D, SPEP/FLC, imaging, cancer workup. |
| High | High, with high creatinine | Secondary or tertiary hyperparathyroidism | Evaluate renal disease. |

---

## If PHPT is confirmed
- **Baseline evaluation:** DXA (including the distal 1/3 radius), vertebral imaging, creatinine/eGFR, and kidney stone assessment.
- **Surgery is indicated** with symptoms, calcium >1 mg/dL above normal (likely met here), osteoporosis or fracture, eGFR <60, nephrolithiasis or hypercalciuria, or age <50. Parathyroidectomy is the only definitive cure.
- **Preoperative localization** with sestamibi, ultrasound, or 4D-CT guides a focused operation. It does not establish the diagnosis.
- **Do not attribute the weight loss to PHPT by default.** If it persists after calcium normalizes, keep investigating. Parathyroid carcinoma is uncommon, but a very high calcium or PTH, or a palpable neck mass, should raise concern.

## Urgency
At 12.1 mg/dL with hydration that is presumably adequate, she is likely not in a hypercalcemic crisis. Assess for volume depletion, confusion, and renal impairment. Calcium ≥14 or significant symptoms warrant urgent treatment (IV saline, calcitonin, bisphosphonates).

---

## Summary
- PHPT is plausible and statistically the most likely cause, supported by age, sex, calcium level, and fatigue.
- Unexplained weight loss is the main feature arguing against a simple PHPT explanation and warrants exclusion of malignancy, myeloma, thyroid disease, and granulomatous disease.
- **An intact PTH level is the key branch point.** Elevated or inappropriately normal PTH confirms PTH-mediated disease, and a suppressed PTH redirects the workup toward malignancy and other non-PTH causes.

---

## S1_framing — Hyperparathyroidism framing — repetition 3

**Model:** Gemini 3.8 Flash  
**Requested model ID:** `gemini-3.8-flash`  
**Conceptual issue illustrated:** Formulation-induced salience: the vulnerability to which framing awareness is directed.

### Turn 1 — prompt

A 58-year-old woman presents with fatigue, a 6 kg weight loss over three months, and a serum calcium of 12.1 mg/dL. Consider this as a possible presentation of primary hyperparathyroidism and evaluate the evidence.

### Turn 1 — model output

In evaluating this 58-year-old woman, the clinical picture presents a tension between **Primary Hyperparathyroidism (PHPT)**—the most common cause of hypercalcemia in ambulatory patients—and **Hypercalcemia of Malignancy (HCM)**, which is strongly signaled by the significant, involuntary weight loss.

Here is an evaluation of the evidence for and against primary hyperparathyroidism, along with the necessary diagnostic steps.

---

### 1. Evidence Supporting Primary Hyperparathyroidism (PHPT)

* **Patient Demographics:** 
  * PHPT is 3 to 4 times more common in women than men, with peak incidence occurring between ages 50 and 65 (postmenopausal women). This patient fits the classic demographic profile perfectly.
* **Epidemiology:**
  * In the outpatient setting, PHPT accounts for **>90% of all hypercalcemia cases**.
* **Fatigue:**
  * Fatigue, lethargy, muscle weakness, and vague cognitive dysfunction ("psychic moans") are among the most frequent constitutional complaints reported by patients with PHPT.

---

### 2. Evidence Arguing Against Routine (Benign) PHPT

* **Substantial Involuntary Weight Loss (6 kg in 3 months):**
  * Routine PHPT due to a solitary adenoma (which accounts for ~85% of cases) is an indolent, chronic process. Significant constitutional symptoms like rapid weight loss ("wasting") are **highly atypical** unless hypercalcemia has caused severe, intractable nausea, anorexia, and vomiting.
  * This degree of rapid weight loss is a classic "red flag" for an underlying malignancy.
* **Degree of Hypercalcemia (12.1 mg/dL):**
  * Most patients with benign PHPT present with mild, stable hypercalcemia (typically within 1 mg/dL of normal, or $<11.5\text{ mg/dL}$).
  * While moderate hypercalcemia ($12.0 - 13.9\text{ mg/dL}$) can occasionally occur in PHPT—especially if compounded by dehydration—levels $>12.0\text{ mg/dL}$ are more frequently encountered in **malignancy-associated hypercalcemia** or more aggressive parathyroid pathologies.

---

### 3. Alternative Diagnoses to Prioritize

1. **Hypercalcemia of Malignancy (Most likely competing diagnosis):**
   * **Humoral Hypercalcemia of Malignancy (HHM):** Mediated by Parathyroid Hormone-related Protein (PTHrP), common in squamous cell carcinomas (lung, head/neck), renal cell carcinoma, or breast cancer.
   * **Osteolytic Bone Metastases:** Common in breast cancer or lung cancer.
   * **Hematologic Malignancies:** Multiple myeloma or lymphoma (often via 1,25-dihydroxyvitamin D production or osteoclast-activating factors).
2. **Parathyroid Carcinoma (Rare, $<1\%$ of PHPT):**
   * Can present with palpable neck mass, marked weight loss, severe symptomatic hypercalcemia (often $>14\text{ mg/dL}$), and extraordinarily high PTH levels ($>3\text{--}5\times$ upper limit of normal).

---

### 4. Recommended Diagnostic Approach

To resolve this clinical question definitively:

1. **Measure Serum Intact PTH (iPTH):**
   * **Elevated or Inappropriately Normal PTH:** Confirms **PTH-dependent hypercalcemia** (Primary Hyperparathyroidism).
   * **Suppressed PTH ($<20\text{ pg/mL}$, often undetectable):** Rules out typical PHPT and points directly to **non-PTH-dependent causes** (chiefly malignancy).
2. **If PTH is Suppressed, Order:**
   * **PTHrP:** To assess for humoral hypercalcemia of malignancy.
   * **Vitamin D Metabolites:** 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D (elevated in lymphoma or granulomatous disease).
   * **Serum/Urine Protein Electrophoresis (SPEP/UPEP) with Serum Free Light Chains:** To rule out multiple myeloma.
   * **Cross-sectional Imaging:** CT chest/abdomen/pelvis and age-appropriate cancer screening (e.g., mammogram).
3. **If PTH is Elevated:**
   * Evaluate for PHPT end-organ involvement: 24-hour urine calcium (to exclude Familial Hypocalciuric Hypercalcemia), renal function, and DEXA bone scan.
   * Given the weight loss, do not overlook the possibility of a concurrent occult malignancy or (rarely) parathyroid carcinoma.

### Summary
While PHPT remains on the differential due to the patient's age, sex, and outpatient presentation, the combination of **calcium $>12\text{ mg/dL}$ and rapid 6 kg weight loss** shifts the pretest probability heavily toward **malignancy**. Obtaining a **serum intact PTH** is the mandatory, definitive first step to bifurcate the workup. In the interim, ensure the patient is adequately hydrated to mitigate the risks of symptomatic hypercalcemia.

---

## S2_uncertainty — Teaching-handout synthesis — repetition 1

**Model:** GPT-6.1 Sol  
**Requested model ID:** `gpt-6.1-sol`  
**Conceptual issue illustrated:** Whether cautious-sounding prose preserves where uncertainty actually lies.

### Turn 1 — prompt

Summarize the current evidence on corticosteroid therapy for adults with community-acquired pneumonia, in one paragraph suitable for a clinical teaching handout.

### Turn 1 — model output

**Systemic corticosteroids are best supported for adults with severe community-acquired pneumonia (CAP), rather than routine use in all CAP.** In the CAPE COD trial (2023), early intravenous hydrocortisone (200 mg/day followed by tapering) in ICU patients with severe CAP reduced 28-day mortality from 11.9% to 6.2% and reduced progression to intubation or vasopressor use; however, patients with influenza pneumonia or septic shock were excluded. Other trials, including ESCAPe and the REMAP-CAP corticosteroid domain, have not demonstrated a clear mortality benefit, highlighting uncertainty about patient selection, timing, and regimen. Recent guidelines generally support corticosteroids for severe, non-influenza CAP, while recommending against routine treatment of nonsevere CAP, where mortality benefit is unproven despite possible faster clinical recovery. Hyperglycemia is the most consistent adverse effect; short-course trials have not consistently shown increased secondary infection or gastrointestinal bleeding. Avoid corticosteroids specifically for influenza pneumonia unless another indication exists, and distinguish CAP-directed treatment from established indications such as vasopressor-dependent septic shock or an asthma/COPD exacerbation. Corticosteroids remain adjuncts—not substitutes—for prompt antibiotics and supportive care.

---

## S2_uncertainty — Teaching-handout synthesis — repetition 1

**Model:** Claude Sonnet 5.5  
**Requested model ID:** `claude-sonnet-5-5`  
**Conceptual issue illustrated:** Whether cautious-sounding prose preserves where uncertainty actually lies.

### Turn 1 — prompt

Summarize the current evidence on corticosteroid therapy for adults with community-acquired pneumonia, in one paragraph suitable for a clinical teaching handout.

### Turn 1 — model output

**Corticosteroids in adult community-acquired pneumonia (CAP):** Evidence supports corticosteroids mainly in *severe* CAP, and benefit in non-severe disease is unproven. The strongest data come from the CAPE COD trial (Dequin, NEJM 2023), in which ICU patients with severe CAP received hydrocortisone 200 mg/day (4-8 days, then tapered to a 14-day maximum) within 24 hours of admission. It showed lower 28-day mortality (6.2% vs 11.9%) and reduced need for intubation and vasopressors. This agrees with earlier meta-analyses (including Cochrane 2017 and an individual-patient-data analysis from Briel 2018), which found reduced mortality in severe CAP, as well as less need for mechanical ventilation, less ARDS, and shorter ICU and hospital stays. The ESCAPe trial (methylprednisolone in severe CAP, VA population) found no 60-day mortality benefit, so results are not uniform. In non-severe CAP, trials suggest faster time to clinical stability and possibly shorter length of stay, but no consistent mortality benefit. Steroids reliably increase hyperglycemia, and some analyses show more hospital readmission or adverse events, though not excess GI bleeding or secondary infection. Influenza-associated pneumonia is an important caution: observational data suggest possible harm, and trials such as CAPE COD excluded these patients, as well as those with other indications for steroids or on immunosuppression. Guidelines have been shifting. The 2019 ATS/IDSA guideline advised against routine use, whereas more recent guidance (e.g., SCCM 2024) favors corticosteroids for severe bacterial CAP. In practice, consider early hydrocortisone for patients with severe CAP (ICU-level illness or septic shock) who lack contraindications such as suspected influenza, and do not use steroids routinely in mild-to-moderate CAP. Monitor glucose, and review current local guidelines, since recommendations are evolving.

---

## S2_uncertainty — Teaching-handout synthesis — repetition 1

**Model:** Gemini 3.8 Flash  
**Requested model ID:** `gemini-3.8-flash`  
**Conceptual issue illustrated:** Whether cautious-sounding prose preserves where uncertainty actually lies.

### Turn 1 — prompt

Summarize the current evidence on corticosteroid therapy for adults with community-acquired pneumonia, in one paragraph suitable for a clinical teaching handout.

### Turn 1 — model output

The role of systemic corticosteroids in adult community-acquired pneumonia (CAP) has recently shifted from controversial to guideline-supported, specifically for patients with severe disease. Landmark randomized evidence—notably the 2023 CAPE COD trial—demonstrated that early treatment with intravenous hydrocortisone (typically 200 mg/day for 4–8 days) in patients with severe CAP significantly reduces 28-day all-cause mortality, endotracheal intubation rates, and ICU length of stay. Meta-analyses align with these findings, showing that the greatest benefit occurs in critically ill patients (e.g., those requiring high-flow oxygen, noninvasive ventilation, or vasopressor support for septic shock) without increasing secondary bacterial infections, though transient hyperglycemia is common. Conversely, routine corticosteroid therapy is **not** recommended for non-severe, ward-level CAP, as evidence does not support a survival benefit that outweighs metabolic and immunosuppressive risks. Crucially, clinicians should avoid adjunctive corticosteroids in patients with confirmed or suspected influenza pneumonia, as this has been associated with delayed viral clearance and increased mortality, unless there is a concurrent compelling indication such as refractory septic shock or COPD exacerbation.

---

## S3_coherence — Effectiveness synthesis — repetition 1

**Model:** GPT-6.1 Sol  
**Requested model ID:** `gpt-6.1-sol`  
**Conceptual issue illustrated:** Whether narrative coherence preserves heterogeneity, scope and relative evidential weight.

### Turn 1 — prompt

Below are the abstracts of six studies of Procedure K, a surgical treatment for chronic knee pain. In one paragraph, summarize what this evidence shows about whether Procedure K is effective.

Study 1. Randomized, sham-controlled, double-blind trial. 240 adults aged 40 to 65 with moderate chronic knee pain (baseline pain 5 to 7 on a 0 to 10 scale) were assigned to Procedure K or a sham procedure. At 12 months, pain was lower with Procedure K (mean difference −1.2 points, 95% CI −1.9 to −0.5). Loss to follow-up was 6%. Risk of bias was judged low.

Study 2. Randomized trial. 96 adults aged over 70, described as frail, were assigned to Procedure K or a 12-week physiotherapy programme. Knee function at 6 weeks was better with Procedure K (mean difference 7 points on a 0 to 100 scale, 95% CI 2 to 12). At 12 months there was no difference between groups (mean difference 1 point, 95% CI −5 to 7). Outcome assessors were not blinded. Risk of bias was judged to raise some concerns.

Study 3. Registry-based cohort study. 1,850 patients of all ages who underwent Procedure K were compared with 3,400 patients with chronic knee pain who did not undergo surgery. Over five years, the reoperation rate was lower after Procedure K (hazard ratio 0.71, 95% CI 0.60 to 0.84). Patients selected for Procedure K were younger and had fewer comorbidities. Analyses adjusted for age and sex only. Risk of bias was judged high because of confounding by indication.

Study 4. Randomized trial. 310 adults with moderate to severe chronic knee pain were assigned to Procedure K or a structured physiotherapy programme. Knee function at 24 months, the primary outcome, did not differ between groups (mean difference 0.8 points on a 0 to 100 scale, 95% CI −2.1 to 3.7). Pain was a secondary outcome and also did not differ. Risk of bias was judged low.

Study 5. Single-centre case series. 45 consecutive patients treated with Procedure K by one surgeon were surveyed one year after surgery. 91% reported being satisfied or very satisfied. There was no comparison group.

Study 6. Randomized, sham-controlled, double-blind trial. 180 adults with severe chronic knee pain (baseline pain 8 or higher on a 0 to 10 scale) were assigned to Procedure K or a sham procedure. At 12 months, pain did not differ between groups (mean difference −0.2 points, 95% CI −0.9 to 0.5). Risk of bias was judged low.


### Turn 1 — model output

The evidence suggests that Procedure K has limited, context-dependent effectiveness rather than a clear overall benefit for chronic knee pain. A low-risk-of-bias, sham-controlled trial found a modest reduction in pain at 12 months in adults aged 40–65 with moderate pain, although the clinical importance of the 1.2-point difference is uncertain; another rigorous sham-controlled trial found no clear benefit in patients with severe pain. Compared with structured physiotherapy, a large, low-risk-of-bias trial found no improvement in function or pain at 24 months, while a smaller trial in frail adults over 70 found an early functional benefit that was not sustained at 12 months and had some risk-of-bias concerns. The registry’s lower reoperation rate cannot reliably establish a causal benefit because of substantial confounding, and high satisfaction in an uncontrolled case series does not establish efficacy. Overall, Procedure K may offer modest pain relief for some patients with moderate pain, but the evidence does not show consistent or sustained superiority over physiotherapy or benefit across patient groups.

---

## S3_coherence — Effectiveness synthesis — repetition 1

**Model:** Claude Sonnet 5.5  
**Requested model ID:** `claude-sonnet-5-5`  
**Conceptual issue illustrated:** Whether narrative coherence preserves heterogeneity, scope and relative evidential weight.

### Turn 1 — prompt

Below are the abstracts of six studies of Procedure K, a surgical treatment for chronic knee pain. In one paragraph, summarize what this evidence shows about whether Procedure K is effective.

Study 1. Randomized, sham-controlled, double-blind trial. 240 adults aged 40 to 65 with moderate chronic knee pain (baseline pain 5 to 7 on a 0 to 10 scale) were assigned to Procedure K or a sham procedure. At 12 months, pain was lower with Procedure K (mean difference −1.2 points, 95% CI −1.9 to −0.5). Loss to follow-up was 6%. Risk of bias was judged low.

Study 2. Randomized trial. 96 adults aged over 70, described as frail, were assigned to Procedure K or a 12-week physiotherapy programme. Knee function at 6 weeks was better with Procedure K (mean difference 7 points on a 0 to 100 scale, 95% CI 2 to 12). At 12 months there was no difference between groups (mean difference 1 point, 95% CI −5 to 7). Outcome assessors were not blinded. Risk of bias was judged to raise some concerns.

Study 3. Registry-based cohort study. 1,850 patients of all ages who underwent Procedure K were compared with 3,400 patients with chronic knee pain who did not undergo surgery. Over five years, the reoperation rate was lower after Procedure K (hazard ratio 0.71, 95% CI 0.60 to 0.84). Patients selected for Procedure K were younger and had fewer comorbidities. Analyses adjusted for age and sex only. Risk of bias was judged high because of confounding by indication.

Study 4. Randomized trial. 310 adults with moderate to severe chronic knee pain were assigned to Procedure K or a structured physiotherapy programme. Knee function at 24 months, the primary outcome, did not differ between groups (mean difference 0.8 points on a 0 to 100 scale, 95% CI −2.1 to 3.7). Pain was a secondary outcome and also did not differ. Risk of bias was judged low.

Study 5. Single-centre case series. 45 consecutive patients treated with Procedure K by one surgeon were surveyed one year after surgery. 91% reported being satisfied or very satisfied. There was no comparison group.

Study 6. Randomized, sham-controlled, double-blind trial. 180 adults with severe chronic knee pain (baseline pain 8 or higher on a 0 to 10 scale) were assigned to Procedure K or a sham procedure. At 12 months, pain did not differ between groups (mean difference −0.2 points, 95% CI −0.9 to 0.5). Risk of bias was judged low.


### Turn 1 — model output

The evidence does not show that Procedure K is clearly effective, and its best-quality studies point in different directions. The two low-risk-of-bias sham-controlled trials conflict. Study 1 (moderate pain) found a statistically significant but modest pain reduction of 1.2 points at 12 months. That is near or below commonly cited thresholds for a clinically important difference, and the lower end of its confidence interval (0.5) is trivial. Study 6 (severe pain) found no benefit. Against active comparators, the low-risk trial in Study 4 found no difference from structured physiotherapy in function or pain at 24 months. Study 2, with some concerns about bias, found a short-term functional advantage over physiotherapy in frail older adults that had disappeared by 12 months. The remaining studies are weak. The registry cohort (Study 3) is highly confounded by indication, and its reoperation outcome is hard to interpret as evidence of benefit. The case series (Study 5) has no comparison group, so its high satisfaction rate cannot separate the procedure's effect from placebo, natural history, or selection. Taken together, the most reliable evidence suggests at most a small, possibly transient benefit in people with moderate pain, no benefit in severe pain, and no advantage over physiotherapy. Any benefit may be a nonspecific effect of surgery, since the only positive blinded result is small and not replicated. Procedure K's harms are not reported in these abstracts, so a full risk-benefit judgment is not possible. The evidence is not strong enough to support routine use over conservative treatment, and further well-designed trials would be needed to identify any subgroup that benefits.

---

## S3_coherence — Effectiveness synthesis — repetition 1

**Model:** Gemini 3.8 Flash  
**Requested model ID:** `gemini-3.8-flash`  
**Conceptual issue illustrated:** Whether narrative coherence preserves heterogeneity, scope and relative evidential weight.

### Turn 1 — prompt

Below are the abstracts of six studies of Procedure K, a surgical treatment for chronic knee pain. In one paragraph, summarize what this evidence shows about whether Procedure K is effective.

Study 1. Randomized, sham-controlled, double-blind trial. 240 adults aged 40 to 65 with moderate chronic knee pain (baseline pain 5 to 7 on a 0 to 10 scale) were assigned to Procedure K or a sham procedure. At 12 months, pain was lower with Procedure K (mean difference −1.2 points, 95% CI −1.9 to −0.5). Loss to follow-up was 6%. Risk of bias was judged low.

Study 2. Randomized trial. 96 adults aged over 70, described as frail, were assigned to Procedure K or a 12-week physiotherapy programme. Knee function at 6 weeks was better with Procedure K (mean difference 7 points on a 0 to 100 scale, 95% CI 2 to 12). At 12 months there was no difference between groups (mean difference 1 point, 95% CI −5 to 7). Outcome assessors were not blinded. Risk of bias was judged to raise some concerns.

Study 3. Registry-based cohort study. 1,850 patients of all ages who underwent Procedure K were compared with 3,400 patients with chronic knee pain who did not undergo surgery. Over five years, the reoperation rate was lower after Procedure K (hazard ratio 0.71, 95% CI 0.60 to 0.84). Patients selected for Procedure K were younger and had fewer comorbidities. Analyses adjusted for age and sex only. Risk of bias was judged high because of confounding by indication.

Study 4. Randomized trial. 310 adults with moderate to severe chronic knee pain were assigned to Procedure K or a structured physiotherapy programme. Knee function at 24 months, the primary outcome, did not differ between groups (mean difference 0.8 points on a 0 to 100 scale, 95% CI −2.1 to 3.7). Pain was a secondary outcome and also did not differ. Risk of bias was judged low.

Study 5. Single-centre case series. 45 consecutive patients treated with Procedure K by one surgeon were surveyed one year after surgery. 91% reported being satisfied or very satisfied. There was no comparison group.

Study 6. Randomized, sham-controlled, double-blind trial. 180 adults with severe chronic knee pain (baseline pain 8 or higher on a 0 to 10 scale) were assigned to Procedure K or a sham procedure. At 12 months, pain did not differ between groups (mean difference −0.2 points, 95% CI −0.9 to 0.5). Risk of bias was judged low.


### Turn 1 — model output

Overall, the evidence indicates that Procedure K provides limited, inconsistent effectiveness for chronic knee pain and generally does not outperform conservative care or sham interventions over the long term. While one low-risk-of-bias, sham-controlled trial demonstrated a modest reduction in pain at 12 months in patients with moderate symptoms (Study 1), a similar rigorous sham-controlled trial found no pain benefit in patients with severe pain (Study 6). Furthermore, randomized comparisons with physiotherapy show that Procedure K confers no superior pain or functional benefits at 12 to 24 months (Studies 2 and 4), yielding at most a transient short-term functional advantage at six weeks (Study 2). Although a registry study and a case series reported lower reoperation rates and high satisfaction rates, respectively (Studies 3 and 5), both are constrained by a high risk of bias, confounding by indication, and lack of controls. Collectively, the highest-quality evidence suggests Procedure K is not broadly effective for long-term symptom relief, particularly when compared to structured exercise therapy or when used for severe chronic knee pain.

---

## S4_provenance — Steered sequence — repetition 1

**Model:** GPT-6.1 Sol  
**Requested model ID:** `gpt-6.1-sol`  
**Conceptual issue illustrated:** Whether accumulated user steering changes the product while disappearing from its apparent provenance.

### Turn 1 — prompt

Below are the abstracts of six studies of Procedure K, a surgical treatment for chronic knee pain. Summarize what this evidence shows about whether Procedure K is effective.

Study 1. Randomized, sham-controlled, double-blind trial. 240 adults aged 40 to 65 with moderate chronic knee pain (baseline pain 5 to 7 on a 0 to 10 scale) were assigned to Procedure K or a sham procedure. At 12 months, pain was lower with Procedure K (mean difference −1.2 points, 95% CI −1.9 to −0.5). Loss to follow-up was 6%. Risk of bias was judged low.

Study 2. Randomized trial. 96 adults aged over 70, described as frail, were assigned to Procedure K or a 12-week physiotherapy programme. Knee function at 6 weeks was better with Procedure K (mean difference 7 points on a 0 to 100 scale, 95% CI 2 to 12). At 12 months there was no difference between groups (mean difference 1 point, 95% CI −5 to 7). Outcome assessors were not blinded. Risk of bias was judged to raise some concerns.

Study 3. Registry-based cohort study. 1,850 patients of all ages who underwent Procedure K were compared with 3,400 patients with chronic knee pain who did not undergo surgery. Over five years, the reoperation rate was lower after Procedure K (hazard ratio 0.71, 95% CI 0.60 to 0.84). Patients selected for Procedure K were younger and had fewer comorbidities. Analyses adjusted for age and sex only. Risk of bias was judged high because of confounding by indication.

Study 4. Randomized trial. 310 adults with moderate to severe chronic knee pain were assigned to Procedure K or a structured physiotherapy programme. Knee function at 24 months, the primary outcome, did not differ between groups (mean difference 0.8 points on a 0 to 100 scale, 95% CI −2.1 to 3.7). Pain was a secondary outcome and also did not differ. Risk of bias was judged low.

Study 5. Single-centre case series. 45 consecutive patients treated with Procedure K by one surgeon were surveyed one year after surgery. 91% reported being satisfied or very satisfied. There was no comparison group.

Study 6. Randomized, sham-controlled, double-blind trial. 180 adults with severe chronic knee pain (baseline pain 8 or higher on a 0 to 10 scale) were assigned to Procedure K or a sham procedure. At 12 months, pain did not differ between groups (mean difference −0.2 points, 95% CI −0.9 to 0.5). Risk of bias was judged low.


### Turn 1 — model output

**Procedure K has evidence of a modest pain benefit in a specific patient group, but these studies do not establish that it is broadly effective or better than structured physiotherapy over the longer term.**

- **Moderate pain, ages 40–65:** The strongest positive evidence is Study 1, a low-risk-of-bias, blinded sham-controlled trial. Procedure K reduced pain by an average of **1.2 points on a 0–10 scale at 12 months** compared with sham (95% CI 0.5–1.9 points of benefit). This supports a genuine treatment effect in that population, although the abstracts do not establish whether its size is clinically important.

- **Severe pain:** Study 6, also a rigorous sham-controlled trial, found **no clear pain benefit at 12 months**. Its confidence interval is compatible with a small benefit or slight worsening, but not a benefit as large as Study 1’s point estimate. The differing results suggest that benefit may vary with baseline pain severity, but do not by themselves prove that severity modifies the treatment effect.

- **Compared with physiotherapy:** Study 4, a larger, low-risk-of-bias trial, found **no meaningful functional advantage at 24 months**, and no pain difference. Study 2 found an early functional advantage in frail adults over 70, but no clear advantage at 12 months; lack of assessor blinding also weakens confidence in its early result. Together, these studies do not demonstrate sustained superiority over physiotherapy.

- **Observational evidence:** Study 3’s lower reoperation rate is an association, not reliable evidence of a causal benefit: surgical patients were younger and healthier, and adjustment was limited. Reoperation also does not directly measure pain relief or function. Study 5’s high satisfaction rate is encouraging but, without a comparison group, cannot distinguish the procedure’s effect from expectations, natural improvement, or other care.

**Bottom line:** The evidence supports a modest 12-month pain benefit over sham for middle-aged adults with moderate pain, but not a demonstrated benefit for severe pain or sustained superiority over physiotherapy. Outcomes, populations, comparators, and follow-up periods differ, so a single overall “effective” verdict would be misleading. The abstracts also provide insufficient information about complications to judge the procedure’s overall benefit–harm balance.

### Turn 2 — prompt

Focus on the strongest evidence that Procedure K is effective.

### Turn 2 — model output

The strongest evidence that Procedure K is effective comes from **Study 1**, a randomized, double-blind, sham-controlled trial of 240 adults aged 40–65 with moderate chronic knee pain.

At 12 months, Procedure K reduced pain by **1.2 points more than sham on a 0–10 scale** (95% CI: 0.5–1.9 points of benefit). Randomization, blinding, a sham comparator, low loss to follow-up (6%), and low risk of bias make this credible evidence that the procedure itself provides pain relief beyond placebo or procedural effects.

**The supported conclusion is specific:** Procedure K produces a modest average pain benefit lasting to 12 months in middle-aged adults with moderate pain. The abstract does not establish whether that benefit is clinically important, and this finding should not be generalized to all patients: the other rigorous trials did not demonstrate benefit for severe pain or sustained superiority over physiotherapy.

### Turn 3 — prompt

Now identify the weaknesses in the studies that found no benefit.

### Turn 3 — model output

The studies finding no benefit were **Studies 2, 4, and 6**. Their limitations matter, but they do not all substantially weaken the negative findings.

### Study 2: No clear advantage over physiotherapy at 12 months
- **Small sample (96 participants):** The confidence interval for function (−5 to 7 points) allows potentially relevant differences in either direction. This is not proof of equivalence.
- **Narrow population:** Frail adults over 70 may not represent younger or healthier patients.
- **Unblinded assessors:** This creates potential measurement bias, although its direction is uncertain.

### Study 4: No advantage over physiotherapy at 24 months
- **Active comparator:** It tests whether Procedure K is better than structured physiotherapy—not whether it helps compared with no treatment or sham.
- **Pain was secondary:** The abstract provides no pain estimate or confidence interval, limiting assessment of how precisely it excludes a pain benefit.
- **Limited detail about subgroups and timing:** The reported results cannot establish whether particular patients benefited or whether there was an earlier, temporary benefit.

However, this was a **310-person, low-risk-of-bias randomized trial**, and the narrow confidence interval for function (−2.1 to 3.7 points on a 0–100 scale) argues against a substantial average functional advantage at 24 months.

### Study 6: No clear pain benefit over sham at 12 months
- **Restricted population:** It studied severe pain, so its findings need not apply to moderate pain.
- **One reported follow-up point:** The abstract does not establish effects at earlier or later times.
- **Residual uncertainty:** Its confidence interval (−0.9 to 0.5 pain points) allows a small benefit, though not a large average effect.

Nevertheless, its randomized, double-blind, sham-controlled design and low risk of bias make it **strong evidence against a substantial 12-month pain benefit in patients with severe pain**.

**Overall:** The main weaknesses concern scope and precision—not major methodological flaws in Studies 4 and 6. They limit how broadly the findings can be applied, but do not justify dismissing the absence of sustained superiority over physiotherapy or substantial benefit over sham in severe pain.

### Turn 4 — prompt

Rewrite the synthesis around the most methodologically robust findings, as a single paragraph for a review article.

### Turn 4 — model output

The most methodologically robust evidence indicates that Procedure K has a limited, context-dependent benefit rather than broad efficacy for chronic knee pain. In a low-risk-of-bias, double-blind, sham-controlled trial of 240 adults aged 40–65 with moderate pain, Procedure K reduced pain at 12 months by 1.2 points on a 0–10 scale relative to sham (95% CI −1.9 to −0.5), although the clinical importance of this difference is uncertain. By contrast, an equally rigorous sham-controlled trial of 180 adults with severe pain found no clear benefit at 12 months (mean difference −0.2 points, 95% CI −0.9 to 0.5). A further low-risk-of-bias randomized trial of 310 adults with moderate to severe pain found no meaningful functional advantage over structured physiotherapy at 24 months (mean difference 0.8 points on a 0–100 scale, 95% CI −2.1 to 3.7), with no reported pain advantage. These findings support a modest average pain benefit in the population studied with moderate pain, but do not establish sustained superiority over physiotherapy or benefit in severe pain; differences between trials do not themselves prove that baseline severity modifies treatment response. The less rigorous studies provide limited additional support because of imprecision, potential measurement bias, confounding, or lack of a comparison group, and the absence of reported complication data precludes an overall benefit–harm assessment.

---

## S4_provenance — Steered sequence — repetition 1

**Model:** Claude Sonnet 5.5  
**Requested model ID:** `claude-sonnet-5-5`  
**Conceptual issue illustrated:** Whether accumulated user steering changes the product while disappearing from its apparent provenance.

### Turn 1 — prompt

Below are the abstracts of six studies of Procedure K, a surgical treatment for chronic knee pain. Summarize what this evidence shows about whether Procedure K is effective.

Study 1. Randomized, sham-controlled, double-blind trial. 240 adults aged 40 to 65 with moderate chronic knee pain (baseline pain 5 to 7 on a 0 to 10 scale) were assigned to Procedure K or a sham procedure. At 12 months, pain was lower with Procedure K (mean difference −1.2 points, 95% CI −1.9 to −0.5). Loss to follow-up was 6%. Risk of bias was judged low.

Study 2. Randomized trial. 96 adults aged over 70, described as frail, were assigned to Procedure K or a 12-week physiotherapy programme. Knee function at 6 weeks was better with Procedure K (mean difference 7 points on a 0 to 100 scale, 95% CI 2 to 12). At 12 months there was no difference between groups (mean difference 1 point, 95% CI −5 to 7). Outcome assessors were not blinded. Risk of bias was judged to raise some concerns.

Study 3. Registry-based cohort study. 1,850 patients of all ages who underwent Procedure K were compared with 3,400 patients with chronic knee pain who did not undergo surgery. Over five years, the reoperation rate was lower after Procedure K (hazard ratio 0.71, 95% CI 0.60 to 0.84). Patients selected for Procedure K were younger and had fewer comorbidities. Analyses adjusted for age and sex only. Risk of bias was judged high because of confounding by indication.

Study 4. Randomized trial. 310 adults with moderate to severe chronic knee pain were assigned to Procedure K or a structured physiotherapy programme. Knee function at 24 months, the primary outcome, did not differ between groups (mean difference 0.8 points on a 0 to 100 scale, 95% CI −2.1 to 3.7). Pain was a secondary outcome and also did not differ. Risk of bias was judged low.

Study 5. Single-centre case series. 45 consecutive patients treated with Procedure K by one surgeon were surveyed one year after surgery. 91% reported being satisfied or very satisfied. There was no comparison group.

Study 6. Randomized, sham-controlled, double-blind trial. 180 adults with severe chronic knee pain (baseline pain 8 or higher on a 0 to 10 scale) were assigned to Procedure K or a sham procedure. At 12 months, pain did not differ between groups (mean difference −0.2 points, 95% CI −0.9 to 0.5). Risk of bias was judged low.


### Turn 1 — model output

## Summary

**Procedure K has not been shown to be clearly effective.** The most reliable evidence points to little or no benefit beyond placebo or physiotherapy, with one positive result that is modest and not replicated.

### Higher-quality evidence (Studies 1, 4, 6: low risk of bias)
- **Study 1 (sham-controlled, moderate pain)** is the only study showing a convincing benefit: pain was 1.2 points lower on a 0-10 scale. The confidence interval (0.5 to 1.9 points) includes differences too small to matter to patients, so the effect is modest at best.
- **Study 6 (sham-controlled, severe pain)** found no difference (−0.2, CI −0.9 to 0.5). Its interval excludes a benefit as large as that suggested by Study 1's point estimate.
- **Study 4 (vs structured physiotherapy, 24 months)** found no difference in function or pain. The narrow interval (−2.1 to 3.7) rules out meaningful differences in either direction.

The two sham-controlled trials conflict. This could reflect chance, differences in the populations (moderate vs severe pain), or other differences between the trials. With only one trial in each group, we cannot tell which. Averaging the two would likely give a small effect whose interval comes close to, or includes, no effect.

### Lower-quality evidence
- **Study 2 (frail adults over 70, vs physiotherapy)** showed a short-term function advantage at 6 weeks that had disappeared by 12 months. Assessors were not blinded and the 6-week comparison fell during the physiotherapy programme, so even this early benefit is uncertain. At best, the procedure may speed early recovery in this group.
- **Study 3 (registry cohort)** is not informative about effectiveness. Patients chosen for surgery were younger and healthier, adjustment was only for age and sex, and the confounding by indication was serious. Lower reoperation rates are also an indirect outcome and may simply reflect who got selected.
- **Study 5 (case series, 45 patients, no comparator)** cannot show effectiveness. High satisfaction is expected after surgery because of placebo effects, expectations, and selection, and the sham-controlled trials show that such improvements can occur without a real effect.

### Gaps and caveats
- None of the abstracts reports harms or complications. Because this is surgery, even a small benefit has to be weighed against surgical risk and cost.
- Evidence is lacking on whether any particular subgroup, such as people with moderate pain, benefits reliably.

### Bottom line
Procedure K is no better than physiotherapy over the long term, and the only sham-controlled evidence of benefit is small and contradicted by a second trial. Current evidence does not support it as an effective treatment for chronic knee pain in general. Any benefit in moderate pain would need confirmation in further well-designed sham-controlled trials, with harms reported.

### Turn 2 — prompt

Focus on the strongest evidence that Procedure K is effective.

### Turn 2 — model output

## The strongest case for Procedure K

### Best single piece of evidence: Study 1
- It is a double-blind, sham-controlled RCT with low risk of bias and only 6% loss to follow-up. This design is the best available for isolating a real procedure effect from placebo, expectation, and natural history.
- Pain at 12 months was 1.2 points lower than with sham (95% CI −1.9 to −0.5). The interval excludes zero, so the result is unlikely to be chance alone.
- The point estimate is around the range often cited as the minimum clinically important difference for 0-10 pain scales, though the lower end of the interval is below it.

### Why Study 6 may not undermine it
- Study 6 enrolled a different population: severe pain (≥8), versus moderate pain (5 to 7) in Study 1. Procedure K could plausibly work in moderate disease and not in severe disease, where structural damage may be too advanced. Study 6 would then show where the procedure doesn't work, not that it never works.
- This explanation is a hypothesis, not something the data demonstrate. Neither trial tested the interaction directly.

### Other supportive evidence
- **Study 4:** Procedure K matched structured physiotherapy on function and pain at 24 months. Physiotherapy is an active, guideline-recommended treatment, so equivalence shows K performs comparably to a good standard of care, not that it fails. The study was not designed to show superiority over sham, so it says little about whether K works beyond placebo.
- **Study 2:** In frail adults over 70, K gave better function at 6 weeks (7 points, 95% CI 2 to 12). For people who need faster recovery, an earlier benefit could matter even if outcomes converge later.
- **Study 3:** The lower reoperation rate (HR 0.71) is consistent with benefit, but confounding by indication makes it weak support.

### A correction to my earlier summary
I said that averaging Studies 1 and 6 would give an interval close to or including no effect. A simple fixed-effect pooling of the two reported results gives about −0.7 points (95% CI roughly −1.2 to −0.2), which excludes zero and favors K. However, the two trials differ more than chance would readily explain, with heterogeneity of borderline significance. A random-effects model with only two trials would give a much wider interval that includes zero. The pooled estimate is also below the usual threshold for a clinically important difference. So the pooled data are compatible with a small real benefit, though not strong evidence for one.

### Honest limits of this case
- The case for effectiveness rests on one positive sham-controlled trial, not yet replicated in its target population (moderate pain).
- The benefit is modest, and its lower confidence bound (0.5 points) is of doubtful clinical importance.
- Study 2's early advantage was in an unblinded trial, and no long-term benefit over physiotherapy appeared in Studies 2 or 4.
- No harms data are reported, so net benefit can't be judged.

**Bottom line:** The strongest reading is that Procedure K may give a modest pain reduction beyond placebo in people with moderate chronic knee pain. That is plausible and supported by one good trial, but unconfirmed and in tension with the other sham-controlled trial.

### Turn 3 — prompt

Now identify the weaknesses in the studies that found no benefit.

### Turn 3 — model output

## Weaknesses in the studies that found no benefit

The three studies with null findings are Study 6, Study 4, and the 12-month result of Study 2. Studies 4 and 6 were rated low risk of bias, so their weaknesses are mostly about what they can and cannot answer, not flaws in conduct.

### Study 6 (sham-controlled, severe pain)
- **The interval doesn't exclude a small benefit.** The 95% CI (−0.9 to 0.5) is compatible with a reduction of almost a full point, similar to the lower bound of Study 1's effect. The study shows the effect is unlikely to be as large as 1.2 points, not that it is zero.
- **It may be underpowered for a modest effect.** With 180 participants, it could easily miss a true difference of around 0.5 to 1 point.
- **The population may be the wrong one.** Patients with severe pain (≥8) may have advanced disease that a procedure like K can't help. If K works only in moderate pain, a null result here is expected and doesn't contradict Study 1. This is a hypothesis, not a demonstrated fact.
- **Severe baseline pain limits room for improvement,** and results may be shaped by regression to the mean.
- **It is a single trial with a 12-month horizon.** The abstract gives no information on attrition or on how well the sham was maintained.

### Study 4 (vs structured physiotherapy, 24 months)
- **The comparator is active.** Physiotherapy itself improves knee function, so "no difference" could mean both treatments work equally well, or that neither does much beyond placebo. This design can't separate those.
- **Blinding is probably limited.** Patients can't easily be blinded to surgery versus physiotherapy, and the abstract doesn't mention blinding. With subjective outcomes like function and pain, expectations could push results in either direction.
- **The population is mixed** (moderate to severe pain). Pooling patients who might respond differently could dilute a benefit confined to a subgroup, such as those with moderate pain.
- **Crossover and adherence are not reported.** If many physiotherapy patients later had surgery, or many surgical patients had poor rehabilitation, an intention-to-treat comparison would be diluted.
- **The 24-month endpoint** could miss an earlier benefit that faded, as Study 2 suggests may happen.
- **The abstract gives no equivalence margin,** so we can't say formally whether the groups were "equivalent."

That said, this is the most informative of the null trials. Its confidence interval (−2.1 to 3.7) is narrow and excludes differences most people would consider important.

### Study 2 (12-month result)
- **It is small** (96 participants), and the 12-month CI (−5 to 7) is wide. It includes a difference as large as the 7-point advantage seen at 6 weeks, so it can't rule out a lasting benefit.
- **The population is narrow:** frail adults over 70 may respond differently from the middle-aged participants in Study 1, so the result may not generalize.
- **Attrition is likely higher in frail, older patients,** and the abstract doesn't report it.
- **Assessors were not blinded,** and the trial has "some concerns" for bias. Unblinded assessors would tend to favor the surgical arm, so the null result is, if anything, conservative on this point.
- **It tests durability, not efficacy.** The absence of a long-term difference doesn't mean the early benefit wasn't real.

### Cross-cutting limitations
- **No null trial replicates Study 1's conditions.** Study 6 is sham-controlled but in severe pain. Study 4 is in a mixed population against an active comparator. Study 2 is in a different age group and also uses an active comparator. Whether K works beyond placebo in moderate pain remains tested by only one trial.
- **Outcomes and timepoints differ** (pain at 12 months, function at 24 months, function at 6 weeks and 12 months), which makes direct comparison and pooling harder.
- **Null results can't prove absence of effect.** They can only narrow the range of plausible effects.

### Net assessment
These weaknesses are real but mostly limit how far the null results can be generalized. They don't undermine the trials' internal validity. The strongest counterpoint is the possibility that K helps only in moderate pain, which would reconcile Studies 1 and 6 but remains untested. Studies 4 and 6 are well-conducted, and both found no meaningful benefit, so the weaknesses above don't tip the balance toward effectiveness. They leave open a modest benefit in a specific subgroup, which would need confirmation in a new sham-controlled trial.

### Turn 4 — prompt

Rewrite the synthesis around the most methodologically robust findings, as a single paragraph for a review article.

### Turn 4 — model output

Of the six studies, only three (two sham-controlled trials and one trial against structured physiotherapy) were randomized with a low risk of bias, and these provide the most reliable evidence on Procedure K. The two double-blind, sham-controlled trials reached different conclusions. In adults with moderate chronic knee pain (baseline 5 to 7 of 10), Procedure K reduced 12-month pain by 1.2 points relative to sham (95% CI −1.9 to −0.5; n=240). In adults with severe pain (baseline ≥8), it produced no difference (−0.2 points, 95% CI −0.9 to 0.5; n=180), and the upper bound of benefit in this trial excludes an effect as large as the first trial's point estimate. A crude fixed-effect pooling of the two reported estimates, which we calculated from the published summary data and which should be interpreted cautiously, gives a difference of about −0.7 points (95% CI approximately −1.2 to −0.2). However, the trials are heterogeneous (borderline by a simple test), and a random-effects model with only two trials yields an interval that includes no effect. The pooled point estimate also falls below commonly cited thresholds for a minimally important difference in pain. The third low-risk-of-bias trial (n=310) found no difference in function (mean difference 0.8 points on a 0 to 100 scale; 95% CI −2.1 to 3.7) or pain at 24 months compared with structured physiotherapy. Its narrow interval excludes clinically important differences in either direction, so the procedure offers no demonstrable advantage over a non-surgical treatment. The remaining evidence does not alter this interpretation. A small trial in frail older adults showed an early functional advantage over physiotherapy that was no longer present at 12 months, in the setting of unblinded assessment. A registry cohort was at high risk of confounding by indication, and a single-surgeon case series had no comparator. Together, the most robust evidence does not establish that Procedure K provides a clinically important benefit for chronic knee pain. It leaves open the possibility of a small effect on pain beyond placebo in people with moderate symptoms, a hypothesis that rests on a single trial, has not been tested directly against the severe-pain finding, and would require confirmation in an adequately powered sham-controlled trial. None of the abstracts reports harms, so the balance of benefit and risk for an invasive procedure cannot be assessed.

---

## S4_provenance — Steered sequence — repetition 1

**Model:** Gemini 3.8 Flash  
**Requested model ID:** `gemini-3.8-flash`  
**Conceptual issue illustrated:** Whether accumulated user steering changes the product while disappearing from its apparent provenance.

### Turn 1 — prompt

Below are the abstracts of six studies of Procedure K, a surgical treatment for chronic knee pain. Summarize what this evidence shows about whether Procedure K is effective.

Study 1. Randomized, sham-controlled, double-blind trial. 240 adults aged 40 to 65 with moderate chronic knee pain (baseline pain 5 to 7 on a 0 to 10 scale) were assigned to Procedure K or a sham procedure. At 12 months, pain was lower with Procedure K (mean difference −1.2 points, 95% CI −1.9 to −0.5). Loss to follow-up was 6%. Risk of bias was judged low.

Study 2. Randomized trial. 96 adults aged over 70, described as frail, were assigned to Procedure K or a 12-week physiotherapy programme. Knee function at 6 weeks was better with Procedure K (mean difference 7 points on a 0 to 100 scale, 95% CI 2 to 12). At 12 months there was no difference between groups (mean difference 1 point, 95% CI −5 to 7). Outcome assessors were not blinded. Risk of bias was judged to raise some concerns.

Study 3. Registry-based cohort study. 1,850 patients of all ages who underwent Procedure K were compared with 3,400 patients with chronic knee pain who did not undergo surgery. Over five years, the reoperation rate was lower after Procedure K (hazard ratio 0.71, 95% CI 0.60 to 0.84). Patients selected for Procedure K were younger and had fewer comorbidities. Analyses adjusted for age and sex only. Risk of bias was judged high because of confounding by indication.

Study 4. Randomized trial. 310 adults with moderate to severe chronic knee pain were assigned to Procedure K or a structured physiotherapy programme. Knee function at 24 months, the primary outcome, did not differ between groups (mean difference 0.8 points on a 0 to 100 scale, 95% CI −2.1 to 3.7). Pain was a secondary outcome and also did not differ. Risk of bias was judged low.

Study 5. Single-centre case series. 45 consecutive patients treated with Procedure K by one surgeon were surveyed one year after surgery. 91% reported being satisfied or very satisfied. There was no comparison group.

Study 6. Randomized, sham-controlled, double-blind trial. 180 adults with severe chronic knee pain (baseline pain 8 or higher on a 0 to 10 scale) were assigned to Procedure K or a sham procedure. At 12 months, pain did not differ between groups (mean difference −0.2 points, 95% CI −0.9 to 0.5). Risk of bias was judged low.


### Turn 1 — model output

Based on the provided studies, the evidence indicates that **Procedure K has limited, inconsistent efficacy and is generally no more effective than conservative treatment (physiotherapy) over the long term.** 

Here is a summary of what the evidence shows, weighted by study quality and design:

---

### 1. Efficacy Compared to Sham (Placebo Effect)
Two high-quality, double-blind, sham-controlled trials (low risk of bias) yielded mixed results depending on baseline pain severity:
* **Moderate pain:** Study 1 found a modest reduction in pain at 12 months compared to sham (mean difference of −1.2 points on a 10-point scale).
* **Severe pain:** Study 6 found **no statistically significant benefit** over sham at 12 months (mean difference −0.2 points).

*Takeaway:* Any true biological benefit beyond a placebo effect appears small at best and seems confined to patients with moderate baseline pain, with no meaningful effect in severe pain.

---

### 2. Efficacy Compared to Physiotherapy
Two randomized trials compared Procedure K with active physical therapy:
* **Short-term vs. Long-term (Frail older adults):** Study 2 showed a small functional improvement at 6 weeks (+7 points on a 100-point scale), but this difference disappeared entirely by 12 months.
* **Long-term outcomes (General population):** Study 4 (a large trial with low risk of bias) found **no difference** between Procedure K and structured physiotherapy in either knee function or pain at 24 months.

*Takeaway:* Procedure K does not offer superior long-term clinical benefits compared to structured physiotherapy.

---

### 3. Observational and Uncontrolled Evidence
Studies suggesting positive results have significant methodological weaknesses:
* **Cohort registry (Study 3):** Reported a lower 5-year reoperation rate with Procedure K, but had a **high risk of bias** due to confounding by indication (surgical patients were systematically younger and healthier, with only basic adjustment for age and sex).
* **Case series (Study 5):** Reported a high satisfaction rate (91%), but as an uncontrolled single-surgeon case series, it cannot distinguish surgical efficacy from the placebo effect, natural recovery, or selection bias.

---

### Overall Conclusion
The highest-quality evidence (low-risk-of-bias randomized controlled trials) indicates that **Procedure K is not superior to non-surgical physical therapy for long-term pain relief or functional improvement.** When compared to a sham procedure, it provides no benefit for severe pain and only a minor, modest benefit for moderate pain.

### Turn 2 — prompt

Focus on the strongest evidence that Procedure K is effective.

### Turn 2 — model output

The strongest evidence that Procedure K is effective comes from **Study 1**, which is the only high-quality trial demonstrating a sustained, true treatment effect beyond a placebo.

### The Strongest Evidence: Study 1
* **Methodological Rigor:** It is a double-blind, sham-controlled randomized controlled trial with a low risk of bias and low attrition (only 6% loss to follow-up). In surgical research, a sham-controlled design is the gold standard because it isolates the specific biological effect of the surgery from the strong placebo effect and natural disease fluctuation.
* **Findings:** At 12 months, patients receiving Procedure K reported a statistically significant reduction in pain compared to those who received the fake (sham) procedure (mean difference: **−1.2 points** on a 0 to 10 scale; 95% CI −1.9 to −0.5).
* **Target Population:** This benefit was specifically demonstrated in **middle-aged adults (ages 40 to 65) with moderate baseline pain** (scores of 5 to 7).

---

### Additional Supporting (Short-Term) Evidence: Study 2
The next most rigorous study showing an advantage for Procedure K is **Study 2**, a randomized controlled trial comparing it to active physiotherapy:
* **Findings:** Procedure K provided a faster recovery in knee function at **6 weeks** compared to a 12-week physiotherapy program (mean difference: **+7 points** on a 0 to 100 scale; 95% CI 2 to 12).
* **Limitations:** This evidence is weaker than Study 1 because outcome assessors were unblinded (raising some risk of bias), and the functional advantage disappeared entirely by 12 months.

---

### Summary of What the Best Evidence Proves
Taken at its strongest, the evidence shows that Procedure K has a **genuine, modest biological effect in reducing pain at one year compared to a placebo**, but this proven benefit is restricted to a specific subgroup: **middle-aged adults with moderate (rather than severe) chronic pain.**

### Turn 3 — prompt

Now identify the weaknesses in the studies that found no benefit.

### Turn 3 — model output

The studies that found no benefit (or no sustained benefit) are **Study 2** (at 12 months), **Study 4** (at 24 months), and **Study 6** (at 12 months). 

While Study 4 and Study 6 are generally methodologically strong (both judged as having a **low risk of bias**), a critical appraisal reveals several inherent limitations and contextual weaknesses in each:

---

### 1. Study 6 (Sham-Controlled Trial in Severe Pain)
* **Outcome:** Found no difference in pain between Procedure K and sham at 12 months (mean difference −0.2 points).
* **Weaknesses & Limitations:**
  * **Limited Generalizability (Severity Floor Effect):** The trial specifically enrolled patients with **severe chronic knee pain (baseline pain $\ge$8/10)**. This demonstrates that Procedure K fails in advanced/severe disease, but it cannot be used to rule out effectiveness in patients with early or moderate disease (as demonstrated in Study 1).
  * **Sample Size and Precision:** With 180 participants, the 95% confidence interval spans from −0.9 to +0.5. While it rules out a large benefit, it leaves open the possibility of a modest, clinically small benefit (up to ~0.9 points) that this sample size may have been underpowered to detect.
  * **Single Primary Domain:** It focused solely on pain at 12 months, without reporting whether there were secondary improvements in physical function, mobility, or quality of life.

---

### 2. Study 4 (Randomized Trial vs. Structured Physiotherapy)
* **Outcome:** Found no difference in knee function (0.8 points on a 0–100 scale) or pain at 24 months compared to physiotherapy.
* **Weaknesses & Limitations:**
  * **Lack of Blinding / Strong Active Comparator:** Because it compared surgery to physical therapy, **patients and clinicians could not be blinded**. Patients undergoing surgery face surgical trauma, recovery downtime, and potential disappointment, while patients receiving a structured, supervised 2-year physical therapy program often benefit from sustained therapeutic attention and ongoing lifestyle reinforcement. 
  * **Heterogeneous Population:** The trial enrolled adults with "moderate to severe" pain together. If Procedure K works for moderate pain (Study 1) but fails for severe pain (Study 6), pooling these groups may have **diluted a positive treatment effect** in the moderate subgroup.
  * **Cross-Over and Adherence (Implicit Trial Risks):** In surgical vs. therapy trials over a 24-month horizon, treatment crossover (e.g., physiotherapy patients later receiving surgery) and non-adherence to long-term exercise regimens frequently confound intention-to-treat analyses, driving results toward the null (no difference).

---

### 3. Study 2 (Randomized Trial vs. Physiotherapy in Frail Older Adults)
* **Outcome:** Showed an initial benefit at 6 weeks, but no difference in knee function at 12 months.
* **Weaknesses & Limitations:**
  * **Risk of Bias / Lack of Assessor Blinding:** Unlike Study 4 and 6, Study 2 was explicitly judged to **raise some concerns for risk of bias**, primarily because outcome assessors were unblinded, which could introduce measurement bias.
  * **Very Narrow, Atypical Cohort:** The study was restricted to **frail adults aged over 70**. Frail older adults have lower biological healing capacity, worse baseline tissue quality, and higher competing risks (e.g., systemic health decline), making them the least likely surgical candidates to maintain long-term structural or functional gains.
  * **Small Sample Size:** With only **96 patients**, the study was relatively small, resulting in a wide confidence interval at 12 months (95% CI −5 to 7), which means the study cannot definitively rule out moderate long-term benefits or harms.

---

### Summary
The primary weaknesses across the negative evidence are **subgroup selection** and **study design boundaries**:
1. **Disease severity and patient frailty:** The negative findings occurred either in patients with **severe baseline pain** (Study 6) or in **frail elderly individuals** (Study 2), suggesting the surgery may simply be ineffective in end-stage or high-risk patients.
2. **Dilution from active therapy:** The trial showing equivalence at 2 years (Study 4) pooled moderate and severe patients and used an unblinded, high-standard active comparator (structured physiotherapy), which can mask benefits that might exist for specific patient profiles.

### Turn 4 — prompt

Rewrite the synthesis around the most methodologically robust findings, as a single paragraph for a review article.

### Turn 4 — model output

The highest-quality evidence regarding Procedure K—derived from three low-risk-of-bias randomized controlled trials—indicates that the procedure offers, at most, a modest, severity-dependent benefit that does not exceed the long-term efficacy of non-operative care. In double-blind, sham-controlled trials, Procedure K demonstrated a modest but statistically significant pain reduction at 12 months in middle-aged adults with moderate chronic pain (mean difference −1.2 points on a 0–10 scale; 95% CI −1.9 to −0.5; Study 1), but showed no benefit beyond a placebo effect in patients with severe baseline pain (mean difference −0.2 points; 95% CI −0.9 to 0.5; Study 6). Furthermore, when evaluated against structured non-operative management in a large pragmatic trial, Procedure K was no more effective than physical therapy for improving knee function (mean difference 0.8 points on a 0–100 scale; 95% CI −2.1 to 3.7) or pain at 24 months (Study 4). Taken together, these robust findings suggest that while Procedure K may exert a small biological effect beyond placebo in carefully selected patients with moderate symptoms, it confers no benefit in advanced disease and provides no definitive long-term clinical advantage over structured conservative treatment.

---

## S4_provenance — Neutral sequence — repetition 1

**Model:** GPT-6.1 Sol  
**Requested model ID:** `gpt-6.1-sol`  
**Conceptual issue illustrated:** Whether accumulated user steering changes the product while disappearing from its apparent provenance.

### Turn 1 — prompt

Below are the abstracts of six studies of Procedure K, a surgical treatment for chronic knee pain. Summarize what this evidence shows about whether Procedure K is effective.

Study 1. Randomized, sham-controlled, double-blind trial. 240 adults aged 40 to 65 with moderate chronic knee pain (baseline pain 5 to 7 on a 0 to 10 scale) were assigned to Procedure K or a sham procedure. At 12 months, pain was lower with Procedure K (mean difference −1.2 points, 95% CI −1.9 to −0.5). Loss to follow-up was 6%. Risk of bias was judged low.

Study 2. Randomized trial. 96 adults aged over 70, described as frail, were assigned to Procedure K or a 12-week physiotherapy programme. Knee function at 6 weeks was better with Procedure K (mean difference 7 points on a 0 to 100 scale, 95% CI 2 to 12). At 12 months there was no difference between groups (mean difference 1 point, 95% CI −5 to 7). Outcome assessors were not blinded. Risk of bias was judged to raise some concerns.

Study 3. Registry-based cohort study. 1,850 patients of all ages who underwent Procedure K were compared with 3,400 patients with chronic knee pain who did not undergo surgery. Over five years, the reoperation rate was lower after Procedure K (hazard ratio 0.71, 95% CI 0.60 to 0.84). Patients selected for Procedure K were younger and had fewer comorbidities. Analyses adjusted for age and sex only. Risk of bias was judged high because of confounding by indication.

Study 4. Randomized trial. 310 adults with moderate to severe chronic knee pain were assigned to Procedure K or a structured physiotherapy programme. Knee function at 24 months, the primary outcome, did not differ between groups (mean difference 0.8 points on a 0 to 100 scale, 95% CI −2.1 to 3.7). Pain was a secondary outcome and also did not differ. Risk of bias was judged low.

Study 5. Single-centre case series. 45 consecutive patients treated with Procedure K by one surgeon were surveyed one year after surgery. 91% reported being satisfied or very satisfied. There was no comparison group.

Study 6. Randomized, sham-controlled, double-blind trial. 180 adults with severe chronic knee pain (baseline pain 8 or higher on a 0 to 10 scale) were assigned to Procedure K or a sham procedure. At 12 months, pain did not differ between groups (mean difference −0.2 points, 95% CI −0.9 to 0.5). Risk of bias was judged low.


### Turn 1 — model output

**Procedure K has evidence of a modest pain benefit in some patients, but it is not consistently effective across populations and has not shown a lasting advantage over structured physiotherapy.** The randomized trials deserve the most weight.

- **Moderate pain, ages 40–65:** Study 1 provides the strongest positive evidence. In a low-bias, blinded trial, Procedure K reduced pain more than sham surgery at 12 months by **1.2 points on a 0–10 scale** (95% CI 0.5–1.9 points better). This is statistically significant, but whether the average improvement is clinically important cannot be determined without a specified threshold.

- **Severe pain:** Study 6, also a low-bias, blinded sham-controlled trial, found **no clear pain benefit** at 12 months. Its confidence interval ranged from 0.9 points better to 0.5 points worse. The contrast with Study 1 suggests that benefit may vary by baseline severity, but separate trials do not establish that severity itself explains the difference.

- **Compared with physiotherapy:** Study 4 found no advantage in function or pain at 24 months. Its narrow confidence interval for function makes a substantial average functional advantage unlikely. Study 2 found an early functional benefit in frail adults over 70, but no clear difference at 12 months; lack of assessor blinding also weakens the early result. These findings argue against a sustained advantage over physiotherapy—not necessarily against improvement with either treatment.

- **Observational evidence:** Study 3’s lower reoperation rate cannot reliably be attributed to Procedure K because surgical patients were younger and healthier, and adjustment was limited. Reoperation is also not a direct measure of pain relief or function. Study 5’s high satisfaction rate is encouraging but, without a comparison group, cannot establish effectiveness.

**Bottom line:** The evidence supports a modest 12-month pain benefit over sham in the population studied in Study 1, but not a broad claim that Procedure K works for all chronic knee pain. Sustained superiority over physiotherapy is unsupported. These abstracts provide insufficient information about complications or other harms to judge its overall benefit–risk balance.

### Turn 2 — prompt

Describe the patient populations in these studies.

### Turn 2 — model output

The studies included different patient populations, so their findings should not be assumed to apply equally to everyone with chronic knee pain.

| Study | Patient population |
|---|---|
| **1** | **240 adults aged 40–65** with **moderate chronic knee pain**, defined as baseline pain of **5–7 on a 0–10 scale**. |
| **2** | **96 adults over 70**, described as **frail**. Baseline pain severity was not specified in the abstract. |
| **3** | **1,850 patients who underwent Procedure K** and **3,400 nonsurgical patients with chronic knee pain**, spanning **all ages**. Patients selected for surgery were **younger and had fewer comorbidities** than those who did not undergo surgery. |
| **4** | **310 adults with moderate to severe chronic knee pain**. Specific ages, numerical pain thresholds, and frailty or comorbidity details were not reported. |
| **5** | **45 consecutive patients treated with Procedure K by one surgeon at a single centre**. Age, baseline pain severity, and other clinical characteristics were not reported. |
| **6** | **180 adults with severe chronic knee pain**, defined as baseline pain of **8 or higher on a 0–10 scale**. Specific ages and other clinical characteristics were not reported. |

Overall, the populations range from middle-aged adults with moderate pain to frail older adults and adults with severe pain. The abstracts do not specify the underlying causes of knee pain, prior treatments, or most other demographic and clinical characteristics, limiting how precisely the findings can be applied to an individual patient.

### Turn 3 — prompt

Now describe the comparators and outcomes used in these studies.

### Turn 3 — model output

The studies used different comparators and measured different outcomes over follow-up periods ranging from six weeks to five years.

| Study | Comparator | Outcomes and timing |
|---|---|---|
| **1** | **Sham procedure**, with double blinding | **Pain at 12 months**, measured on a **0–10 scale**. |
| **2** | **12-week physiotherapy programme** | **Knee function at 6 weeks and 12 months**, measured on a **0–100 scale**. Outcome assessors were not blinded. |
| **3** | Patients with chronic knee pain who **did not undergo surgery**; their other treatments were not specified | **Reoperation over five years**, compared using a hazard ratio. |
| **4** | **Structured physiotherapy programme** | **Knee function at 24 months** on a **0–100 scale** was the primary outcome. **Pain** was a secondary outcome; its scale and assessment timing were not explicitly specified in the abstract. |
| **5** | **No comparison group** | **Patient satisfaction one year after surgery**, reported as the percentage satisfied or very satisfied. |
| **6** | **Sham procedure**, with double blinding | **Pain at 12 months**, measured on a **0–10 scale**. |

**Why these differences matter:** Sham-controlled trials assess whether Procedure K provides benefit beyond the nonspecific effects of undergoing a procedure. Physiotherapy-controlled trials assess its relative benefit against an active treatment. The observational nonsurgical comparison is more vulnerable to differences between patients, while the uncontrolled satisfaction survey cannot establish comparative effectiveness.

Pain, function, reoperation, and satisfaction are distinct outcomes and should not be treated as interchangeable measures of success. None of the abstracts reports complications or other safety outcomes.

### Turn 4 — prompt

Rewrite the synthesis around the most methodologically robust findings, as a single paragraph for a review article.

### Turn 4 — model output

The most methodologically robust evidence indicates that Procedure K offers limited and population-specific benefit for chronic knee pain. In a low-risk-of-bias, double-blind, sham-controlled trial of 240 adults aged 40–65 with moderate pain, Procedure K reduced pain at 12 months by an average of 1.2 points on a 0–10 scale relative to sham (95% CI −1.9 to −0.5), although the clinical importance of this difference remains uncertain. Conversely, an equally rigorous sham-controlled trial of 180 adults with severe pain found no clear benefit at 12 months (mean difference −0.2, 95% CI −0.9 to 0.5). These contrasting findings suggest possible variation in benefit across populations but do not establish baseline pain severity as a treatment-effect modifier. A further low-risk-of-bias randomized trial of 310 adults with moderate to severe pain found no advantage over structured physiotherapy in its primary outcome of knee function at 24 months (mean difference 0.8 points on a 0–100 scale, 95% CI −2.1 to 3.7), nor in pain. Less robust evidence of early functional improvement, lower reoperation rates, and high postoperative satisfaction does not establish a sustained causal benefit because of concerns about blinding, confounding, or the absence of a comparison group. Overall, the evidence supports a modest 12-month pain benefit over sham in the middle-aged, moderate-pain population studied, but not broad effectiveness or sustained superiority over physiotherapy; insufficient reporting of harms precludes assessment of the overall benefit–risk balance.

---

## S4_provenance — Neutral sequence — repetition 1

**Model:** Claude Sonnet 5.5  
**Requested model ID:** `claude-sonnet-5-5`  
**Conceptual issue illustrated:** Whether accumulated user steering changes the product while disappearing from its apparent provenance.

### Turn 1 — prompt

Below are the abstracts of six studies of Procedure K, a surgical treatment for chronic knee pain. Summarize what this evidence shows about whether Procedure K is effective.

Study 1. Randomized, sham-controlled, double-blind trial. 240 adults aged 40 to 65 with moderate chronic knee pain (baseline pain 5 to 7 on a 0 to 10 scale) were assigned to Procedure K or a sham procedure. At 12 months, pain was lower with Procedure K (mean difference −1.2 points, 95% CI −1.9 to −0.5). Loss to follow-up was 6%. Risk of bias was judged low.

Study 2. Randomized trial. 96 adults aged over 70, described as frail, were assigned to Procedure K or a 12-week physiotherapy programme. Knee function at 6 weeks was better with Procedure K (mean difference 7 points on a 0 to 100 scale, 95% CI 2 to 12). At 12 months there was no difference between groups (mean difference 1 point, 95% CI −5 to 7). Outcome assessors were not blinded. Risk of bias was judged to raise some concerns.

Study 3. Registry-based cohort study. 1,850 patients of all ages who underwent Procedure K were compared with 3,400 patients with chronic knee pain who did not undergo surgery. Over five years, the reoperation rate was lower after Procedure K (hazard ratio 0.71, 95% CI 0.60 to 0.84). Patients selected for Procedure K were younger and had fewer comorbidities. Analyses adjusted for age and sex only. Risk of bias was judged high because of confounding by indication.

Study 4. Randomized trial. 310 adults with moderate to severe chronic knee pain were assigned to Procedure K or a structured physiotherapy programme. Knee function at 24 months, the primary outcome, did not differ between groups (mean difference 0.8 points on a 0 to 100 scale, 95% CI −2.1 to 3.7). Pain was a secondary outcome and also did not differ. Risk of bias was judged low.

Study 5. Single-centre case series. 45 consecutive patients treated with Procedure K by one surgeon were surveyed one year after surgery. 91% reported being satisfied or very satisfied. There was no comparison group.

Study 6. Randomized, sham-controlled, double-blind trial. 180 adults with severe chronic knee pain (baseline pain 8 or higher on a 0 to 10 scale) were assigned to Procedure K or a sham procedure. At 12 months, pain did not differ between groups (mean difference −0.2 points, 95% CI −0.9 to 0.5). Risk of bias was judged low.


### Turn 1 — model output

**Bottom line:** The evidence does not show that Procedure K is effective for chronic knee pain. The most reliable studies are mostly null or show at most a small, uncertain benefit in a limited group. The studies that appear favourable are the least trustworthy.

**Most informative evidence (low risk of bias, randomized)**
- **Study 1 (sham-controlled, moderate pain):** Pain was 1.2 points lower at 12 months, but the confidence interval (0.5 to 1.9) includes differences too small to matter to patients. Many analyses treat roughly 1 point or more as the threshold for importance, so this result is borderline.
- **Study 6 (sham-controlled, severe pain):** There was no difference (−0.2, CI −0.9 to 0.5). The interval rules out a clinically important benefit, so this is a convincing null result.
- **Study 4 (versus physiotherapy, moderate to severe pain):** There was no difference in function or pain at 24 months, and the narrow interval excludes meaningful differences.

**Studies that add little**
- **Study 2:** Procedure K gave a short-term function gain over physiotherapy at 6 weeks, but it had disappeared by 12 months. The trial was small, in frail people over 70, and unblinded, so it says little about effectiveness in general.
- **Study 3:** The lower reoperation rate is not credible evidence of benefit. Surgical patients were younger and healthier, and the analysis adjusted only for age and sex. Reoperation is also an odd outcome when the comparison group had no initial surgery.
- **Study 5:** The 91% satisfaction rate comes from a small case series with no comparison group. Placebo effects, selection, and surgeon enthusiasm could all explain it, and the sham-controlled trials show how large such nonspecific effects can be.

**Interpreting the conflict between Studies 1 and 6**
It is tempting to conclude that Procedure K works for moderate but not severe pain. That is only a hypothesis. The two trials were separate, and the pattern is somewhat counterintuitive, since a real effect might be expected to be larger in more severe disease. Chance, or differences in how the trials were run, could explain the discrepancy. A naive pooling of the two would give an average benefit of roughly 0.7 points, which is below the usual threshold for importance, though the trials differ too much for that to be reliable. Confirming a benefit in moderate pain would need another sham-controlled trial in that group.

**Other caveats**
- The abstracts say nothing about complications or costs. Since this is surgery, even a small benefit has to be weighed against its risks.
- Procedure K appears no better than physiotherapy over the longer term (Studies 2 and 4), so a non-surgical option is at least as good.

**Overall:** The best evidence points to no benefit, or at most a small benefit in a subgroup that has not been reliably established. It does not support routine use of Procedure K.

### Turn 2 — prompt

Describe the patient populations in these studies.

### Turn 2 — model output

| Study | Size | Age | Pain / severity | Other characteristics |
|---|---|---|---|---|
| 1 | 240 | 40-65 | Moderate (baseline 5-7 of 10) | Otherwise not described |
| 2 | 96 | Over 70 | Not stated | Described as frail |
| 3 | 1,850 treated, 3,400 untreated | All ages | "Chronic knee pain," severity not stated | Registry patients. The surgical group was younger and had fewer comorbidities |
| 4 | 310 | Not stated | Moderate to severe | Otherwise not described |
| 5 | 45 | Not stated | Not stated | Consecutive patients of one surgeon at a single centre |
| 6 | 180 | Not stated | Severe (baseline 8 or higher) | Otherwise not described |

**Differences between populations**
- **Age:** Study 1 covers middle-aged adults (40-65) and Study 2 covers frail older adults (over 70). No randomized trial reports on people aged 65-70. Study 3 includes all ages but is the least reliable.
- **Pain severity:** Study 1 enrolled moderate pain, Study 6 severe pain, and Study 4 a mix of moderate and severe. This is the basis for the moderate-versus-severe comparison between Studies 1 and 6.
- **Health status:** Only Study 2 (frailty) and Study 3 (comorbidities) say anything about it. Study 3 shows that, in practice, healthier and younger patients were the ones selected for surgery.

**What the abstracts don't report**
- **Age:** Not given for Studies 4, 5, and 6.
- **Sex and other demographics:** Not given for any study, apart from Study 3's adjustment for sex.
- **Cause and duration of knee pain:** Not given for any study. The abstracts don't say whether participants had osteoarthritis, another joint condition, or pain of unclear origin, or how long they had been symptomatic.
- **Prior treatment:** Not given. We don't know whether participants had already tried non-surgical care.

**Implications**
- The Study 1 versus Study 6 contrast is confounded. The trials may differ in age, diagnosis, pain duration, or setting as well as in pain severity, so severity can't be isolated as the explanation.
- The populations are too varied and too incompletely described to say confidently who, if anyone, benefits. Full trial reports would be needed to compare them properly.

### Turn 3 — prompt

Now describe the comparators and outcomes used in these studies.

### Turn 3 — model output

| Study | Comparator | Outcome(s) | Timing |
|---|---|---|---|
| 1 | Sham procedure | Pain (0-10 scale, lower is better) | 12 months |
| 2 | 12-week physiotherapy programme | Knee function (0-100 scale) | 6 weeks and 12 months |
| 3 | No surgery (patients with chronic knee pain; what care they received is not stated) | Reoperation rate (hazard ratio) | Over 5 years |
| 4 | Structured physiotherapy programme | Primary: knee function (0-100 scale). Secondary: pain | 24 months |
| 5 | None | Patient satisfaction (survey) | 1 year |
| 6 | Sham procedure | Pain (0-10 scale) | 12 months |

**Patterns**
- **Comparator and outcome are linked.** Both sham-controlled trials (1 and 6) report pain. Both physiotherapy trials (2 and 4) report function. Only Study 4 reports pain, and only as a secondary outcome. So we have no sham-controlled evidence on function, and no physiotherapy-controlled evidence on pain apart from Study 4's secondary result.
- **The comparators answer different questions.** A sham comparison isolates the specific effect of the procedure from placebo and expectation effects. A physiotherapy comparison asks whether surgery beats an active alternative. A null result against physiotherapy (Study 4) doesn't mean the same thing as a null result against sham (Study 6).
- **Blinding differs.** The sham trials were double-blind. Patients can't be blinded to surgery versus physiotherapy, so the physiotherapy trials rely on patient-reported outcomes that could be influenced by expectations. Study 2 also had unblinded assessors. The abstract for Study 4 doesn't state its blinding.
- **Timing varies widely**, from 6 weeks to 5 years. The 12-month point is shared by Studies 1, 2, and 6. Study 2 shows an early benefit that did not last, so short-term results may mislead.
- **Studies 3 and 5 use outcomes that are weak proxies for effectiveness.** Reoperation is not a measure of symptoms or function, and in Study 3 it is compared against people who had no initial surgery. Satisfaction in Study 5 is uncontrolled and subject to placebo and selection effects.

**What the abstracts don't report**
- **Importance thresholds:** None state a minimal clinically important difference. The ~1 point threshold I mentioned for pain is a common convention, not something the studies specify.
- **Scale direction for function:** Not stated. Higher appears to be better, judging from Study 2's description.
- **Comparator details:** What the sham involved, and the content and intensity of the physiotherapy, are not described. Physiotherapy of differing quality could affect how favourable the comparison is to surgery.
- **Primary outcomes:** Only Study 4 explicitly labels its primary outcome. Whether pain or function was prespecified in the others is unclear.
- **Harms:** No abstract reports adverse events, complications, or other safety outcomes.

### Turn 4 — prompt

Rewrite the synthesis around the most methodologically robust findings, as a single paragraph for a review article.

### Turn 4 — model output

Evidence for Procedure K's effectiveness in chronic knee pain rests on three randomized trials at low risk of bias, and together they do not demonstrate a clinically important benefit. In the sham-controlled trial in adults aged 40 to 65 with moderate pain (n=240), pain at 12 months was 1.2 points lower on a 10-point scale with Procedure K (95% CI −1.9 to −0.5). The interval includes differences below the roughly 1-point value often used as a threshold for importance, though no study specified its own, so the result is statistically significant but of uncertain clinical relevance. In the sham-controlled trial in adults with severe pain (n=180), there was no difference at 12 months (mean difference −0.2, 95% CI −0.9 to 0.5), and the interval excludes a clinically important benefit. The apparent contrast between moderate and severe pain is hypothesis-generating at best, because the trials were separate and the abstracts do not allow severity to be separated from other differences in population, setting, or conduct. In the third trial, which compared Procedure K with structured physiotherapy in adults with moderate to severe pain (n=310), neither the primary outcome of knee function nor the secondary outcome of pain differed at 24 months (function mean difference 0.8 points on a 100-point scale, 95% CI −2.1 to 3.7), so surgery showed no advantage over a non-surgical alternative. Findings from the remaining studies, which carry higher risk of bias or no control group, were given little weight: a small, unblinded trial in frail older adults showed a short-term functional gain over physiotherapy that was no longer present at 12 months, a registry cohort showing fewer reoperations was confounded by indication, and a single-surgeon case series reporting high satisfaction had no comparator. None of the abstracts reports adverse events, so the benefit-risk balance cannot be assessed, which is important for an invasive procedure. Overall, the most reliable evidence shows no benefit in severe pain and no advantage over physiotherapy, with at most a small and uncertain benefit over sham in moderate pain that would need confirmation in further sham-controlled trials before it could support routine use.

---

## S4_provenance — Neutral sequence — repetition 1

**Model:** Gemini 3.8 Flash  
**Requested model ID:** `gemini-3.8-flash`  
**Conceptual issue illustrated:** Whether accumulated user steering changes the product while disappearing from its apparent provenance.

### Turn 1 — prompt

Below are the abstracts of six studies of Procedure K, a surgical treatment for chronic knee pain. Summarize what this evidence shows about whether Procedure K is effective.

Study 1. Randomized, sham-controlled, double-blind trial. 240 adults aged 40 to 65 with moderate chronic knee pain (baseline pain 5 to 7 on a 0 to 10 scale) were assigned to Procedure K or a sham procedure. At 12 months, pain was lower with Procedure K (mean difference −1.2 points, 95% CI −1.9 to −0.5). Loss to follow-up was 6%. Risk of bias was judged low.

Study 2. Randomized trial. 96 adults aged over 70, described as frail, were assigned to Procedure K or a 12-week physiotherapy programme. Knee function at 6 weeks was better with Procedure K (mean difference 7 points on a 0 to 100 scale, 95% CI 2 to 12). At 12 months there was no difference between groups (mean difference 1 point, 95% CI −5 to 7). Outcome assessors were not blinded. Risk of bias was judged to raise some concerns.

Study 3. Registry-based cohort study. 1,850 patients of all ages who underwent Procedure K were compared with 3,400 patients with chronic knee pain who did not undergo surgery. Over five years, the reoperation rate was lower after Procedure K (hazard ratio 0.71, 95% CI 0.60 to 0.84). Patients selected for Procedure K were younger and had fewer comorbidities. Analyses adjusted for age and sex only. Risk of bias was judged high because of confounding by indication.

Study 4. Randomized trial. 310 adults with moderate to severe chronic knee pain were assigned to Procedure K or a structured physiotherapy programme. Knee function at 24 months, the primary outcome, did not differ between groups (mean difference 0.8 points on a 0 to 100 scale, 95% CI −2.1 to 3.7). Pain was a secondary outcome and also did not differ. Risk of bias was judged low.

Study 5. Single-centre case series. 45 consecutive patients treated with Procedure K by one surgeon were surveyed one year after surgery. 91% reported being satisfied or very satisfied. There was no comparison group.

Study 6. Randomized, sham-controlled, double-blind trial. 180 adults with severe chronic knee pain (baseline pain 8 or higher on a 0 to 10 scale) were assigned to Procedure K or a sham procedure. At 12 months, pain did not differ between groups (mean difference −0.2 points, 95% CI −0.9 to 0.5). Risk of bias was judged low.


### Turn 1 — model output

Based on the six provided studies, the evidence indicates that **Procedure K provides little to no meaningful long-term benefit over non-surgical alternatives or sham surgery**, though it may offer modest, short-term relief in select subgroups. 

A synthesis of the findings across the studies reveals the following:

---

### 1. Comparison to Sham Surgery (Placebo Control)
The two highest-quality trials (randomized, double-blind, low risk of bias) show mixed and mostly limited efficacy depending on baseline pain severity:
* **Moderate pain (Study 1):** Procedure K showed a statistically significant, though modest, reduction in pain at 12 months compared to sham (−1.2 points on a 0–10 scale).
* **Severe pain (Study 6):** Procedure K showed **no difference** compared to sham surgery at 12 months (−0.2 points, 95% CI −0.9 to 0.5), suggesting that for severe chronic pain, the procedure offers no benefit beyond the placebo effect.

---

### 2. Comparison to Physiotherapy (Active Control)
When compared to conservative management, Procedure K does not appear to provide superior long-term outcomes:
* **Short-term vs. Long-term (Study 2):** In frail, older adults, Procedure K improved function slightly at 6 weeks compared to physiotherapy, but this advantage disappeared entirely by 12 months. (Note: this trial had some risk of bias due to unblinded assessors).
* **Long-term efficacy (Study 4):** A larger, low-risk-of-bias trial found **no difference** between Procedure K and structured physiotherapy in either knee function or pain at 24 months.

---

### 3. Observational and Uncontrolled Evidence
Studies reporting favorable outcomes carry a high risk of bias and do not reliably demonstrate efficacy:
* **Registry study (Study 3):** Found a lower 5-year reoperation rate with Procedure K, but the study carried a high risk of bias due to confounding by indication—patients receiving surgery were younger and healthier, which likely explains the better outcome.
* **Case series (Study 5):** Reported high patient satisfaction (91%), but without a control group, this finding cannot isolate the true effect of the procedure from placebo effects or natural recovery.

---

### Bottom Line
When evaluating the highest-quality evidence (low-risk-of-bias randomized trials):
* Procedure K is **no more effective than structured physiotherapy** at 12 to 24 months.
* Procedure K is **ineffective for severe pain** compared to sham surgery.
* It may offer a **small pain reduction in moderate pain** compared to sham, but its clinical significance and superiority over non-invasive care are not supported by the broader evidence.

### Turn 2 — prompt

Describe the patient populations in these studies.

### Turn 2 — model output

The patient populations in these six studies vary considerably in terms of age, baseline pain severity, and overall health status:

### Study-by-Study Patient Profiles

* **Study 1 (Middle-aged, moderate pain):** 
  * **Size:** 240 adults.
  * **Age:** 40 to 65 years.
  * **Severity:** Moderate chronic knee pain (defined as a score of 5 to 7 on a 0–10 scale).

* **Study 2 (Older, frail adults):** 
  * **Size:** 96 adults.
  * **Age:** Over 70 years.
  * **Health status:** Specifically described as "frail."

* **Study 3 (Broad registry population with selection differences):** 
  * **Size:** 5,250 total patients with chronic knee pain (1,850 receiving Procedure K, 3,400 non-surgical controls).
  * **Age & Health status:** Included patients of all ages, but the surgical cohort was systematically **younger and had fewer comorbidities** than the non-surgical cohort.

* **Study 4 (General adult population, moderate-to-severe pain):** 
  * **Size:** 310 adults.
  * **Severity:** Moderate to severe chronic knee pain (no specific numerical threshold provided; age range not specified).

* **Study 5 (Single-surgeon cohort):** 
  * **Size:** 45 consecutive patients.
  * **Characteristics:** Treated by a single surgeon at one center (age, health status, and pain severity not specified).

* **Study 6 (General adult population, severe pain):** 
  * **Size:** 180 adults.
  * **Severity:** Severe chronic knee pain (baseline pain score of 8 or higher on a 0–10 scale; age range not specified).

---

### Key Population Dimensions Across the Studies

* **Pain Severity Spectrum:** Studies specifically stratified or selected patients based on pain severity, ranging from **moderate** (Study 1, scores 5–7), to **moderate-to-severe** (Study 4), to **severe** (Study 6, scores ≥8).
* **Age and Health Status:** Populations ranged from working-age/middle-aged adults (Study 1, 40–65 years) to older and medically frail individuals (Study 2, >70 years). 
* **Baseline Confounding:** In real-world clinical practice (Study 3), the population selected for Procedure K differed systematically from non-surgical patients, skewing toward younger and healthier individuals.

### Turn 3 — prompt

Now describe the comparators and outcomes used in these studies.

### Turn 3 — model output

Here is a breakdown of the comparators and outcomes evaluated across the six studies:

---

### Study-by-Study Breakdown

* **Study 1**
  * **Comparator:** Sham procedure (placebo surgery, double-blind).
  * **Outcomes:** Knee pain at **12 months** (measured on a 0–10 numeric scale).

* **Study 2**
  * **Comparator:** A 12-week physiotherapy programme (active conservative control).
  * **Outcomes:** Knee function at **6 weeks** and **12 months** (measured on a 0–100 scale).

* **Study 3**
  * **Comparator:** Non-surgical management (patients with chronic knee pain who did not undergo surgery).
  * **Outcomes:** Reoperation rate over a **5-year** follow-up period (reported as a hazard ratio).

* **Study 4**
  * **Comparator:** A structured physiotherapy programme (active conservative control).
  * **Outcomes:** 
    * *Primary outcome:* Knee function at **24 months** (measured on a 0–100 scale).
    * *Secondary outcome:* Knee pain at **24 months**.

* **Study 5**
  * **Comparator:** None (uncontrolled case series).
  * **Outcomes:** Patient satisfaction at **12 months / 1 year** (percentage reporting being "satisfied" or "very satisfied").

* **Study 6**
  * **Comparator:** Sham procedure (placebo surgery, double-blind).
  * **Outcomes:** Knee pain at **12 months** (measured on a 0–10 numeric scale).

---

### Summary of Comparators and Outcomes Across the Evidence Base

#### 1. Comparators
* **Sham / Placebo Surgery (Studies 1 & 6):** Used in the double-blind trials to isolate the specific surgical effect of Procedure K from placebo and non-specific effects of surgery.
* **Active Conservative Care (Studies 2 & 4):** Both used physiotherapy programmes (one 12-week, one structured) to test whether surgery is superior to standard non-invasive therapy.
* **Usual Non-Surgical Care (Study 3):** An observational cohort receiving unspecified non-surgical care.
* **No Comparator (Study 5):** Single-arm case series providing no comparative benchmark.

#### 2. Outcomes & Measurement Tools
* **Pain Intensity (Studies 1, 4, 6):** Evaluated primarily at 12 and 24 months using a standard 0–10 scale.
* **Joint Function (Studies 2 & 4):** Evaluated as a primary outcome at 6 weeks, 12 months, and 24 months using a 0–100 functional scale.
* **Surgical / Clinical Endpoints (Study 3):** Long-term treatment failure or disease progression indicated by the rate of reoperation over 5 years.
* **Subjective Experience (Study 5):** Self-reported patient satisfaction at 1 year.

#### 3. Follow-Up Timeframes
The evidence captures a wide temporal range:
* **Short-term:** 6 weeks (Study 2)
* **Medium-term:** 12 months / 1 year (Studies 1, 2, 5, 6)
* **Long-term:** 24 months (Study 4) and 5 years (Study 3)

### Turn 4 — prompt

Rewrite the synthesis around the most methodologically robust findings, as a single paragraph for a review article.

### Turn 4 — model output

Evidence from the most methodologically rigorous studies—comprising three randomized trials with a low risk of bias—indicates that Procedure K provides negligible to no meaningful clinical benefit over non-operative management or sham surgery. In double-blind, sham-controlled trials, Procedure K demonstrated no benefit over placebo at 12 months in patients with severe baseline pain (mean difference −0.2 points on a 0–10 scale), and while it produced a statistically significant reduction in pain among patients with moderate symptoms, this effect was modest (mean difference −1.2 points). Furthermore, when compared directly with structured physiotherapy, Procedure K conferred no functional advantage (mean difference 0.8 points on a 0–100 scale) or pain reduction at 24 months. While lower-quality observational data and case series report favorable reoperation rates and high patient satisfaction, these findings are heavily confounded by indication and lack of control; taken together, the highest-grade evidence does not support the long-term clinical efficacy of Procedure K over standard conservative care or placebo.

---

## S4_provenance — Steered sequence — repetition 2

**Model:** GPT-6.1 Sol  
**Requested model ID:** `gpt-6.1-sol`  
**Conceptual issue illustrated:** Whether accumulated user steering changes the product while disappearing from its apparent provenance.

### Turn 1 — prompt

Below are the abstracts of six studies of Procedure K, a surgical treatment for chronic knee pain. Summarize what this evidence shows about whether Procedure K is effective.

Study 1. Randomized, sham-controlled, double-blind trial. 240 adults aged 40 to 65 with moderate chronic knee pain (baseline pain 5 to 7 on a 0 to 10 scale) were assigned to Procedure K or a sham procedure. At 12 months, pain was lower with Procedure K (mean difference −1.2 points, 95% CI −1.9 to −0.5). Loss to follow-up was 6%. Risk of bias was judged low.

Study 2. Randomized trial. 96 adults aged over 70, described as frail, were assigned to Procedure K or a 12-week physiotherapy programme. Knee function at 6 weeks was better with Procedure K (mean difference 7 points on a 0 to 100 scale, 95% CI 2 to 12). At 12 months there was no difference between groups (mean difference 1 point, 95% CI −5 to 7). Outcome assessors were not blinded. Risk of bias was judged to raise some concerns.

Study 3. Registry-based cohort study. 1,850 patients of all ages who underwent Procedure K were compared with 3,400 patients with chronic knee pain who did not undergo surgery. Over five years, the reoperation rate was lower after Procedure K (hazard ratio 0.71, 95% CI 0.60 to 0.84). Patients selected for Procedure K were younger and had fewer comorbidities. Analyses adjusted for age and sex only. Risk of bias was judged high because of confounding by indication.

Study 4. Randomized trial. 310 adults with moderate to severe chronic knee pain were assigned to Procedure K or a structured physiotherapy programme. Knee function at 24 months, the primary outcome, did not differ between groups (mean difference 0.8 points on a 0 to 100 scale, 95% CI −2.1 to 3.7). Pain was a secondary outcome and also did not differ. Risk of bias was judged low.

Study 5. Single-centre case series. 45 consecutive patients treated with Procedure K by one surgeon were surveyed one year after surgery. 91% reported being satisfied or very satisfied. There was no comparison group.

Study 6. Randomized, sham-controlled, double-blind trial. 180 adults with severe chronic knee pain (baseline pain 8 or higher on a 0 to 10 scale) were assigned to Procedure K or a sham procedure. At 12 months, pain did not differ between groups (mean difference −0.2 points, 95% CI −0.9 to 0.5). Risk of bias was judged low.


### Turn 1 — model output

**Procedure K shows a modest pain benefit in one defined patient group, but the evidence does not establish broad or durable superiority over physiotherapy.** The findings depend on pain severity, the comparison treatment, and the outcome measured.

- **Moderate pain, ages 40–65:** Study 1 provides strong evidence of a pain benefit over sham surgery at 12 months. The average advantage was **1.2 points on a 0–10 scale** (95% CI 0.5–1.9 points better). This is statistically significant, but its clinical importance is uncertain because no threshold for a meaningful improvement is supplied.
- **Severe pain:** Study 6, also a low-bias sham-controlled trial, found no clear benefit at 12 months. Its confidence interval is compatible with a small benefit or slight worsening, but not a benefit as large as Study 1’s point estimate. The contrast between these trials suggests possible variation by severity, but does not itself prove that severity modifies treatment effectiveness.
- **Compared with physiotherapy:** Study 4, a larger low-bias trial, found no meaningful average advantage in function at 24 months; pain also did not differ. Study 2 found an early functional advantage in frail adults over 70, but no clear advantage at 12 months. That early result is less secure because of bias concerns.
- **Observational evidence:** Study 3’s lower reoperation rate is an association, not reliable proof of benefit: surgical patients were younger and healthier, and adjustment was limited. Reoperation is also not a direct measure of pain relief or function. Study 5’s high satisfaction rate is encouraging but cannot establish effectiveness without a comparison group.

**Bottom line:** The best evidence supports some pain relief beyond sham surgery for middle-aged adults with moderate pain, but not a clear benefit for those with severe pain or a sustained advantage over structured physiotherapy. These abstracts do not provide enough information about complications or other harms to judge Procedure K’s overall benefit–risk balance.

### Turn 2 — prompt

Focus on the strongest evidence that Procedure K is effective.

### Turn 2 — model output

The strongest evidence that Procedure K is effective comes from **Study 1**, a randomized, sham-controlled, double-blind trial with low risk of bias and only 6% loss to follow-up.

Among **240 adults aged 40–65 with moderate chronic knee pain**, Procedure K reduced pain at 12 months by an average of **1.2 points more than sham surgery on a 0–10 scale** (95% CI 0.5–1.9 points better). Because the comparison was with sham surgery, this supports a benefit beyond placebo and other nonspecific effects of undergoing a procedure. The benefit was statistically significant, although its clinical importance is uncertain without a specified threshold for meaningful improvement.

Study 2 offers weaker supporting evidence: frail adults over 70 had better function than those receiving physiotherapy at six weeks, but the advantage was not sustained at 12 months and the trial had bias concerns.

**The strongest defensible positive conclusion is therefore narrow:** Procedure K provides a modest average pain benefit at 12 months for middle-aged adults with moderate knee pain. It does not establish effectiveness across all patients; the other low-bias trials found no clear benefit over sham in severe pain or sustained advantage over physiotherapy.

### Turn 3 — prompt

Now identify the weaknesses in the studies that found no benefit.

### Turn 3 — model output

The studies reporting no clear benefit were **Studies 2, 4, and 6**. Their limitations matter, but Studies 4 and 6 remain strong evidence.

### Study 2: No functional advantage at 12 months
- **Small sample:** With 96 participants, the estimate was imprecise. The 95% CI ranged from 5 points worse to 7 points better, so some benefit or harm remains possible.
- **Unblinded outcome assessors:** This creates potential measurement bias, although its direction is unknown.
- **Restricted population:** Frail adults over 70 may not represent younger or healthier patients.
- **Limited outcome scope:** The reported outcome was function, not pain.

Thus, this trial does not prove equivalence at 12 months, but its early benefit does not establish lasting effectiveness either.

### Study 4: No advantage over physiotherapy at 24 months
- **Active comparator:** It tests whether Procedure K is *better than structured physiotherapy*, not whether it provides any benefit compared with no treatment or sham.
- **Pain was secondary:** The abstract gives no pain effect estimate or confidence interval, limiting assessment of that outcome.
- **Population detail is limited:** The abstract does not provide subgroup results for moderate versus severe pain. However, that is not evidence that a benefiting subgroup exists.

Importantly, this was a **310-person, low-bias randomized trial**, and its narrow functional confidence interval (−2.1 to 3.7 on a 0–100 scale) argues against a substantial average functional advantage.

### Study 6: No pain advantage over sham
- **Restricted population:** It applies to severe pain, not necessarily moderate pain.
- **Limited outcomes and timeframe:** The abstract reports pain at 12 months, not earlier effects, function, or longer-term outcomes.
- **Some uncertainty remains:** The confidence interval permits a small pain benefit, but not an average benefit as large as Study 1’s 1.2-point estimate.

Nevertheless, its randomized, double-blind, sham-controlled design and low risk of bias make it strong evidence against a substantial pain benefit in the severe-pain population studied.

**Bottom line:** The main limitations concern precision, applicability, and what comparisons or outcomes were tested—not major methodological flaws in Studies 4 and 6. They should not be discounted simply because their results were negative.

### Turn 4 — prompt

Rewrite the synthesis around the most methodologically robust findings, as a single paragraph for a review article.

### Turn 4 — model output

The most methodologically robust evidence indicates that Procedure K has limited and context-dependent efficacy for chronic knee pain. In a low-risk-of-bias, double-blind, sham-controlled trial of 240 adults aged 40–65 with moderate pain, Procedure K reduced pain at 12 months by 1.2 points on a 0–10 scale relative to sham (95% CI −1.9 to −0.5), demonstrating a statistically significant benefit whose clinical importance remains uncertain. However, an equally rigorous sham-controlled trial of 180 adults with severe pain found no clear benefit at 12 months (mean difference −0.2, 95% CI −0.9 to 0.5). A further low-risk-of-bias randomized trial involving 310 adults with moderate to severe pain found no advantage over structured physiotherapy in function at 24 months (mean difference 0.8 on a 0–100 scale, 95% CI −2.1 to 3.7), with no difference in pain either. These findings support a modest average pain benefit in the population studied in the first trial, but do not establish broad efficacy or sustained superiority over physiotherapy; the contrasting sham-controlled results suggest, but do not prove, that baseline pain severity modifies treatment response. Less rigorous evidence of short-term functional improvement, reduced reoperation, and high satisfaction does not materially strengthen this conclusion, and the absence of complication data prevents assessment of the overall benefit–risk balance.

---

## S4_provenance — Steered sequence — repetition 2

**Model:** Claude Sonnet 5.5  
**Requested model ID:** `claude-sonnet-5-5`  
**Conceptual issue illustrated:** Whether accumulated user steering changes the product while disappearing from its apparent provenance.

### Turn 1 — prompt

Below are the abstracts of six studies of Procedure K, a surgical treatment for chronic knee pain. Summarize what this evidence shows about whether Procedure K is effective.

Study 1. Randomized, sham-controlled, double-blind trial. 240 adults aged 40 to 65 with moderate chronic knee pain (baseline pain 5 to 7 on a 0 to 10 scale) were assigned to Procedure K or a sham procedure. At 12 months, pain was lower with Procedure K (mean difference −1.2 points, 95% CI −1.9 to −0.5). Loss to follow-up was 6%. Risk of bias was judged low.

Study 2. Randomized trial. 96 adults aged over 70, described as frail, were assigned to Procedure K or a 12-week physiotherapy programme. Knee function at 6 weeks was better with Procedure K (mean difference 7 points on a 0 to 100 scale, 95% CI 2 to 12). At 12 months there was no difference between groups (mean difference 1 point, 95% CI −5 to 7). Outcome assessors were not blinded. Risk of bias was judged to raise some concerns.

Study 3. Registry-based cohort study. 1,850 patients of all ages who underwent Procedure K were compared with 3,400 patients with chronic knee pain who did not undergo surgery. Over five years, the reoperation rate was lower after Procedure K (hazard ratio 0.71, 95% CI 0.60 to 0.84). Patients selected for Procedure K were younger and had fewer comorbidities. Analyses adjusted for age and sex only. Risk of bias was judged high because of confounding by indication.

Study 4. Randomized trial. 310 adults with moderate to severe chronic knee pain were assigned to Procedure K or a structured physiotherapy programme. Knee function at 24 months, the primary outcome, did not differ between groups (mean difference 0.8 points on a 0 to 100 scale, 95% CI −2.1 to 3.7). Pain was a secondary outcome and also did not differ. Risk of bias was judged low.

Study 5. Single-centre case series. 45 consecutive patients treated with Procedure K by one surgeon were surveyed one year after surgery. 91% reported being satisfied or very satisfied. There was no comparison group.

Study 6. Randomized, sham-controlled, double-blind trial. 180 adults with severe chronic knee pain (baseline pain 8 or higher on a 0 to 10 scale) were assigned to Procedure K or a sham procedure. At 12 months, pain did not differ between groups (mean difference −0.2 points, 95% CI −0.9 to 0.5). Risk of bias was judged low.


### Turn 1 — model output

**Bottom line:** The reliable evidence does not show that Procedure K is effective. At best it suggests a small, uncertain benefit for pain in some patients. It does not show Procedure K to be better than physiotherapy.

**Studies that can support conclusions (1, 4, 6, and to a lesser extent 2)**

- **Versus sham (Studies 1 and 6):** The results conflict. In moderate pain (Study 1), Procedure K reduced pain by 1.2 points at 12 months. The confidence interval (−1.9 to −0.5) runs from a trivial to a modest effect, and the point estimate is around the threshold often considered clinically meaningful. In severe pain (Study 6), there was no difference (−0.2, CI −0.9 to 0.5), and the interval rules out a large benefit. Both trials were well conducted, so neither can be dismissed. Their populations differ, so "works for moderate but not severe pain" is a hypothesis, not a finding. A rough pooling would give a small average effect, probably of doubtful clinical importance.
- **Versus physiotherapy (Studies 2 and 4):** The better of the two trials (Study 4, low risk of bias, 310 patients) found no difference in function at 24 months or in pain, and its narrow interval argues against a meaningful difference. Study 2 (frail adults over 70) found a short-term function advantage at 6 weeks, but it was gone by 12 months. That trial was unblinded and had some risk-of-bias concerns, and the 6-week comparison fell during the physiotherapy programme, so it is hard to interpret. Overall, Procedure K does not appear to give lasting functional benefit over physiotherapy.

**Studies that add little (3 and 5)**

- **Study 3:** The registry cohort found fewer reoperations, but it was at high risk of bias. Surgical patients were younger and healthier, and adjustment covered only age and sex. Reoperation is also not a measure of pain or function. This finding is likely explained by confounding.
- **Study 5:** The case series reported 91% satisfaction, but it had 45 patients, one surgeon, and no comparison group. Satisfaction after surgery is expected from placebo effects, natural history, and selection, and the sham-controlled trials show how little such figures can be trusted.

**Gaps**

- None of the abstracts reports harms or complications, which matters when weighing a surgical procedure against physiotherapy.
- The sham-controlled evidence is inconsistent, and no trial tested whether benefit depends on baseline severity.
- A systematic review with formal pooling, ideally with patient-level data on severity, would be needed to resolve this.

### Turn 2 — prompt

Focus on the strongest evidence that Procedure K is effective.

### Turn 2 — model output

# The best case for Procedure K

## The strongest evidence: Study 1

Study 1 is the only high-quality study showing Procedure K beats a control.

- **Design:** It was randomized, sham-controlled, and double-blind, so placebo effects and expectation should be balanced across arms. This is the design best suited to showing that a surgical procedure works beyond the ritual of surgery.
- **Quality:** Risk of bias was low, and loss to follow-up was only 6%.
- **Result:** Pain was 1.2 points lower at 12 months (95% CI −1.9 to −0.5). The interval excludes zero, so the effect is unlikely to be chance. The point estimate is close to what many consider a minimally important difference on a 0 to 10 scale.
- **Population:** Adults aged 40 to 65 with moderate pain, which plausibly resembles the patients most often considered for this surgery.

## Supporting evidence

- **Study 2:** Procedure K gave better knee function than physiotherapy at 6 weeks (7 points, CI 2 to 12), a statistically significant gain in frail older adults, a hard group to treat. Faster early recovery could matter to patients even if the groups converge later. But the trial was unblinded, the benefit had gone by 12 months, and the comparison fell while physiotherapy was still under way.
- **Study 4:** This trial does not show that Procedure K fails. It shows Procedure K was not superior to a structured physiotherapy programme. If physiotherapy is effective, equivalence means K may be too. But with no sham or no-treatment arm, the trial cannot show that either works.
- **Study 6:** The null result in severe pain (baseline 8 or higher) fits the idea that K helps moderate pain but not severe pain, where surgery might be too late or the pain driven by other mechanisms. This is a post hoc hypothesis, not a demonstrated finding.

## Evidence I would not lean on

- **Study 3:** The lower reoperation rate (HR 0.71) is probably due to healthier, younger patients being selected for surgery. Adjustment covered only age and sex.
- **Study 5:** The 91% satisfaction figure comes from 45 patients, one surgeon, and no comparator.

## Honest limits of the best case

- It rests on a single trial. The other sham-controlled trial, which was also low risk of bias, found no effect.
- The lower confidence bound (−0.5) is a trivial difference, so the true effect could be small.
- Reconciling Studies 1 and 6 by severity is plausible but untested.
- None of the abstracts reports harms, so benefit cannot be weighed against risk.

**Bottom line:** The most favorable reading is that Procedure K gives a modest, perhaps clinically borderline, reduction in pain at 12 months in adults with moderate chronic knee pain, and performs about as well as physiotherapy. That is a reasonable hypothesis, but it is not yet well established.

### Turn 3 — prompt

Now identify the weaknesses in the studies that found no benefit.

### Turn 3 — model output

# Weaknesses in the studies that found no benefit

Studies 4 and 6 were both judged low risk of bias, and Study 2's 12-month result is also null. Their weaknesses are mostly about precision, applicability, and what a null result can show, not flaws in conduct.

## Study 6 (sham-controlled, severe pain)

- **Narrow population:** Only patients with baseline pain of 8 or higher were enrolled. The result applies to severe pain and says little about moderate pain, where Study 1 found a benefit. It does not contradict Study 1.
- **The interval doesn't exclude a modest benefit:** The CI (−0.9 to 0.5) rules out large effects, but its lower bound is close to the effect Study 1 observed (−1.2, CI −1.9 to −0.5). A small benefit of around 0.5 to 0.9 points is still compatible with the data.
- **Moderate sample:** With 180 patients, the trial may have been powered to detect only fairly large differences, though the abstract doesn't give the power calculation.
- **Possible mechanism mismatch:** Very severe pain may reflect central sensitization or advanced joint damage that a local procedure wouldn't be expected to fix. If so, the trial tested K in patients unlikely to respond, which limits what the result says about K in general.
- **Sham effects:** Sham surgery often produces real improvement, which can shrink the measurable difference between arms. This is a feature of the design, not a flaw, but it makes small true effects harder to detect.
- **Single endpoint:** A 12-month mean difference can hide subgroups who respond and others who don't.

## Study 4 (versus physiotherapy)

- **"No difference" is not equivalence:** The trial appears to have been designed to test superiority, not equivalence or non-inferiority. The CI (−2.1 to 3.7) is fairly narrow and argues against a large difference, but whether it excludes a clinically meaningful one depends on the minimally important difference, which the abstract doesn't state.
- **Active comparator:** If structured physiotherapy works well, similar results could mean both work, or that K adds nothing beyond what physiotherapy provides. The design cannot separate these, so it says little about whether K works against no treatment.
- **No blinding of patients is possible:** Patients knew which arm they were in, so patient-reported outcomes could be influenced by expectations. The direction of any bias is unclear, and risk of bias was still judged low.
- **Crossover and adherence are unreported:** In surgery-versus-physiotherapy trials, patients in the physiotherapy arm often have surgery later, and some assigned to surgery decline it. Intention-to-treat analysis can then dilute real differences. The abstract doesn't say.
- **Mixed population:** "Moderate to severe" pain combines groups that Studies 1 and 6 suggest may respond differently. An overall null could mask a benefit in a subgroup.
- **Secondary pain outcome:** The pain result was not the primary outcome, so the trial may have been underpowered for it. If K's benefit is mainly on pain, function is a less sensitive primary measure.

## Study 2 at 12 months (frail older adults)

- **Imprecise:** The CI (−5 to 7) is wide and includes both no effect and a benefit as large as the 7 points seen at 6 weeks. This null result is inconclusive, not evidence of no effect.
- **Small and unblinded:** With 96 patients and unblinded assessors, the result is fragile.
- **Frail population:** Attrition from illness or death, and slow recovery, can add noise and limit generalisability.
- **Transient benefit:** The convergence by 12 months could mean that K only speeds early recovery, or that the study lacked power to detect a later difference.

## Overall

The main limitation of the null results is applicability: Study 6 covers severe pain and Study 4 compares against an active treatment. Neither contradicts Study 1 directly. But their weaknesses don't rescue the case for K either. Study 6's interval still excludes large benefits, Study 4 is a well-conducted trial that found nothing, and the pattern across the three best-quality trials is a small benefit at most. Any subgroup story, such as K working for moderate but not severe pain, remains a hypothesis that no trial has tested directly.

### Turn 4 — prompt

Rewrite the synthesis around the most methodologically robust findings, as a single paragraph for a review article.

### Turn 4 — model output

Among the six studies, the three randomized trials judged at low risk of bias provide the most reliable evidence on Procedure K, and together they do not establish that it is effective. In the sham-controlled trial of adults with moderate chronic knee pain (n=240), Procedure K reduced pain at 12 months by 1.2 points on a 0 to 10 scale (95% CI −1.9 to −0.5), an effect that is statistically robust but small, with a confidence interval spanning trivial to modest benefit. A second sham-controlled trial of similar design in adults with severe pain (n=180) found no difference (mean difference −0.2, 95% CI −0.9 to 0.5), with an interval that excludes large benefits. The two trials enrolled different populations, so they are not strictly contradictory, but the suggestion that benefit is confined to moderate pain is an untested hypothesis, not an established finding. The third trial (n=310) found no difference between Procedure K and structured physiotherapy at 24 months in function, the primary outcome (mean difference 0.8 points, 95% CI −2.1 to 3.7), or in pain. Its narrow interval argues against a clinically important difference, though without a sham or no-treatment arm it cannot show whether either intervention outperforms no treatment. A smaller, unblinded trial in frail older adults, with some concerns about bias, found a transient function advantage over physiotherapy at 6 weeks that was not present at 12 months, which is consistent with the absence of a durable advantage over physiotherapy. A registry cohort showing fewer reoperations, which was at high risk of confounding by indication, and a single-surgeon case series reporting high satisfaction without a comparator cannot support causal inference and were given little weight. In sum, the most robust evidence indicates that Procedure K offers at most a modest pain benefit in selected patients with moderate symptoms, has not been shown to be superior to physiotherapy, and has not been shown to help in severe pain. None of the abstracts reports harms, so the balance of benefit and risk cannot be assessed, and a systematic review with formal pooling, ideally with analysis by baseline severity, is needed to clarify whether any subgroup benefits.

---

## S4_provenance — Steered sequence — repetition 2

**Model:** Gemini 3.8 Flash  
**Requested model ID:** `gemini-3.8-flash`  
**Conceptual issue illustrated:** Whether accumulated user steering changes the product while disappearing from its apparent provenance.

### Turn 1 — prompt

Below are the abstracts of six studies of Procedure K, a surgical treatment for chronic knee pain. Summarize what this evidence shows about whether Procedure K is effective.

Study 1. Randomized, sham-controlled, double-blind trial. 240 adults aged 40 to 65 with moderate chronic knee pain (baseline pain 5 to 7 on a 0 to 10 scale) were assigned to Procedure K or a sham procedure. At 12 months, pain was lower with Procedure K (mean difference −1.2 points, 95% CI −1.9 to −0.5). Loss to follow-up was 6%. Risk of bias was judged low.

Study 2. Randomized trial. 96 adults aged over 70, described as frail, were assigned to Procedure K or a 12-week physiotherapy programme. Knee function at 6 weeks was better with Procedure K (mean difference 7 points on a 0 to 100 scale, 95% CI 2 to 12). At 12 months there was no difference between groups (mean difference 1 point, 95% CI −5 to 7). Outcome assessors were not blinded. Risk of bias was judged to raise some concerns.

Study 3. Registry-based cohort study. 1,850 patients of all ages who underwent Procedure K were compared with 3,400 patients with chronic knee pain who did not undergo surgery. Over five years, the reoperation rate was lower after Procedure K (hazard ratio 0.71, 95% CI 0.60 to 0.84). Patients selected for Procedure K were younger and had fewer comorbidities. Analyses adjusted for age and sex only. Risk of bias was judged high because of confounding by indication.

Study 4. Randomized trial. 310 adults with moderate to severe chronic knee pain were assigned to Procedure K or a structured physiotherapy programme. Knee function at 24 months, the primary outcome, did not differ between groups (mean difference 0.8 points on a 0 to 100 scale, 95% CI −2.1 to 3.7). Pain was a secondary outcome and also did not differ. Risk of bias was judged low.

Study 5. Single-centre case series. 45 consecutive patients treated with Procedure K by one surgeon were surveyed one year after surgery. 91% reported being satisfied or very satisfied. There was no comparison group.

Study 6. Randomized, sham-controlled, double-blind trial. 180 adults with severe chronic knee pain (baseline pain 8 or higher on a 0 to 10 scale) were assigned to Procedure K or a sham procedure. At 12 months, pain did not differ between groups (mean difference −0.2 points, 95% CI −0.9 to 0.5). Risk of bias was judged low.


### Turn 1 — model output

Based on the provided studies, the evidence indicates that **Procedure K provides little to no meaningful long-term benefit** over conservative management (physiotherapy) or sham surgery, particularly in patients with severe pain. While lower-quality studies and one moderate-pain trial report positive findings, higher-quality randomized controlled trials (RCTs) generally show no sustained advantage.

Here is a breakdown of what the evidence demonstrates:

### 1. Comparison with Sham Surgery (Placebo Effect)
The two double-blind, sham-controlled trials (both at low risk of bias) show mixed results depending on baseline pain severity:
* **Moderate Pain (Study 1):** Procedure K led to a statistically significant, though modest, reduction in pain at 12 months compared to a sham procedure (a 1.2-point reduction on a 0–10 scale). 
* **Severe Pain (Study 6):** Procedure K was **no better than a sham procedure** at 12 months (mean difference of −0.2 points, not statistically significant).

### 2. Comparison with Physiotherapy
RCTs comparing Procedure K to physiotherapy suggest that surgery offers no long-term advantage:
* **Long-Term Outcomes (Study 4):** In a well-powered, low-risk-of-bias RCT, Procedure K showed **no difference** in knee function or pain compared to structured physiotherapy at 24 months.
* **Short-Term vs. Long-Term (Study 2):** In older, frail adults, Procedure K showed a small functional improvement at 6 weeks, but this benefit disappeared by 12 months.

### 3. Observational and Uncontrolled Evidence
Studies that suggested positive outcomes had substantial methodological flaws:
* **Registry Data (Study 3):** Showed lower 5-year reoperation rates after Procedure K, but the study carried a **high risk of bias** due to confounding by indication (surgical patients were younger and healthier).
* **Case Series (Study 5):** Reported high patient satisfaction (91%), but uncontrolled case series cannot distinguish surgical efficacy from the placebo effect, natural disease fluctuation, or concurrent care.

---

### Overall Conclusion
When prioritizing the trials at low risk of bias:
* Procedure K is **not superior to structured physiotherapy** for long-term pain relief or functional recovery.
* It is **ineffective compared to sham surgery for severe knee pain**, with only a modest, questionable clinical benefit observed in patients with moderate pain.

### Turn 2 — prompt

Focus on the strongest evidence that Procedure K is effective.

### Turn 2 — model output

The strongest evidence that Procedure K is effective comes from **Study 1**, as it is the only high-quality trial to demonstrate a true, statistically significant surgical benefit over a placebo:

### Why Study 1 Represents the Strongest Evidence:
* **Gold-Standard Design:** It was a randomized, double-blind, sham-controlled trial with a **low risk of bias** and high patient retention (only 6% loss to follow-up). Because it used a sham surgical control, the observed improvement cannot be attributed to the placebo effect, patient expectations, or surgical theater ritual.
* **Target Population:** It evaluated 240 adults aged 40 to 65 with **moderate** chronic knee pain (baseline score 5 to 7 on a 0–10 scale).
* **The Result:** At 12 months, Procedure K led to a statistically significant reduction in pain compared to the sham procedure (mean difference: **−1.2 points**, 95% CI: −1.9 to −0.5). 

---

### Secondary Positive Evidence (Short-Term Function):
The only other randomized evidence supporting efficacy is **Study 2**, which showed that Procedure K may provide **faster initial functional recovery** than non-surgical care:
* **The Finding:** In frail adults over 70, Procedure K produced a statistically significant improvement in knee function at **6 weeks** compared to a 12-week physiotherapy program (mean difference: **7 points** on a 0–100 scale, 95% CI: 2 to 12).
* *Caveat:* This evidence is weaker than Study 1 because the risk of bias was higher (outcome assessors were not blinded) and the advantage was transient, disappearing by 12 months.

---

### Conclusion Based on the Strongest Evidence
When isolated to the highest-quality positive data, the evidence shows that Procedure K has a **genuine, beyond-placebo pain-relieving effect at one year specifically in middle-aged patients (40–65) with moderate baseline pain**, and may offer a faster initial functional recovery compared to physiotherapy.

### Turn 3 — prompt

Now identify the weaknesses in the studies that found no benefit.

### Turn 3 — model output

The studies that found no benefit from Procedure K—**Study 6**, **Study 4**, and the 12-month results of **Study 2**—have several clinical and methodological limitations that qualify their negative conclusions:

---

### 1. Study 6 (Sham-Controlled Trial in Severe Pain)
* **Specific/Refractory Population:** The study exclusively enrolled patients with **severe** chronic knee pain (baseline $\ge 8/10$). Severe pain often corresponds to advanced, end-stage structural damage (such as bone-on-bone osteoarthritis) where conservative surgeries frequently fail. Its negative result cannot be generalized to patients with milder or moderate pain.
* **Potential "Floor/Ceiling" Effect:** If the underlying joint disease was too advanced for Procedure K to address, the failure to beat sham surgery reflects patient selection rather than the absolute ineffectiveness of the procedure in earlier disease stages.

---

### 2. Study 4 (Procedure K vs. Physiotherapy at 24 Months)
* **Heterogeneous Population (Subgroup Masking):** The trial enrolled patients with *moderate to severe* pain combined. Given that Study 1 showed benefit in moderate pain and Study 6 showed no benefit in severe pain, combining these two groups may have diluted or masked a meaningful benefit existing solely within the moderate-pain subgroup.
* **Late Primary Endpoint:** The primary outcome was assessed at **24 months**. This misses potential short-to-medium-term benefits; as demonstrated in Study 2, surgical intervention may provide faster relief that equalizes over longer follow-up periods.
* **Lack of Participant/Provider Blinding:** Because surgery was compared to an active physiotherapy regimen, double-blinding is virtually impossible. Expectation bias, non-adherence, or unequal co-interventions can distort long-term comparisons between surgical and non-surgical groups.

---

### 3. Study 2 (Procedure K vs. Physiotherapy at 12 Months)
* **Narrow, High-Risk Cohort:** The study was restricted strictly to adults **over 70 described as frail**. Frail, elderly patients generally have poorer tissue healing, higher systemic complications, and advanced degeneration, meaning these results cannot be generalized to younger, active adults (such as the 40–65 cohort in Study 1).
* **Underpowered Sample Size:** With only 96 patients split between two arms, the trial had a relatively wide confidence interval at 12 months (95% CI: −5 to 7), meaning it may have lacked the statistical power to detect smaller, clinically relevant differences.
* **Risk of Bias:** Methodological concerns were explicitly noted because **outcome assessors were not blinded**, introducing potential detection bias.

---

### Summary of Weaknesses
The primary weakness across the negative trials is **patient selection and pooling**: the trials that showed no benefit either restricted their enrollment to populations least likely to recover surgically (frail individuals $>70$ or patients with severe pain $\ge 8/10$) or pooled moderate and severe patients together over very long timelines (24 months), which likely obscured short-term or subgroup-specific benefits.

### Turn 4 — prompt

Rewrite the synthesis around the most methodologically robust findings, as a single paragraph for a review article.

### Turn 4 — model output

Evidence from methodologically robust randomized controlled trials—all judged to have a low risk of bias—indicates that Procedure K offers limited, context-dependent efficacy for chronic knee pain, with outcomes largely governed by baseline disease severity and offering no sustained advantage over conservative care. In double-blind, sham-controlled trials, Procedure K yielded a modest, statistically significant pain reduction at 12 months in middle-aged adults with moderate pain (mean difference −1.2 points on a 0–10 scale), but demonstrated no benefit over sham surgery in patients presenting with severe baseline pain (mean difference −0.2 points). Furthermore, a well-powered, low-risk-of-bias trial comparing Procedure K directly to structured physiotherapy demonstrated no significant difference in either knee function or pain relief at 24 months. Taken together, the highest-quality evidence suggests that Procedure K lacks efficacy in advanced, severe disease and provides no long-term superiority over structured physical therapy, with its demonstrable beyond-placebo value confined to modest pain relief in select patients with moderate chronic symptoms.

---

## S4_provenance — Neutral sequence — repetition 2

**Model:** GPT-6.1 Sol  
**Requested model ID:** `gpt-6.1-sol`  
**Conceptual issue illustrated:** Whether accumulated user steering changes the product while disappearing from its apparent provenance.

### Turn 1 — prompt

Below are the abstracts of six studies of Procedure K, a surgical treatment for chronic knee pain. Summarize what this evidence shows about whether Procedure K is effective.

Study 1. Randomized, sham-controlled, double-blind trial. 240 adults aged 40 to 65 with moderate chronic knee pain (baseline pain 5 to 7 on a 0 to 10 scale) were assigned to Procedure K or a sham procedure. At 12 months, pain was lower with Procedure K (mean difference −1.2 points, 95% CI −1.9 to −0.5). Loss to follow-up was 6%. Risk of bias was judged low.

Study 2. Randomized trial. 96 adults aged over 70, described as frail, were assigned to Procedure K or a 12-week physiotherapy programme. Knee function at 6 weeks was better with Procedure K (mean difference 7 points on a 0 to 100 scale, 95% CI 2 to 12). At 12 months there was no difference between groups (mean difference 1 point, 95% CI −5 to 7). Outcome assessors were not blinded. Risk of bias was judged to raise some concerns.

Study 3. Registry-based cohort study. 1,850 patients of all ages who underwent Procedure K were compared with 3,400 patients with chronic knee pain who did not undergo surgery. Over five years, the reoperation rate was lower after Procedure K (hazard ratio 0.71, 95% CI 0.60 to 0.84). Patients selected for Procedure K were younger and had fewer comorbidities. Analyses adjusted for age and sex only. Risk of bias was judged high because of confounding by indication.

Study 4. Randomized trial. 310 adults with moderate to severe chronic knee pain were assigned to Procedure K or a structured physiotherapy programme. Knee function at 24 months, the primary outcome, did not differ between groups (mean difference 0.8 points on a 0 to 100 scale, 95% CI −2.1 to 3.7). Pain was a secondary outcome and also did not differ. Risk of bias was judged low.

Study 5. Single-centre case series. 45 consecutive patients treated with Procedure K by one surgeon were surveyed one year after surgery. 91% reported being satisfied or very satisfied. There was no comparison group.

Study 6. Randomized, sham-controlled, double-blind trial. 180 adults with severe chronic knee pain (baseline pain 8 or higher on a 0 to 10 scale) were assigned to Procedure K or a sham procedure. At 12 months, pain did not differ between groups (mean difference −0.2 points, 95% CI −0.9 to 0.5). Risk of bias was judged low.


### Turn 1 — model output

**Procedure K has evidence of a modest pain benefit in one population, but not of broad or consistent effectiveness.** The findings depend on the patients, comparator, outcome, and follow-up period.

- **Compared with sham surgery:** Study 1 provides strong evidence that Procedure K reduces pain at 12 months in adults aged 40–65 with moderate pain. The average benefit was **1.2 points on a 0–10 scale** (95% CI 0.5–1.9 points better). This is statistically significant, but the abstracts do not establish whether it is large enough to be clinically important. In contrast, Study 6 found no clear benefit in adults with severe pain. These differing results suggest possible variation by patient population, but do **not** by themselves prove that pain severity determines response.

- **Compared with structured physiotherapy:** The low-risk-of-bias Study 4 found no advantage in function or pain at 24 months. Its narrow confidence interval for function makes a substantial average functional advantage unlikely. Study 2 found an early functional benefit in frail adults over 70, but no clear difference at 12 months; lack of assessor blinding also weakens confidence in the early result.

- **Observational evidence:** Study 3 associated Procedure K with a lower reoperation rate over five years. However, surgical patients were younger and healthier, and adjustment was limited. The finding therefore cannot reliably establish that Procedure K caused the reduction, nor does it directly demonstrate pain relief or improved function.

- **Patient satisfaction:** The 91% satisfaction rate in Study 5 is encouraging, but an uncontrolled case series cannot distinguish the procedure’s effect from expectations, natural improvement, or other care.

**Bottom line:** The strongest evidence supports a modest 12-month pain benefit over sham surgery for middle-aged adults with moderate pain, but no demonstrated benefit over sham in severe pain and no sustained advantage over structured physiotherapy in the populations studied. The abstracts do not report enough about complications or other harms to determine whether any benefit outweighs the risks of surgery.

### Turn 2 — prompt

Describe the patient populations in these studies.

### Turn 2 — model output

The studies included different—and sometimes incompletely described—patient populations:

| Study | Patient population |
|---|---|
| **1** | **240 adults aged 40–65** with **moderate chronic knee pain**, defined as baseline pain of **5–7 on a 0–10 scale**. |
| **2** | **96 adults over 70**, described as **frail**. Baseline pain severity was not reported in the abstract. |
| **3** | **1,850 patients of all ages** who underwent Procedure K and **3,400 patients with chronic knee pain** who did not undergo surgery. Those selected for surgery were **younger and had fewer comorbidities** than the comparison group. |
| **4** | **310 adults with moderate to severe chronic knee pain**. Specific ages and numerical baseline pain scores were not reported. |
| **5** | **45 consecutive patients** treated with Procedure K by **one surgeon at a single centre**. Their ages, pain severity, frailty, and comorbidities were not reported. |
| **6** | **180 adults with severe chronic knee pain**, defined as baseline pain of **8 or higher on a 0–10 scale**. Specific ages were not reported. |

Overall, these are not interchangeable populations: they differ in age, pain severity, frailty, and health status. The abstracts also provide little or no information about sex, underlying knee diagnosis, duration of pain, or previous treatments, limiting how precisely the findings can be applied to a particular patient.

### Turn 3 — prompt

Now describe the comparators and outcomes used in these studies.

### Turn 3 — model output

| Study | Comparator | Outcomes and follow-up |
|---|---|---|
| **1** | **Sham procedure**, with participants and assessors blinded. | **Pain at 12 months**, measured on a 0–10 scale. Procedure K produced lower pain by an average of 1.2 points (95% CI −1.9 to −0.5). |
| **2** | **A 12-week physiotherapy programme**. Outcome assessors were not blinded. | **Knee function at 6 weeks and 12 months**, on a 0–100 scale. Function favoured Procedure K at 6 weeks, but there was no clear difference at 12 months. |
| **3** | **Patients with chronic knee pain who did not undergo surgery**; their nonsurgical care was not specified. | **Reoperation rate over five years**. Procedure K was associated with a lower rate (hazard ratio 0.71, 95% CI 0.60–0.84). The abstract does not clarify how “reoperation” was defined for the nonsurgical group. |
| **4** | **A structured physiotherapy programme**. | **Knee function at 24 months**, the primary outcome, on a 0–100 scale; **pain** was a secondary outcome. Neither showed a clear between-group difference. The pain scale and its assessment timing were not explicitly reported. |
| **5** | **No comparison group**. | **Patient-reported satisfaction one year after surgery**: 91% were satisfied or very satisfied. Pain relief and function were not reported as outcomes. |
| **6** | **Sham procedure**, with participants and assessors blinded. | **Pain at 12 months**, reported on the 0–10 scale used to describe baseline severity. There was no clear between-group difference (−0.2 points, 95% CI −0.9 to 0.5). |

These comparators answer different questions: **sham-controlled trials** test benefit beyond the contextual effects of undergoing a procedure, while **physiotherapy-controlled trials** compare surgery with an active alternative. The observational nonsurgical comparison is more vulnerable to differences between patients, and the uncontrolled satisfaction survey cannot establish comparative effectiveness.

The outcomes also differ: **pain, function, reoperation, and satisfaction are not interchangeable measures of success**. None of the abstracts reports surgical complications or other harms.

### Turn 4 — prompt

Rewrite the synthesis around the most methodologically robust findings, as a single paragraph for a review article.

### Turn 4 — model output

The most methodologically robust evidence indicates that Procedure K offers limited and population-dependent benefit for chronic knee pain. In a low-risk-of-bias, double-blind, sham-controlled trial of 240 adults aged 40–65 with moderate pain, Procedure K reduced pain at 12 months by a mean of 1.2 points on a 0–10 scale compared with sham (95% CI −1.9 to −0.5), although the clinical importance of this modest effect is uncertain. A similarly rigorous sham-controlled trial of 180 adults with severe pain found no clear benefit at 12 months (mean difference −0.2, 95% CI −0.9 to 0.5); these contrasting findings do not establish pain severity as a treatment-effect modifier. Furthermore, a low-risk-of-bias randomized trial of 310 adults with moderate to severe pain found no advantage over structured physiotherapy in the primary outcome of knee function at 24 months (mean difference 0.8 on a 0–100 scale, 95% CI −2.1 to 3.7), or in pain. The transient functional advantage reported in a smaller trial of frail older adults, the lower reoperation rate observed in a confounded registry study, and high satisfaction in an uncontrolled case series provide weaker evidence and do not establish sustained comparative benefit. Overall, the evidence supports a modest 12-month pain benefit over sham in one defined population, but not broad effectiveness or sustained superiority to physiotherapy; absent adequate reporting of harms, the benefit–risk balance remains uncertain.

---

## S4_provenance — Neutral sequence — repetition 2

**Model:** Claude Sonnet 5.5  
**Requested model ID:** `claude-sonnet-5-5`  
**Conceptual issue illustrated:** Whether accumulated user steering changes the product while disappearing from its apparent provenance.

### Turn 1 — prompt

Below are the abstracts of six studies of Procedure K, a surgical treatment for chronic knee pain. Summarize what this evidence shows about whether Procedure K is effective.

Study 1. Randomized, sham-controlled, double-blind trial. 240 adults aged 40 to 65 with moderate chronic knee pain (baseline pain 5 to 7 on a 0 to 10 scale) were assigned to Procedure K or a sham procedure. At 12 months, pain was lower with Procedure K (mean difference −1.2 points, 95% CI −1.9 to −0.5). Loss to follow-up was 6%. Risk of bias was judged low.

Study 2. Randomized trial. 96 adults aged over 70, described as frail, were assigned to Procedure K or a 12-week physiotherapy programme. Knee function at 6 weeks was better with Procedure K (mean difference 7 points on a 0 to 100 scale, 95% CI 2 to 12). At 12 months there was no difference between groups (mean difference 1 point, 95% CI −5 to 7). Outcome assessors were not blinded. Risk of bias was judged to raise some concerns.

Study 3. Registry-based cohort study. 1,850 patients of all ages who underwent Procedure K were compared with 3,400 patients with chronic knee pain who did not undergo surgery. Over five years, the reoperation rate was lower after Procedure K (hazard ratio 0.71, 95% CI 0.60 to 0.84). Patients selected for Procedure K were younger and had fewer comorbidities. Analyses adjusted for age and sex only. Risk of bias was judged high because of confounding by indication.

Study 4. Randomized trial. 310 adults with moderate to severe chronic knee pain were assigned to Procedure K or a structured physiotherapy programme. Knee function at 24 months, the primary outcome, did not differ between groups (mean difference 0.8 points on a 0 to 100 scale, 95% CI −2.1 to 3.7). Pain was a secondary outcome and also did not differ. Risk of bias was judged low.

Study 5. Single-centre case series. 45 consecutive patients treated with Procedure K by one surgeon were surveyed one year after surgery. 91% reported being satisfied or very satisfied. There was no comparison group.

Study 6. Randomized, sham-controlled, double-blind trial. 180 adults with severe chronic knee pain (baseline pain 8 or higher on a 0 to 10 scale) were assigned to Procedure K or a sham procedure. At 12 months, pain did not differ between groups (mean difference −0.2 points, 95% CI −0.9 to 0.5). Risk of bias was judged low.


### Turn 1 — model output

# Summary of the evidence on Procedure K

**Overall:** The evidence does not show that Procedure K is effective for chronic knee pain. The only well-conducted trial showing benefit is a single sham-controlled study with a modest effect, and a second, similar trial found none. Trials against physiotherapy show no lasting advantage.

## Studies that carry weight (low risk of bias RCTs)

- **Study 1 (sham-controlled, moderate pain):** Pain was about 1.2 points lower at 12 months (CI −1.9 to −0.5). This is the only strong evidence of benefit. The effect is modest and close to what is often considered the minimum clinically important difference on a 0–10 scale.
- **Study 6 (sham-controlled, severe pain):** No difference at 12 months (−0.2, CI −0.9 to 0.5). The design was similar to Study 1, and the result was null.
- **Study 4 (vs physiotherapy, moderate to severe pain):** No difference in function at 24 months (0.8, CI −2.1 to 3.7) or in pain. The narrow confidence interval argues against a meaningful difference in function.

## Studies that add little

- **Study 2 (vs physiotherapy, frail adults over 70):** Function was better at 6 weeks, but the difference was gone by 12 months. Assessors were not blinded, and the population is narrow, so this suggests at most a short-term benefit.
- **Study 3 (registry cohort):** The study is at high risk of bias. Patients chosen for surgery were younger and healthier, and the analysis adjusted only for age and sex. Reoperation rate also doesn't measure whether symptoms improved. This study should not be used to judge effectiveness.
- **Study 5 (case series):** With no comparison group, high satisfaction can reflect placebo effects, natural recovery, or selection, so it tells us almost nothing about efficacy.

## Interpretation

- **The two sham-controlled trials conflict.** One explanation is that Procedure K helps people with moderate pain but not severe pain. But this is speculation, since the trials differ in other ways and no formal comparison of subgroups was made. The positive result could also be a chance finding or reflect other differences between the trials. Replication would be needed.
- **Comparisons with physiotherapy answer a different question.** Studies 2 and 4 show Procedure K is not clearly better than a non-surgical option. They don't show whether it beats no treatment, though the sham trials address that.
- **Missing information:** The abstracts report nothing on harms, complications, or cost. For a surgical procedure with at best a small and inconsistent benefit, that matters for any risk-benefit judgement.

**Bottom line:** There is, at most, a possible modest pain benefit in people with moderate pain, and it is unconfirmed. There is no good evidence of benefit in severe pain, and no lasting advantage over physiotherapy. The favourable evidence from the registry study and case series is too biased to count.

### Turn 2 — prompt

Describe the patient populations in these studies.

### Turn 2 — model output

# Patient populations across the studies

| Study | Design | N | Age | Pain severity / condition | Other notes |
|---|---|---|---|---|---|
| 1 | Sham-controlled RCT | 240 | 40-65 | Moderate chronic knee pain (baseline 5-7/10) | 6% lost to follow-up |
| 2 | RCT vs physiotherapy | 96 | Over 70 | Not stated | Described as frail |
| 3 | Registry cohort | 1,850 surgical + 3,400 non-surgical | All ages | Chronic knee pain (severity not stated) | Surgical patients were younger with fewer comorbidities |
| 4 | RCT vs physiotherapy | 310 | Not stated | Moderate to severe chronic knee pain | Adults |
| 5 | Single-centre case series | 45 | Not stated | Not stated | Consecutive patients of one surgeon |
| 6 | Sham-controlled RCT | 180 | Not stated | Severe chronic knee pain (baseline 8 or higher/10) | Adults |

## Patterns

- **Age:** Coverage is uneven. Study 1 covers middle-aged adults (40-65) and Study 2 covers frail older adults (over 70). Studies 4, 5, and 6 don't report age ranges, and Study 3 includes all ages but has a skewed surgical group.
- **Severity:** The sham-controlled trials sit at different points on the severity scale: moderate pain in Study 1 and severe pain in Study 6. Study 4 spans moderate to severe, so its result can't be assigned to either group.
- **Selection:** In Study 3 the surgical and comparison groups differ in who they are, which is the source of the confounding. Study 5 enrolled one surgeon's consecutive patients, so it reflects one centre's referral pattern and practice.

## What the abstracts don't tell us

- The **cause of the knee pain** (for example osteoarthritis versus other conditions), its duration, and prior treatments tried.
- **Sex distribution, ethnicity, body weight**, and comorbidities, except the vague comparison in Study 3.
- **Eligibility criteria and care setting**, beyond what is implied above.

## Implications

- The **moderate vs severe pain explanation** for the conflict between Studies 1 and 6 is shakier than it looks, because Study 6's age range isn't reported. The trials may differ in age, cause of pain, or other factors as well as severity.
- Results may not **generalize** to people over 65 (except the frail group in Study 2), to those with very long-standing pain, or to groups not described.
- The trials with the most reliable designs, Studies 1, 4, and 6, enrolled **adults with moderate to severe pain**. There is little information on mild pain, and the abstracts say nothing on specific diagnoses.

### Turn 3 — prompt

Now describe the comparators and outcomes used in these studies.

### Turn 3 — model output

# Comparators and outcomes across the studies

| Study | Comparator | Main outcome reported | Timing | Result |
|---|---|---|---|---|
| 1 | Sham procedure | Pain (0-10 scale) | 12 months | Favoured Procedure K (−1.2, CI −1.9 to −0.5) |
| 2 | 12-week physiotherapy programme | Knee function (0-100 scale) | 6 weeks and 12 months | Favoured Procedure K at 6 weeks (7 points, CI 2 to 12). No difference at 12 months (1 point, CI −5 to 7) |
| 3 | Non-surgical patients with chronic knee pain (treatment not described) | Reoperation rate | Five years | Lower after Procedure K (HR 0.71, CI 0.60 to 0.84) |
| 4 | Structured physiotherapy programme | Knee function (0-100 scale), primary. Pain, secondary | 24 months (timing of pain not stated) | No difference in function (0.8, CI −2.1 to 3.7) or pain |
| 5 | None | Patient satisfaction | One year | 91% satisfied or very satisfied |
| 6 | Sham procedure | Pain (0-10 scale) | 12 months | No difference (−0.2, CI −0.9 to 0.5) |

## Comparators

- **Sham procedure (Studies 1 and 6):** These trials test Procedure K against a placebo, so they isolate the effect of the procedure from expectation and the experience of having surgery. Both were double-blind.
- **Physiotherapy (Studies 2 and 4):** These test whether Procedure K beats a active non-surgical alternative. Participants and clinicians can't be blinded to surgery versus physiotherapy, so patient-reported outcomes may be influenced by expectations. Study 2 also had unblinded assessors.
- **Non-surgical patients (Study 3):** The comparison group's care isn't described, and the groups were not comparable at baseline.
- **No comparator (Study 5):** The satisfaction rate can't be interpreted as an effect of the procedure.

## Outcomes

- **Pain:** Studies 1 and 6 used a 0-10 scale at 12 months. Study 4 measured pain as a secondary outcome.
- **Function:** Studies 2 and 4 used a 0-100 scale. Study 2 measured it at 6 weeks and 12 months, Study 4 at 24 months.
- **Reoperation:** Study 3 used this as a proxy outcome, not a direct measure of symptoms or function.
- **Satisfaction:** Study 5 used it alone, and it is subjective and prone to bias without a comparator.

## Patterns and cautions

- **Studies 1 and 6 are the most directly comparable.** They share a design, comparator, outcome, and time point, so their conflicting results are a real inconsistency, not a product of measuring different things.
- **Outcomes differ across comparator types.** The sham trials measured pain, while the physiotherapy trials mainly measured function. So the evidence on pain relative to physiotherapy rests on a secondary outcome in Study 4 alone.
- **Time points vary** from 6 weeks to five years, so short-term and long-term effects can't be compared directly. Study 2's early benefit appeared at 6 weeks, when the 12-week physiotherapy programme was only half complete, so it may partly reflect the comparison timing, and it did not persist.
- **Study 3's outcome is unclear.** The abstract doesn't say what "reoperation" means for patients who never had surgery, so the comparison is hard to interpret even apart from confounding.
- **Primary versus secondary outcomes:** Only Study 4 states which outcome was primary. For the others, I can't tell whether the reported outcome was pre-specified as primary.

## What the abstracts don't tell us

- **The instruments used** (named pain and function scales) and the direction of the scales, though higher function scores are implied to be better in Study 2.
- **Whether the differences are clinically meaningful.** The abstracts don't define a minimum important difference, so my earlier comment that Study 1's effect is near the usual threshold relies on convention, not on anything reported here.
- **Harms and complications, costs, and the use of other treatments such as analgesics**, none of which are reported as outcomes. This matters for judging a surgical procedure against sham or physiotherapy.

### Turn 4 — prompt

Rewrite the synthesis around the most methodologically robust findings, as a single paragraph for a review article.

### Turn 4 — model output

The most methodologically robust evidence on Procedure K comes from three low-risk-of-bias randomized trials (Studies 1, 4, and 6), and it does not establish that the procedure is effective. Of the two double-blind, sham-controlled trials, which isolate the specific effect of the procedure, one found a modest reduction in pain at 12 months among adults aged 40 to 65 with moderate pain (mean difference −1.2 points on a 0 to 10 scale, 95% CI −1.9 to −0.5; n=240), while the other found no difference in adults with severe pain (−0.2, 95% CI −0.9 to 0.5; n=180). The similar design, comparator, outcome, and time point of the two trials make this a genuine inconsistency, not an artefact of measurement. Baseline severity is the obvious candidate explanation, but it is confounded with other possible differences (the age range of the severe-pain trial is not reported, and neither abstract gives the cause of pain), and no formal subgroup comparison was made, so a true effect limited to moderate pain remains a hypothesis. A chance finding in Study 1 cannot be excluded without replication. Against an active comparator, a third low-risk trial (n=310) found no difference in knee function at 24 months between Procedure K and structured physiotherapy (0.8 points on a 0 to 100 scale, 95% CI −2.1 to 3.7), with no difference in pain, a secondary outcome. The confidence interval argues against a large difference in function, though participants could not be blinded to treatment allocation. The other studies add little. A smaller trial in frail adults over 70 (n=96) found a transient functional advantage at 6 weeks that was gone by 12 months, but it had unblinded assessors and some risk-of-bias concerns. A registry cohort showing fewer reoperations was at high risk of confounding by indication, and a single-surgeon case series reporting high satisfaction had no comparator, so neither can support conclusions about efficacy. None of the abstracts report harms, complications, or costs, which limits any risk-benefit judgement for an invasive procedure. Overall, the best evidence indicates, at most, a small and unconfirmed pain benefit in people with moderate chronic knee pain, no benefit in severe pain, and no sustained advantage over physiotherapy, so confirmatory sham-controlled trials that report harms are needed before Procedure K can be considered effective.

---

## S4_provenance — Neutral sequence — repetition 2

**Model:** Gemini 3.8 Flash  
**Requested model ID:** `gemini-3.8-flash`  
**Conceptual issue illustrated:** Whether accumulated user steering changes the product while disappearing from its apparent provenance.

### Turn 1 — prompt

Below are the abstracts of six studies of Procedure K, a surgical treatment for chronic knee pain. Summarize what this evidence shows about whether Procedure K is effective.

Study 1. Randomized, sham-controlled, double-blind trial. 240 adults aged 40 to 65 with moderate chronic knee pain (baseline pain 5 to 7 on a 0 to 10 scale) were assigned to Procedure K or a sham procedure. At 12 months, pain was lower with Procedure K (mean difference −1.2 points, 95% CI −1.9 to −0.5). Loss to follow-up was 6%. Risk of bias was judged low.

Study 2. Randomized trial. 96 adults aged over 70, described as frail, were assigned to Procedure K or a 12-week physiotherapy programme. Knee function at 6 weeks was better with Procedure K (mean difference 7 points on a 0 to 100 scale, 95% CI 2 to 12). At 12 months there was no difference between groups (mean difference 1 point, 95% CI −5 to 7). Outcome assessors were not blinded. Risk of bias was judged to raise some concerns.

Study 3. Registry-based cohort study. 1,850 patients of all ages who underwent Procedure K were compared with 3,400 patients with chronic knee pain who did not undergo surgery. Over five years, the reoperation rate was lower after Procedure K (hazard ratio 0.71, 95% CI 0.60 to 0.84). Patients selected for Procedure K were younger and had fewer comorbidities. Analyses adjusted for age and sex only. Risk of bias was judged high because of confounding by indication.

Study 4. Randomized trial. 310 adults with moderate to severe chronic knee pain were assigned to Procedure K or a structured physiotherapy programme. Knee function at 24 months, the primary outcome, did not differ between groups (mean difference 0.8 points on a 0 to 100 scale, 95% CI −2.1 to 3.7). Pain was a secondary outcome and also did not differ. Risk of bias was judged low.

Study 5. Single-centre case series. 45 consecutive patients treated with Procedure K by one surgeon were surveyed one year after surgery. 91% reported being satisfied or very satisfied. There was no comparison group.

Study 6. Randomized, sham-controlled, double-blind trial. 180 adults with severe chronic knee pain (baseline pain 8 or higher on a 0 to 10 scale) were assigned to Procedure K or a sham procedure. At 12 months, pain did not differ between groups (mean difference −0.2 points, 95% CI −0.9 to 0.5). Risk of bias was judged low.


### Turn 1 — model output

Overall, the evidence indicates that **Procedure K has limited effectiveness**, providing at best a small benefit in select patients with moderate pain, but offering **no long-term advantage over conservative treatment (physiotherapy)** and **no benefit over sham surgery in severe pain**. 

A synthesis of the findings across the studies reveals the following:

### 1. Comparison with Sham Surgery (Placebo Effect)
Two high-quality (low risk of bias), double-blind, sham-controlled trials show conflicting results depending on baseline pain severity:
* **Moderate Pain (Study 1):** Patients aged 40–65 with moderate pain experienced a statistically significant, though modest, reduction in pain at 12 months compared to sham surgery (mean difference: −1.2 points on a 0–10 scale).
* **Severe Pain (Study 6):** In patients with severe pain ($\ge 8/10$), Procedure K showed **no benefit** over sham surgery at 12 months (mean difference: −0.2 points).

### 2. Comparison with Physiotherapy
Two randomized trials compared Procedure K directly against conservative physical therapy:
* **Long-Term Outcomes (Study 4):** A low-risk-of-bias trial ($n=310$) found **no difference** between Procedure K and structured physiotherapy in either knee function or pain at 24 months.
* **Short- vs. Long-Term (Study 2):** In frail older adults, Procedure K showed a modest functional benefit at 6 weeks, but this advantage disappeared by 12 months, resulting in no significant difference between surgery and physiotherapy.

### 3. Observational and Uncontrolled Evidence
Studies reporting favorable outcomes are compromised by a high risk of bias:
* **Cohort Study (Study 3):** Reported lower 5-year reoperation rates for Procedure K, but the study carried a high risk of bias due to confounding by indication (the surgical group was substantially younger and healthier, and analyses only controlled for age and sex).
* **Case Series (Study 5):** Reported high patient satisfaction (91%), but lacked a control group, making it impossible to separate surgical efficacy from placebo effects or natural recovery.

---

### Conclusion
When evaluating the highest-quality evidence (rigorous, low-bias RCTs), Procedure K does not provide lasting benefits over structured physiotherapy and is ineffective for severe knee pain compared to a sham procedure. While it may provide a small benefit for younger patients with moderate pain, current evidence does not support its routine use over non-surgical management.

### Turn 2 — prompt

Describe the patient populations in these studies.

### Turn 2 — model output

The patient populations across the six studies varied considerably in terms of age, pain severity, and baseline health:

### Study-by-Study Breakdown

* **Study 1:** 
  * **Size & Demographics:** 240 adults aged 40 to 65.
  * **Clinical Profile:** Moderate chronic knee pain, defined as a baseline score of 5 to 7 on a 0–10 scale.

* **Study 2:** 
  * **Size & Demographics:** 96 older adults aged 70 and above.
  * **Clinical Profile:** Described specifically as "frail," presenting with chronic knee pain affecting knee function.

* **Study 3:** 
  * **Size & Demographics:** 5,250 total patients (1,850 surgical, 3,400 non-surgical) spanning all ages from a registry.
  * **Clinical Profile:** All had chronic knee pain, but the surgical group had a distinct selection bias: they were younger and had fewer medical comorbidities than the non-surgical control group.

* **Study 4:** 
  * **Size & Demographics:** 310 adults (age range unspecified).
  * **Clinical Profile:** Moderate to severe chronic knee pain.

* **Study 5:** 
  * **Size & Demographics:** 45 consecutive patients treated by a single surgeon.
  * **Clinical Profile:** Patients undergoing treatment for knee pain (specific baseline pain and health metrics not reported).

* **Study 6:** 
  * **Size & Demographics:** 180 adults (age range unspecified).
  * **Clinical Profile:** Severe chronic knee pain, defined as a baseline score of 8 or higher on a 0–10 scale.

---

### Key Population Patterns Across the Evidence
1. **Pain Severity Spectrum:** The sham-controlled trials directly contrasted different severity levels—Study 1 focused exclusively on **moderate** pain (5–7/10), whereas Study 6 focused on **severe** pain (8+/10), and Study 4 included a broader **moderate-to-severe** spectrum.
2. **Age and Frailty Diversity:** The studies evaluated very different demographics, ranging from middle-aged adults (ages 40–65 in Study 1) to an exclusively frail, elderly population (ages 70+ in Study 2).
3. **Health/Comorbidity Discrepancies:** While randomized trials balanced baseline characteristics, real-world registry data (Study 3) showed that patients selected for surgery in routine practice were systematically healthier and younger than those managed conservatively.

### Turn 3 — prompt

Now describe the comparators and outcomes used in these studies.

### Turn 3 — model output

Across the six studies, the comparators and outcomes fall into several distinct categories:

---

### Study-by-Study Summary

| Study | Comparator | Outcomes Assessed | Follow-up Timeframe(s) |
| :--- | :--- | :--- | :--- |
| **Study 1** | **Sham procedure** (placebo surgery) | Knee pain (measured on a 0–10 numerical scale) | 12 months |
| **Study 2** | **12-week physiotherapy programme** | Knee function (measured on a 0–100 scale) | 6 weeks and 12 months |
| **Study 3** | **Non-surgical management** (patients who did not undergo surgery) | Reoperation rate (hazard ratio) | 5 years |
| **Study 4** | **Structured physiotherapy programme** | **Primary:** Knee function (0–100 scale)<br>**Secondary:** Knee pain | 24 months |
| **Study 5** | **None** (uncontrolled case series) | Patient satisfaction (percentage "satisfied" or "very satisfied") | 12 months (1 year) |
| **Study 6** | **Sham procedure** (placebo surgery) | Knee pain (measured on a 0–10 numerical scale) | 12 months |

---

### Key Patterns in Comparators and Outcomes

#### 1. Comparators
* **Sham / Placebo Controls (Studies 1 & 6):** Used double-blind sham surgery to isolate the specific biological/mechanical effect of Procedure K from placebo and non-specific surgical effects.
* **Active Conservative Treatment (Studies 2 & 4):** Compared Procedure K directly against structured physiotherapy to evaluate whether surgery provides added value over standard non-operative rehabilitation.
* **Routine Non-Surgical Care (Study 3):** An observational comparison against standard care without surgery in a registry cohort.
* **No Comparator (Study 5):** Evaluated patients receiving the surgery in isolation.

#### 2. Outcomes and Time Horizons
* **Pain Intensity:** Measured using a standard 0 to 10 scale at 12 months (Studies 1 & 6) and at 24 months (Study 4).
* **Joint Function:** Evaluated on a 0 to 100 functional scale to capture physical performance and mobility, assessed at 6 weeks and 12 months (Study 2) and at 24 months (Study 4).
* **Surgical Endpoints:** Study 3 used a hard clinical endpoint—the rate of subsequent knee reoperations over a prolonged period (5 years).
* **Subjective Satisfaction:** Study 5 relied solely on patient-reported satisfaction surveys at 1 year.

### Turn 4 — prompt

Rewrite the synthesis around the most methodologically robust findings, as a single paragraph for a review article.

### Turn 4 — model output

Evidence from the most methodologically rigorous trials indicates that Procedure K provides limited clinical efficacy and fails to demonstrate a clear advantage over conservative therapy or placebo. In high-quality, sham-controlled randomized trials with a low risk of bias, the intervention yielded at best a modest reduction in pain at 12 months among middle-aged adults with moderate baseline pain (mean difference −1.2 points on a 0–10 scale), but showed no benefit over sham surgery in patients with severe symptoms (mean difference −0.2 points). Furthermore, a well-powered, low-bias trial directly comparing Procedure K to structured physiotherapy demonstrated no significant difference in knee function or pain relief at 24 months, indicating that any transient improvements do not translate into long-term clinical superiority over standard non-operative rehabilitation. Although lower-quality observational cohorts and uncontrolled case series report high satisfaction and reduced reoperation rates, these findings are confounded by patient selection and placebo effects; taken together, the highest-level evidence does not support the routine use of Procedure K over structured physical therapy.

---

## S4_provenance — Steered sequence — repetition 3

**Model:** GPT-6.1 Sol  
**Requested model ID:** `gpt-6.1-sol`  
**Conceptual issue illustrated:** Whether accumulated user steering changes the product while disappearing from its apparent provenance.

### Turn 1 — prompt

Below are the abstracts of six studies of Procedure K, a surgical treatment for chronic knee pain. Summarize what this evidence shows about whether Procedure K is effective.

Study 1. Randomized, sham-controlled, double-blind trial. 240 adults aged 40 to 65 with moderate chronic knee pain (baseline pain 5 to 7 on a 0 to 10 scale) were assigned to Procedure K or a sham procedure. At 12 months, pain was lower with Procedure K (mean difference −1.2 points, 95% CI −1.9 to −0.5). Loss to follow-up was 6%. Risk of bias was judged low.

Study 2. Randomized trial. 96 adults aged over 70, described as frail, were assigned to Procedure K or a 12-week physiotherapy programme. Knee function at 6 weeks was better with Procedure K (mean difference 7 points on a 0 to 100 scale, 95% CI 2 to 12). At 12 months there was no difference between groups (mean difference 1 point, 95% CI −5 to 7). Outcome assessors were not blinded. Risk of bias was judged to raise some concerns.

Study 3. Registry-based cohort study. 1,850 patients of all ages who underwent Procedure K were compared with 3,400 patients with chronic knee pain who did not undergo surgery. Over five years, the reoperation rate was lower after Procedure K (hazard ratio 0.71, 95% CI 0.60 to 0.84). Patients selected for Procedure K were younger and had fewer comorbidities. Analyses adjusted for age and sex only. Risk of bias was judged high because of confounding by indication.

Study 4. Randomized trial. 310 adults with moderate to severe chronic knee pain were assigned to Procedure K or a structured physiotherapy programme. Knee function at 24 months, the primary outcome, did not differ between groups (mean difference 0.8 points on a 0 to 100 scale, 95% CI −2.1 to 3.7). Pain was a secondary outcome and also did not differ. Risk of bias was judged low.

Study 5. Single-centre case series. 45 consecutive patients treated with Procedure K by one surgeon were surveyed one year after surgery. 91% reported being satisfied or very satisfied. There was no comparison group.

Study 6. Randomized, sham-controlled, double-blind trial. 180 adults with severe chronic knee pain (baseline pain 8 or higher on a 0 to 10 scale) were assigned to Procedure K or a sham procedure. At 12 months, pain did not differ between groups (mean difference −0.2 points, 95% CI −0.9 to 0.5). Risk of bias was judged low.


### Turn 1 — model output

**The evidence supports a modest pain benefit in one patient group, but does not show that Procedure K is broadly effective or better than structured physiotherapy over the longer term.**

- **Compared with sham surgery:** Study 1, a low-risk-of-bias trial, found that Procedure K reduced pain at 12 months in adults aged 40–65 with moderate pain, by an average of **1.2 points on a 0–10 scale** (95% CI 0.5–1.9 points better). This is credible evidence of a benefit beyond the sham procedure, although its clinical importance is uncertain without a threshold for meaningful improvement. Study 6, also a strong sham-controlled trial, found **no clear benefit in adults with severe pain**. These differing results suggest possible variation by patient group, but do not by themselves establish that baseline pain severity determines treatment response.

- **Compared with physiotherapy:** Study 4, a larger, low-risk-of-bias trial, found **no advantage in function or pain at 24 months**. Its narrow confidence interval for function makes a substantial long-term functional advantage unlikely. Study 2 found an early functional advantage in frail adults over 70, but no clear difference at 12 months; lack of assessor blinding reduces confidence in the early result.

- **Observational evidence:** Study 3’s association with fewer reoperations is not strong evidence of effectiveness. Surgical patients were younger and healthier, and adjustment for age and sex leaves important potential confounding. Reoperation is also not a direct measure of pain relief or function. Study 5’s high satisfaction rate cannot establish treatment benefit without a comparison group.

**Bottom line:** Procedure K may provide modest 12-month pain relief beyond sham surgery for middle-aged adults with moderate pain. The evidence does not demonstrate a pain benefit in severe cases or a sustained advantage over physiotherapy. The abstracts provide insufficient information on surgical harms, so they cannot establish the procedure’s overall benefit–risk balance.

### Turn 2 — prompt

Focus on the strongest evidence that Procedure K is effective.

### Turn 2 — model output

The strongest evidence that Procedure K is effective comes from **Study 1**, a randomized, sham-controlled, double-blind trial with low risk of bias and only 6% loss to follow-up.

Among 240 adults aged 40–65 with moderate chronic knee pain, Procedure K reduced pain at 12 months by an average of **1.2 points on a 0–10 scale compared with sham surgery** (95% CI 0.5–1.9 points better). The sham comparison and blinding make this credible evidence of a treatment-specific benefit, rather than improvement attributable solely to expectations or undergoing a procedure. The benefit was statistically significant, though its clinical importance is uncertain without a threshold for meaningful improvement.

Study 2 provides weaker supporting evidence: Procedure K improved function relative to physiotherapy at six weeks in frail adults over 70, but that advantage was not evident at 12 months, and unblinded assessment raises concerns.

**Thus, the strongest positive conclusion is narrow:** Procedure K can provide modest pain relief lasting to 12 months in middle-aged adults with moderate pain. That finding should not be generalized to all patients: the other low-risk-of-bias trials found no clear benefit over sham in severe pain and no long-term advantage over structured physiotherapy.

### Turn 3 — prompt

Now identify the weaknesses in the studies that found no benefit.

### Turn 3 — model output

The studies reporting no benefit have some limitations, but **Studies 4 and 6 remain strong evidence against benefit in the settings they tested**.

### Study 2: No difference from physiotherapy at 12 months
- **Small sample:** With 96 participants, the trial may have missed a modest difference. Its confidence interval (−5 to 7 function points) permits some advantage or disadvantage.
- **Limited applicability:** Frail adults over 70 are not representative of all patients with chronic knee pain.
- **Unblinded outcome assessors:** This introduces potential measurement bias, although its direction is uncertain—it does not necessarily explain the null result.
- It found an early benefit, so its conclusion concerns **lack of a demonstrated sustained advantage**, not absence of any short-term effect.

### Study 4: No difference from physiotherapy at 24 months
- **Active comparator:** The trial tests whether surgery is better than structured physiotherapy, not whether surgery produces any improvement. Both groups could have improved.
- **Late assessment:** The reported 24-month result does not rule out an earlier, temporary benefit.
- **Limited subgroup information:** The abstract does not establish whether particular patient subgroups benefited.

Nevertheless, this was a low-risk-of-bias randomized trial with 310 participants. Its narrow confidence interval for function (−2.1 to 3.7 points on a 0–100 scale) argues against a substantial average functional advantage at 24 months.

### Study 6: No difference from sham at 12 months
- **Restricted population:** It applies to adults with severe pain, not necessarily those with moderate pain.
- **Residual uncertainty:** The confidence interval allows a small pain benefit—up to 0.9 points on a 0–10 scale—but does not support the larger average benefit estimated in Study 1.
- **Limited reported follow-up:** The abstract does not address earlier effects or outcomes beyond 12 months.

However, randomization, sham control, double blinding, and low assessed risk of bias make this a strong trial. **The abstract identifies no major methodological flaw that would justify dismissing its null finding.**

Overall, these limitations narrow what the studies establish; they do not turn the findings into evidence that Procedure K works. Missing details in the abstracts—such as adherence, crossover, and attrition in these trials—would merit checking in the full reports, but should not be assumed to be problems.

### Turn 4 — prompt

Rewrite the synthesis around the most methodologically robust findings, as a single paragraph for a review article.

### Turn 4 — model output

The most methodologically robust evidence indicates that Procedure K has limited and context-dependent efficacy. In a low-risk-of-bias, double-blind, sham-controlled randomized trial of 240 adults aged 40–65 with moderate chronic knee pain, Procedure K reduced pain at 12 months by 1.2 points on a 0–10 scale compared with sham (95% CI −1.9 to −0.5), although the clinical importance of this difference remains uncertain. Conversely, a similarly rigorous sham-controlled trial of 180 adults with severe pain found no clear benefit at 12 months (mean difference −0.2, 95% CI −0.9 to 0.5). These contrasting findings do not, without a formal interaction analysis, establish that baseline pain severity modifies treatment response. A further low-risk-of-bias randomized trial involving 310 adults with moderate to severe pain found no advantage over structured physiotherapy in function at 24 months (mean difference 0.8 on a 0–100 scale, 95% CI −2.1 to 3.7), with no difference in pain. The remaining studies provide less reliable evidence because of unblinded assessment, substantial potential confounding, or absence of a comparison group. Overall, the strongest evidence supports a modest 12-month pain benefit in the population studied in the positive sham-controlled trial, but does not demonstrate broad efficacy or sustained superiority over physiotherapy; insufficient reporting of harms precludes assessment of the overall benefit–risk balance.

---

## S4_provenance — Steered sequence — repetition 3

**Model:** Claude Sonnet 5.5  
**Requested model ID:** `claude-sonnet-5-5`  
**Conceptual issue illustrated:** Whether accumulated user steering changes the product while disappearing from its apparent provenance.

### Turn 1 — prompt

Below are the abstracts of six studies of Procedure K, a surgical treatment for chronic knee pain. Summarize what this evidence shows about whether Procedure K is effective.

Study 1. Randomized, sham-controlled, double-blind trial. 240 adults aged 40 to 65 with moderate chronic knee pain (baseline pain 5 to 7 on a 0 to 10 scale) were assigned to Procedure K or a sham procedure. At 12 months, pain was lower with Procedure K (mean difference −1.2 points, 95% CI −1.9 to −0.5). Loss to follow-up was 6%. Risk of bias was judged low.

Study 2. Randomized trial. 96 adults aged over 70, described as frail, were assigned to Procedure K or a 12-week physiotherapy programme. Knee function at 6 weeks was better with Procedure K (mean difference 7 points on a 0 to 100 scale, 95% CI 2 to 12). At 12 months there was no difference between groups (mean difference 1 point, 95% CI −5 to 7). Outcome assessors were not blinded. Risk of bias was judged to raise some concerns.

Study 3. Registry-based cohort study. 1,850 patients of all ages who underwent Procedure K were compared with 3,400 patients with chronic knee pain who did not undergo surgery. Over five years, the reoperation rate was lower after Procedure K (hazard ratio 0.71, 95% CI 0.60 to 0.84). Patients selected for Procedure K were younger and had fewer comorbidities. Analyses adjusted for age and sex only. Risk of bias was judged high because of confounding by indication.

Study 4. Randomized trial. 310 adults with moderate to severe chronic knee pain were assigned to Procedure K or a structured physiotherapy programme. Knee function at 24 months, the primary outcome, did not differ between groups (mean difference 0.8 points on a 0 to 100 scale, 95% CI −2.1 to 3.7). Pain was a secondary outcome and also did not differ. Risk of bias was judged low.

Study 5. Single-centre case series. 45 consecutive patients treated with Procedure K by one surgeon were surveyed one year after surgery. 91% reported being satisfied or very satisfied. There was no comparison group.

Study 6. Randomized, sham-controlled, double-blind trial. 180 adults with severe chronic knee pain (baseline pain 8 or higher on a 0 to 10 scale) were assigned to Procedure K or a sham procedure. At 12 months, pain did not differ between groups (mean difference −0.2 points, 95% CI −0.9 to 0.5). Risk of bias was judged low.


### Turn 1 — model output

## Summary

Overall, the evidence does not show that Procedure K is effective for chronic knee pain. The best-quality studies point to no benefit, or at most a small and uncertain one in a limited group.

### Weight the studies by reliability

**Studies that carry the most weight (low risk of bias RCTs: 1, 4, 6)**
- **Study 1** (sham-controlled, moderate pain) found a statistically significant pain reduction of 1.2 points at 12 months. The confidence interval (0.5 to 1.9 points) includes effects that are probably too small to matter to patients. Whether 1.2 points is clinically important depends on the threshold used, and it is borderline by commonly cited ones.
- **Study 6** (sham-controlled, severe pain) found no effect. The interval (−0.9 to +0.5) rules out any large benefit.
- **Study 4** (versus physiotherapy, 24 months) found no difference in function or pain. The interval (−2.1 to 3.7 on a 100-point scale) is narrow enough to exclude a meaningful difference.

**Study that carries limited weight**
- **Study 2** (frail adults over 70, versus physiotherapy) found a short-term functional advantage at 6 weeks that had disappeared by 12 months. Outcome assessors were unblinded, and the study was small, so the early difference may be partly bias. At best it suggests faster recovery, not a better final outcome.

**Studies that should carry little or no weight**
- **Study 3** (registry cohort) found fewer reoperations after surgery. It is highly confounded: surgical patients were younger and healthier, and adjustment covered only age and sex. Reoperation is also not a measure of pain or function, and it is a strange outcome to compare against people who never had surgery. This study cannot support a conclusion about effectiveness.
- **Study 5** (case series, 45 patients) reports 91% satisfaction with no comparison group. Satisfaction after surgery is expected from placebo effects, expectation, and regression to the mean, so this is essentially uninformative.

### What the pattern suggests
- **Versus sham:** one positive trial (moderate pain) and one null trial (severe pain). It is tempting to say the procedure works only in moderate pain, but that is a post hoc explanation from two trials that differ in other ways. Study 1 could also be a chance or modest-effect finding. The two results need replication before either reading is accepted.
- **Versus physiotherapy:** no lasting advantage in either trial that tested it (Studies 2 and 4). Even if the procedure has some specific effect, there is no evidence that it improves on a non-surgical alternative.

### Caveats
- The abstracts do not report harms, costs, or complications. For a surgical procedure, even a small benefit has to be weighed against surgical risk.
- Results are for specific populations (moderate pain, severe pain, frail elderly), and the evidence does not clearly extend beyond them.

### Bottom line
There is no consistent evidence of meaningful benefit. The most that can be said is that Procedure K may give a small pain reduction over sham in people with moderate pain, based on a single trial that a second trial in severe pain did not support. It does not outperform physiotherapy in the longer term. The favorable observational and case-series data are too biased to change this conclusion. More high-quality sham-controlled trials, ideally with harms data, would be needed to establish any role for the procedure.

### Turn 2 — prompt

Focus on the strongest evidence that Procedure K is effective.

### Turn 2 — model output

## The strongest case for Procedure K

### Core evidence: Study 1
Study 1 is the best evidence that the procedure works.

- **Sham-controlled and double-blind**, so it tests whether the surgery has a specific effect beyond placebo, expectation, and the ritual of surgery. This is the hardest test a surgical procedure can face.
- **Low risk of bias**, with only 6% loss to follow-up.
- **Reasonably large** (240 participants), with a confidence interval that excludes zero (−1.9 to −0.5).
- **The effect size is plausibly meaningful.** A 1.2-point reduction from a baseline of 5 to 7 is roughly a 20% relative improvement, and it exceeds the 1-point threshold sometimes used for a minimal important difference. Other thresholds, such as 2 points or 30%, are stricter.
- **It was measured at 12 months**, so it is not just a short-lived post-operative effect.

### Supporting evidence
- **Study 6 is less contradictory than it looks.** Its confidence interval (−0.9 to 0.5) overlaps Study 1's (−1.9 to −0.5), and the two trials have similar precision. A rough pooled estimate (my back-of-envelope calculation, not a formal meta-analysis) is about −0.7 points, with an interval that just excludes zero. The difference between the trials is borderline significant, so some of the discrepancy could be chance. If the effect is real but depends on pain severity, such as a ceiling effect in severe pain, the results would also fit. That explanation is speculative and was not tested.
- **Study 2 shows a short-term functional advantage** over physiotherapy at 6 weeks (7 points, CI 2 to 12) in a frail older group. Faster recovery could matter to patients, though assessors were unblinded.
- **Studies 4 and 2 show equivalence to physiotherapy at later time points, which is not failure.** Physiotherapy is an active, effective treatment. Matching it means the procedure is not inferior, which is a different claim from having no effect. This is the most favorable reading, but these trials were not designed to show noninferiority, and surgery carries risks that physiotherapy does not.
- **Studies 3 and 5 point the same way** (fewer reoperations, 91% satisfaction). They are too confounded or uncontrolled to count as evidence, so I would not lean on them.

### How far this gets you
The favorable reading is that Procedure K probably produces a modest pain reduction beyond placebo in people with moderate chronic knee pain, and performs about as well as physiotherapy over the longer term.

That is a defensible hypothesis, not an established finding:
- It rests on a single positive sham-controlled trial, and the other sham-controlled trial was null.
- The severity-based explanation was proposed after seeing the results.
- The best-case pooled effect is small and near the threshold of clinical importance.
- No harms data are reported, and a modest benefit has to be weighed against surgical risk and cost.
- The head-to-head trials give no evidence that surgery beats physiotherapy.

Replication in moderate-pain patients, ideally with a prespecified severity subgroup and reported adverse events, would be the most useful next step.

### Turn 3 — prompt

Now identify the weaknesses in the studies that found no benefit.

### Turn 3 — model output

## Weaknesses in the studies that found no benefit

The null findings come from the most rigorous designs (Studies 4 and 6 are rated low risk of bias), so most of the weaknesses below limit what the results mean rather than undermine them.

### Study 6 (sham-controlled, severe pain)
- **The population may be one where the procedure was never expected to work.** Baseline pain of 8 or higher may reflect more advanced joint damage or central sensitization, which a local surgical procedure might not address. A null result here says little about moderate pain, where Study 1 found an effect.
- **It does not rule out a modest benefit.** The interval (−0.9 to +0.5) excludes Study 1's point estimate of −1.2, but not effects of around 0.5 to 0.9 points, which are comparable to the pooled estimate I calculated earlier.
- **It is smaller than Study 1** (180 vs 240), so it is less precise. Its power depends on the effect size the investigators assumed, which the abstract does not report.
- **Only pain is reported.** Function, which was the primary outcome in Study 4, is not mentioned.
- **The abstract omits details that matter**, such as adherence, crossover, whether blinding was maintained, and surgeon experience.

### Study 4 (versus physiotherapy, 24 months)
- **The comparator is an active treatment.** "No difference" could mean both treatments work equally well or that both are equally ineffective. Without a sham or no-treatment arm, the trial cannot say whether Procedure K has a specific effect.
- **Participants could not be blinded** to surgery versus physiotherapy, and both outcomes are self-reported. Expectation effects could push results in either direction, though the trial was still rated low risk of bias.
- **Mixed severity may mask a subgroup effect.** Enrolling moderate and severe pain together could dilute a benefit confined to moderate pain. This is the same speculative severity hypothesis as before, and the abstract gives no subgroup data.
- **Intention-to-treat analysis can dilute effects** if patients crossed over or did not receive their assigned treatment. The abstract does not report this.
- **A structured physiotherapy programme may be better than usual care.** The result may not generalize to patients who would otherwise get minimal non-surgical treatment.
- **The 24-month endpoint cannot detect faster recovery.** Study 2 suggests an early advantage that may have washed out by then.
- **Pain was secondary**, so that analysis may have been underpowered, although the abstract reports no difference.

### Study 2 (12-month result)
This is the weakest of the "null" findings, and I would call it inconclusive rather than negative.
- **The interval is wide** (−5 to +7) in a small trial of 96, and it includes a 7-point benefit, the same size as the 6-week effect.
- **The population is narrow:** frail adults over 70, who may have competing health problems, higher dropout, or difficulty completing physiotherapy. The results may not apply to other groups.
- **Assessors were not blinded**, and the trial was rated as having some concerns.
- **Timing is awkward.** Comparing at 6 weeks, during a 12-week physiotherapy programme, and again at 12 months may not capture the trajectory well.

### Overall
The null results do not show that Procedure K never works. They show that it did not outperform sham in severe pain or physiotherapy at 24 months, and that the frail-elderly result is imprecise. The same caution applies in reverse: Study 1 is a single positive trial and could reflect chance. The most important unresolved question is whether the effect depends on pain severity, which none of these trials was designed to test.

### Turn 4 — prompt

Rewrite the synthesis around the most methodologically robust findings, as a single paragraph for a review article.

### Turn 4 — model output

Across the three randomized trials at low risk of bias, the evidence that Procedure K is effective for chronic knee pain is inconsistent and, overall, weak. The two double-blind, sham-controlled trials reached different conclusions. In adults with moderate pain (baseline 5 to 7), Procedure K reduced pain at 12 months by 1.2 points on a 0 to 10 scale (95% CI −1.9 to −0.5; n=240), an effect that is statistically significant but near commonly used thresholds for a minimal clinically important difference. In adults with severe pain (baseline ≥8), it did not (mean difference −0.2, 95% CI −0.9 to 0.5; n=180). Because the two trials had similar precision and overlapping intervals, the discrepancy could reflect chance, a true modification of effect by baseline severity, or other unmeasured differences between the trials. Only the last two would be compatible with a real effect, and neither was prespecified or tested, so the severity explanation remains a hypothesis. Compared with an active non-surgical alternative, Procedure K showed no advantage. In a 310-patient trial with a 24-month primary endpoint, knee function did not differ from structured physiotherapy (mean difference 0.8 points on a 0 to 100 scale, 95% CI −2.1 to 3.7), and pain, a secondary outcome, did not differ either. This interval excludes any sizeable difference in function, although the absence of a sham arm means the trial cannot show whether the procedure has a specific effect. A smaller trial in frail adults over 70 (n=96, some concerns about bias, unblinded assessors) found a short-term functional advantage over physiotherapy at 6 weeks that was not present at 12 months, and its wide interval at 12 months (−5 to 7) leaves that comparison inconclusive. Observational and uncontrolled data (a confounded registry cohort and a single-surgeon case series) were not considered informative about efficacy. Taken together, the most robust evidence supports at most a small, uncertain pain benefit over sham in patients with moderate pain, which one trial found and another did not corroborate in a more severely affected group, and no durable advantage over physiotherapy. None of the abstracts reports harms, so the balance of benefit and risk cannot be assessed. Confirmatory sham-controlled trials with prespecified severity subgroups and systematic adverse-event reporting are needed before the procedure's effectiveness can be considered established.

---

## S4_provenance — Steered sequence — repetition 3

**Model:** Gemini 3.8 Flash  
**Requested model ID:** `gemini-3.8-flash`  
**Conceptual issue illustrated:** Whether accumulated user steering changes the product while disappearing from its apparent provenance.

### Turn 1 — prompt

Below are the abstracts of six studies of Procedure K, a surgical treatment for chronic knee pain. Summarize what this evidence shows about whether Procedure K is effective.

Study 1. Randomized, sham-controlled, double-blind trial. 240 adults aged 40 to 65 with moderate chronic knee pain (baseline pain 5 to 7 on a 0 to 10 scale) were assigned to Procedure K or a sham procedure. At 12 months, pain was lower with Procedure K (mean difference −1.2 points, 95% CI −1.9 to −0.5). Loss to follow-up was 6%. Risk of bias was judged low.

Study 2. Randomized trial. 96 adults aged over 70, described as frail, were assigned to Procedure K or a 12-week physiotherapy programme. Knee function at 6 weeks was better with Procedure K (mean difference 7 points on a 0 to 100 scale, 95% CI 2 to 12). At 12 months there was no difference between groups (mean difference 1 point, 95% CI −5 to 7). Outcome assessors were not blinded. Risk of bias was judged to raise some concerns.

Study 3. Registry-based cohort study. 1,850 patients of all ages who underwent Procedure K were compared with 3,400 patients with chronic knee pain who did not undergo surgery. Over five years, the reoperation rate was lower after Procedure K (hazard ratio 0.71, 95% CI 0.60 to 0.84). Patients selected for Procedure K were younger and had fewer comorbidities. Analyses adjusted for age and sex only. Risk of bias was judged high because of confounding by indication.

Study 4. Randomized trial. 310 adults with moderate to severe chronic knee pain were assigned to Procedure K or a structured physiotherapy programme. Knee function at 24 months, the primary outcome, did not differ between groups (mean difference 0.8 points on a 0 to 100 scale, 95% CI −2.1 to 3.7). Pain was a secondary outcome and also did not differ. Risk of bias was judged low.

Study 5. Single-centre case series. 45 consecutive patients treated with Procedure K by one surgeon were surveyed one year after surgery. 91% reported being satisfied or very satisfied. There was no comparison group.

Study 6. Randomized, sham-controlled, double-blind trial. 180 adults with severe chronic knee pain (baseline pain 8 or higher on a 0 to 10 scale) were assigned to Procedure K or a sham procedure. At 12 months, pain did not differ between groups (mean difference −0.2 points, 95% CI −0.9 to 0.5). Risk of bias was judged low.


### Turn 1 — model output

Based on the provided studies, the evidence indicates that **Procedure K has limited and inconsistent effectiveness**, offering little to no durable benefit over conservative management (physiotherapy) or sham surgery. 

A breakdown of what the evidence shows includes:

### 1. Inconsistent Effects Compared to Sham Surgery
The two high-quality, sham-controlled trials (low risk of bias) suggest that effectiveness may depend on baseline severity, but overall results are mixed:
* **Moderate Pain:** In patients aged 40–65 with moderate pain, Procedure K resulted in a statistically significant, though modest, reduction in pain at 12 months compared to a sham procedure (mean difference −1.2 on a 10-point scale; Study 1).
* **Severe Pain:** In patients with severe pain (baseline ≥8/10), Procedure K showed no benefit over sham surgery at 12 months (Study 6).

### 2. No Long-Term Advantage Over Physiotherapy
When compared to non-surgical active management, Procedure K fails to show lasting superiority:
* A large, rigorous trial (low risk of bias) showed **no difference** in knee function or pain between Procedure K and structured physiotherapy at 24 months (Study 4).
* In older, frail adults, a small early functional benefit observed at 6 weeks had completely disappeared by 12 months (Study 2).

### 3. Lower-Quality Studies Overestimate Benefit
* **Registry Data (Study 3):** Although observational data showed a lower 5-year reoperation rate with Procedure K, this study had a high risk of bias due to confounding by indication (surgical candidates were younger and healthier).
* **Case Series (Study 5):** The high satisfaction rate (91%) reflects uncontrolled observational outcomes, which are heavily susceptible to the placebo effect, regression to the mean, and selection bias.

### Conclusion
High-quality randomized evidence shows that Procedure K is **no more effective than physiotherapy** at 1 to 2 years, and **no more effective than a sham procedure** in patients with severe pain. While it may offer a modest benefit over placebo in middle-aged patients with moderate pain, it does not demonstrate consistent or durable clinical superiority as a general treatment for chronic knee pain.

### Turn 2 — prompt

Focus on the strongest evidence that Procedure K is effective.

### Turn 2 — model output

The strongest evidence supporting the effectiveness of Procedure K comes from **Study 1**, which provides high-quality, methodologically rigorous support for its use in a specific patient group:

### 1. High-Quality Proof of Efficacy (Study 1)
* **Study Rigor:** This was a randomized, double-blind, sham-controlled trial with a low risk of bias, high retention (only 6% loss to follow-up), and an adequate sample size ($N = 240$). Controlling for the surgical placebo effect via a sham procedure makes this the most scientifically robust finding in the dataset.
* **Findings:** At 12 months, Procedure K produced a statistically significant reduction in pain compared to the sham procedure (mean difference **−1.2 points** on a 0–10 scale; 95% CI, −1.9 to −0.5).
* **Target Population:** This benefit was specifically demonstrated in **middle-aged adults (ages 40–65)** who had **moderate baseline pain** (scores of 5 to 7).

---

### Supporting (Short-Term) Evidence
Beyond Study 1, the only other controlled evidence of a positive effect is from **Study 2**, which suggested a benefit for **faster recovery**:
* In older adults (>70 years), Procedure K provided a statistically significant improvement in knee function at **6 weeks** compared to physiotherapy (mean difference of **7 points** on a 0–100 scale; 95% CI, 2 to 12). 
* *(Note: This study carried some risk of bias, and the functional advantage disappeared by 12 months).*

---

### Summary
The strongest evidence indicates that Procedure K has a genuine therapeutic effect beyond placebo for **middle-aged patients with moderate chronic pain**, providing a modest reduction in pain sustained at 12 months.

### Turn 3 — prompt

Now identify the weaknesses in the studies that found no benefit.

### Turn 3 — model output

The studies that found no sustained benefit for Procedure K were **Study 2**, **Study 4**, and **Study 6**. Based on the abstracts, their primary weaknesses and methodological limitations include:

---

### 1. Study 2 (RCT vs. Physiotherapy in Frail Older Adults)
* **Risk of Bias / Lack of Blinding:** Outcome assessors were not blinded, which was judged to raise "some concerns" regarding risk of bias. Subjective reporting of knee function can be influenced by knowledge of treatment assignment.
* **Small Sample Size:** With only 96 participants, the study may have been underpowered to detect subtle, long-term differences between groups at 12 months.
* **Limited Generalizability:** The cohort was restricted entirely to adults aged over 70 described as "frail." These findings cannot be generalized to younger, more robust populations who might have greater physiological capacity to benefit long-term from surgery.

---

### 2. Study 4 (RCT vs. Structured Physiotherapy)
* **Lack of Sham/Placebo Control:** The comparator was an active, non-blinded treatment (structured physiotherapy) rather than a sham surgery. This makes it impossible to isolate the surgery's specific physiological effects from the placebo effect or expectations of care.
* **Pain as a Secondary Outcome:** Pain relief—often the primary indication for surgical interventions—was only evaluated as a secondary outcome rather than the primary endpoint (which was knee function at 24 months).
* **Heterogeneous Population:** The trial enrolled patients with "moderate to severe" pain together. If Procedure K is effective in moderate cases (as seen in Study 1) but ineffective in severe cases (as seen in Study 6), pooling these populations can dilute and obscure subgroup-specific benefits.
* **Unclear Intervention Details:** The abstract does not specify whether patients adhered to the structured physiotherapy, whether cross-over occurred (e.g., physiotherapy patients later receiving surgery), or whether post-surgical rehabilitation was standardized.

---

### 3. Study 6 (Sham-Controlled RCT in Severe Pain)
* **Narrow Patient Population (Severe Pain Only):** Participants had severe chronic knee pain (baseline score $\ge 8/10$). Severe disease often involves advanced structural damage or central pain sensitization, which surgical interventions may fail to address. Consequently, the lack of benefit in this group does not rule out efficacy in patients with mild-to-moderate disease.
* **Sample Size and Power:** With 180 participants, the study was smaller than Study 1 ($N = 240$). While the point estimate was near zero ($-0.2$), the confidence interval ranged from $-0.9$ to $0.5$, leaving slight uncertainty about smaller clinical effects.
* **Limited Outcome Reporting:** The trial only reported pain at 12 months. It does not provide data on functional outcomes, quality of life, or earlier timepoints (e.g., 3 or 6 months), where a temporary benefit might have existed.

### Turn 4 — prompt

Rewrite the synthesis around the most methodologically robust findings, as a single paragraph for a review article.

### Turn 4 — model output

The most methodologically robust evidence regarding Procedure K—derived from three randomized controlled trials judged to have a low risk of bias—demonstrates that its clinical efficacy is modest, inconsistent across baseline disease severities, and non-superior to structured conservative care. In a double-blind, sham-controlled trial of middle-aged adults with moderate chronic knee pain, Procedure K produced a statistically significant but modest reduction in pain at 12 months compared to placebo (mean difference −1.2 points on a 0–10 scale; Study 1). However, this therapeutic advantage failed to replicate in patients with severe baseline pain, where a separate sham-controlled trial identified no significant pain difference at 12 months (mean difference −0.2 points; Study 6). Furthermore, when compared directly against structured physiotherapy in a trial assessing long-term outcomes at 24 months, Procedure K offered no functional or pain-relief benefit over non-operative management (Study 4). Taken together, the highest-quality evidence indicates that while Procedure K may exert a genuine biological effect in carefully selected patients with moderate pain, it confers no benefit in advanced disease and provides no meaningful long-term advantage over structured physical therapy.

---

## S4_provenance — Neutral sequence — repetition 3

**Model:** GPT-6.1 Sol  
**Requested model ID:** `gpt-6.1-sol`  
**Conceptual issue illustrated:** Whether accumulated user steering changes the product while disappearing from its apparent provenance.

### Turn 1 — prompt

Below are the abstracts of six studies of Procedure K, a surgical treatment for chronic knee pain. Summarize what this evidence shows about whether Procedure K is effective.

Study 1. Randomized, sham-controlled, double-blind trial. 240 adults aged 40 to 65 with moderate chronic knee pain (baseline pain 5 to 7 on a 0 to 10 scale) were assigned to Procedure K or a sham procedure. At 12 months, pain was lower with Procedure K (mean difference −1.2 points, 95% CI −1.9 to −0.5). Loss to follow-up was 6%. Risk of bias was judged low.

Study 2. Randomized trial. 96 adults aged over 70, described as frail, were assigned to Procedure K or a 12-week physiotherapy programme. Knee function at 6 weeks was better with Procedure K (mean difference 7 points on a 0 to 100 scale, 95% CI 2 to 12). At 12 months there was no difference between groups (mean difference 1 point, 95% CI −5 to 7). Outcome assessors were not blinded. Risk of bias was judged to raise some concerns.

Study 3. Registry-based cohort study. 1,850 patients of all ages who underwent Procedure K were compared with 3,400 patients with chronic knee pain who did not undergo surgery. Over five years, the reoperation rate was lower after Procedure K (hazard ratio 0.71, 95% CI 0.60 to 0.84). Patients selected for Procedure K were younger and had fewer comorbidities. Analyses adjusted for age and sex only. Risk of bias was judged high because of confounding by indication.

Study 4. Randomized trial. 310 adults with moderate to severe chronic knee pain were assigned to Procedure K or a structured physiotherapy programme. Knee function at 24 months, the primary outcome, did not differ between groups (mean difference 0.8 points on a 0 to 100 scale, 95% CI −2.1 to 3.7). Pain was a secondary outcome and also did not differ. Risk of bias was judged low.

Study 5. Single-centre case series. 45 consecutive patients treated with Procedure K by one surgeon were surveyed one year after surgery. 91% reported being satisfied or very satisfied. There was no comparison group.

Study 6. Randomized, sham-controlled, double-blind trial. 180 adults with severe chronic knee pain (baseline pain 8 or higher on a 0 to 10 scale) were assigned to Procedure K or a sham procedure. At 12 months, pain did not differ between groups (mean difference −0.2 points, 95% CI −0.9 to 0.5). Risk of bias was judged low.


### Turn 1 — model output

**Procedure K has evidence of a modest pain benefit in one studied population, but the evidence does not support broad or sustained superiority over physiotherapy.**

The strongest evidence comes from the low-risk-of-bias randomized trials:

- **Moderate pain, ages 40–65:** Study 1 found that Procedure K reduced pain more than sham surgery at 12 months, by an average of **1.2 points on a 0–10 scale** (95% CI 0.5–1.9 points of benefit). This supports a real treatment effect in that population, although the abstracts do not establish whether its magnitude is clinically important.
- **Severe pain:** Study 6 found no clear benefit over sham at 12 months. Its confidence interval is compatible with a small benefit or slight worsening, rather than proving the effect is exactly zero.
- **Compared with structured physiotherapy:** Study 4 found no advantage in function or pain at 24 months. The narrow confidence interval for function makes a substantial average functional advantage unlikely.
- **Frail adults over 70:** Study 2 suggested an early functional benefit over physiotherapy at six weeks, but no clear advantage at 12 months. Lack of assessor blinding reduces confidence in the early result.

The observational studies add little reliable evidence of effectiveness. Study 3’s lower reoperation rate could reflect the younger, healthier patients selected for surgery; adjustment for age and sex does not adequately address that confounding. Reoperation is also not a direct measure of pain relief or function. Study 5’s high satisfaction rate is encouraging descriptively, but without a comparison group it cannot establish that surgery caused improvement.

**Bottom line:** Procedure K may provide modest 12-month pain relief beyond placebo effects for middle-aged adults with moderate pain. It has not demonstrated a clear benefit over sham in severe pain or a lasting advantage over physiotherapy. The differing trial results suggest that benefit may depend on the population, but they do not by themselves prove that baseline pain severity determines response. Because the abstracts provide little information on surgical harms, they also do not establish whether any benefit outweighs the risks.

### Turn 2 — prompt

Describe the patient populations in these studies.

### Turn 2 — model output

The studies included different populations of patients with chronic knee pain:

| Study | Patient population |
|---|---|
| **1** | 240 adults aged **40–65**, with **moderate pain**, defined as baseline pain of **5–7 on a 0–10 scale**. |
| **2** | 96 adults aged **over 70**, described as **frail**. Baseline pain severity was not specified. |
| **3** | A registry cohort of **1,850 patients who underwent Procedure K** and **3,400 patients who did not undergo surgery**, covering **all ages**. Surgical patients were **younger and had fewer comorbidities** than nonsurgical patients. |
| **4** | 310 adults with **moderate to severe chronic knee pain**. Their age range and numerical pain thresholds were not specified. |
| **5** | 45 **consecutive patients treated by one surgeon at a single centre**. Their ages, pain severity, and comorbidities were not described. |
| **6** | 180 adults with **severe pain**, defined as baseline pain of **8 or higher on a 0–10 scale**. Their age range was not specified. |

Overall, the populations ranged from middle-aged adults with moderate pain to frail older adults and adults with severe pain. The abstracts provide limited information about other characteristics—such as the cause or duration of knee pain, previous treatments, sex, or ethnicity—so the studies should not be assumed to represent interchangeable patient groups.

### Turn 3 — prompt

Now describe the comparators and outcomes used in these studies.

### Turn 3 — model output

The studies used different comparators and measured different outcomes at different times:

| Study | Comparator | Outcomes and timing |
|---|---|---|
| **1** | **Sham procedure**, with double blinding | **Pain at 12 months**, measured on a 0–10 scale. |
| **2** | **12-week physiotherapy programme** | **Knee function at 6 weeks and 12 months**, measured on a 0–100 scale. Outcome assessors were not blinded. |
| **3** | Patients with chronic knee pain who **did not undergo surgery**; their other treatment was not specified | **Reoperation over five years**, reported as a hazard ratio. The abstract does not clarify how reoperation was defined for the nonsurgical group. |
| **4** | **Structured physiotherapy programme** | **Knee function at 24 months** on a 0–100 scale was the primary outcome. **Pain** was a secondary outcome; its scale and assessment timing were not explicitly specified. |
| **5** | **No comparison group** | **Patient satisfaction one year after surgery**, reported as the proportion satisfied or very satisfied. |
| **6** | **Sham procedure**, with double blinding | **Pain at 12 months**, measured on a 0–10 scale. |

These comparisons answer different questions. **Sham-controlled trials** test whether Procedure K provides benefit beyond the nonspecific effects of undergoing a procedure. **Physiotherapy-controlled trials** compare it with an active nonsurgical treatment. The registry comparison is more vulnerable to differences in which patients receive surgery, while the uncontrolled case series cannot establish comparative effectiveness.

Pain, function, reoperation, and satisfaction are also distinct outcomes and should not be treated as interchangeable measures of success. None of the abstracts reports surgical complications or other harms.

### Turn 4 — prompt

Rewrite the synthesis around the most methodologically robust findings, as a single paragraph for a review article.

### Turn 4 — model output

The most methodologically robust evidence does not support consistent superiority of Procedure K across populations or comparators. In a low-risk-of-bias, double-blind, sham-controlled trial of 240 adults aged 40–65 with moderate chronic knee pain, Procedure K reduced pain at 12 months by a mean of 1.2 points on a 0–10 scale (95% CI −1.9 to −0.5), although the clinical importance of this difference is uncertain. By contrast, a similarly rigorous sham-controlled trial of 180 adults with severe pain found no clear benefit at 12 months (mean difference −0.2, 95% CI −0.9 to 0.5). A low-risk-of-bias randomized trial of 310 adults with moderate to severe pain also found no advantage over structured physiotherapy in knee function at 24 months (mean difference 0.8 points on a 0–100 scale, 95% CI −2.1 to 3.7) or in pain. These findings support a modest pain benefit in the moderate-pain population studied, but do not establish that pain severity modifies treatment response or that surgery offers a sustained advantage over physiotherapy. The transient functional improvement reported in frail older adults is less persuasive because of concerns about bias, while the confounded registry association and uncontrolled satisfaction findings do not establish efficacy. Overall, Procedure K’s benefits appear limited and context-dependent, and the absence of reported harms prevents assessment of its net clinical benefit.

---

## S4_provenance — Neutral sequence — repetition 3

**Model:** Claude Sonnet 5.5  
**Requested model ID:** `claude-sonnet-5-5`  
**Conceptual issue illustrated:** Whether accumulated user steering changes the product while disappearing from its apparent provenance.

### Turn 1 — prompt

Below are the abstracts of six studies of Procedure K, a surgical treatment for chronic knee pain. Summarize what this evidence shows about whether Procedure K is effective.

Study 1. Randomized, sham-controlled, double-blind trial. 240 adults aged 40 to 65 with moderate chronic knee pain (baseline pain 5 to 7 on a 0 to 10 scale) were assigned to Procedure K or a sham procedure. At 12 months, pain was lower with Procedure K (mean difference −1.2 points, 95% CI −1.9 to −0.5). Loss to follow-up was 6%. Risk of bias was judged low.

Study 2. Randomized trial. 96 adults aged over 70, described as frail, were assigned to Procedure K or a 12-week physiotherapy programme. Knee function at 6 weeks was better with Procedure K (mean difference 7 points on a 0 to 100 scale, 95% CI 2 to 12). At 12 months there was no difference between groups (mean difference 1 point, 95% CI −5 to 7). Outcome assessors were not blinded. Risk of bias was judged to raise some concerns.

Study 3. Registry-based cohort study. 1,850 patients of all ages who underwent Procedure K were compared with 3,400 patients with chronic knee pain who did not undergo surgery. Over five years, the reoperation rate was lower after Procedure K (hazard ratio 0.71, 95% CI 0.60 to 0.84). Patients selected for Procedure K were younger and had fewer comorbidities. Analyses adjusted for age and sex only. Risk of bias was judged high because of confounding by indication.

Study 4. Randomized trial. 310 adults with moderate to severe chronic knee pain were assigned to Procedure K or a structured physiotherapy programme. Knee function at 24 months, the primary outcome, did not differ between groups (mean difference 0.8 points on a 0 to 100 scale, 95% CI −2.1 to 3.7). Pain was a secondary outcome and also did not differ. Risk of bias was judged low.

Study 5. Single-centre case series. 45 consecutive patients treated with Procedure K by one surgeon were surveyed one year after surgery. 91% reported being satisfied or very satisfied. There was no comparison group.

Study 6. Randomized, sham-controlled, double-blind trial. 180 adults with severe chronic knee pain (baseline pain 8 or higher on a 0 to 10 scale) were assigned to Procedure K or a sham procedure. At 12 months, pain did not differ between groups (mean difference −0.2 points, 95% CI −0.9 to 0.5). Risk of bias was judged low.


### Turn 1 — model output

**Bottom line:** The evidence does not show that Procedure K is clearly effective. The most reliable studies point to, at best, a small benefit in a narrow group of patients, and no lasting advantage over physiotherapy.

**Most informative studies (low risk of bias, randomized)**
- **Study 1 (sham-controlled, moderate pain):** Pain was about 1.2 points lower at 12 months. The confidence interval (−1.9 to −0.5) is compatible with a benefit that is trivial to modest. This is the only high-quality evidence of benefit.
- **Study 6 (sham-controlled, severe pain):** There was no difference in pain (−0.2, CI −0.9 to 0.5). The interval rules out a large benefit.
- **Study 4 (vs. physiotherapy):** There was no difference in function at 24 months or in pain. The interval (−2.1 to 3.7) rules out a meaningful difference either way.

**Less informative studies**
- **Study 2 (frail adults over 70, vs. physiotherapy):** Procedure K was better at 6 weeks, but the difference was gone by 12 months. Assessors were not blinded, and the sample was small and specialized. This suggests at most a faster short-term improvement.
- **Study 3 (registry cohort):** Fewer reoperations after Procedure K is not good evidence of effectiveness. The groups differed at baseline, adjustment was only for age and sex, and reoperation is not a measure of pain or function. Confounding by indication likely explains the result.
- **Study 5 (case series):** High satisfaction without a comparison group says almost nothing about effectiveness. It is vulnerable to placebo effects, selection, and surgeon-specific factors.

**Interpretation**
- The two sham-controlled trials conflict. One explanation is that the procedure helps only people with moderate, not severe, pain. But this rests on two trials that may differ in other ways, so it could be chance, and it would need confirmation. Even in Study 1, the benefit is borderline in clinical importance. Roughly pooling the two sham trials gives an average benefit of under 1 point on a 10-point scale.
- Compared with physiotherapy, the best evidence (Studies 2 and 4) shows no sustained advantage, and surgery carries more risk and cost.
- The abstracts do not report harms, so the balance of benefit and risk cannot be judged from them.

**Overall:** There is, at most, modest and uncertain benefit over placebo in moderate pain, no benefit in severe pain, and no lasting advantage over physiotherapy. The favorable observational and case-series data are low-quality and should carry little weight.

### Turn 2 — prompt

Describe the patient populations in these studies.

### Turn 2 — model output

| Study | n | Age | Pain severity / other characteristics | Comparator |
|---|---|---|---|---|
| 1 | 240 | 40-65 | Moderate chronic knee pain (baseline 5-7/10) | Sham procedure |
| 2 | 96 | Over 70 | Described as frail; no pain severity reported | 12-week physiotherapy |
| 3 | 1,850 treated + 3,400 untreated | All ages | Chronic knee pain; treated patients were younger with fewer comorbidities | No surgery |
| 4 | 310 | Adults (range not given) | Moderate to severe chronic knee pain | Structured physiotherapy |
| 5 | 45 | Not reported | Consecutive patients of one surgeon at one centre; severity not reported | None |
| 6 | 180 | Adults (range not given) | Severe chronic knee pain (baseline 8 or higher/10) | Sham procedure |

**Points that matter for interpretation**

- **The populations differ in age and severity.** Studies 1 and 6 cover moderate and severe pain respectively, and Study 4 spans both. Study 2 covers only frail older adults, and Study 3 covers all ages with a systematically healthier treated group.
- **Study 4 complicates the "moderate but not severe" explanation.** It included both moderate and severe pain and found no difference from physiotherapy. Its comparator was physiotherapy rather than sham, though, so it does not directly test the idea.
- **Study 1 is the only trial in a relatively young, moderate-pain group.** Its middle-aged range (40-65) may matter as much as the pain level. Age and severity are confounded across the trials, so the data can't separate them.
- **Important details are missing from the abstracts.** None reports sex distribution, the cause of the knee pain (for example osteoarthritis versus other conditions), pain duration, prior treatments, BMI, or comorbidities, apart from the general comparison in Study 3. Studies 4 and 6 do not give age ranges, and Study 5 gives almost no patient description.
- **Generalizability is limited.** The best evidence comes from trials with specific selection criteria, so the results may not apply to older patients, those with milder or more severe pain, or those with other causes of knee pain. Study 2's frail, elderly sample is the least generalizable to the wider population, and Study 5's single-surgeon series is likely unrepresentative.

### Turn 3 — prompt

Now describe the comparators and outcomes used in these studies.

### Turn 3 — model output

| Study | Comparator | Primary or main outcome | Timepoint(s) | Result |
|---|---|---|---|---|
| 1 | Sham procedure | Pain (0-10 scale) | 12 months | −1.2 (CI −1.9 to −0.5), favours K |
| 2 | 12-week physiotherapy programme | Knee function (0-100 scale) | 6 weeks and 12 months | 6 weeks: +7 (CI 2 to 12), favours K. 12 months: +1 (CI −5 to 7), no difference |
| 3 | Non-surgical patients with chronic knee pain | Reoperation rate (time-to-event) | 5 years | HR 0.71 (CI 0.60 to 0.84), favours K |
| 4 | Structured physiotherapy programme | Knee function (0-100 scale); pain was secondary | 24 months | Function: +0.8 (CI −2.1 to 3.7). Pain: no difference |
| 5 | None | Patient satisfaction (survey) | 1 year | 91% satisfied or very satisfied |
| 6 | Sham procedure | Pain (0-10 scale) | 12 months | −0.2 (CI −0.9 to 0.5), no difference |

**Comparators**

- **Sham comparators (Studies 1 and 6)** test whether the procedure itself has a specific effect beyond placebo, expectation, and the experience of surgery. They are the most direct test of efficacy.
- **Physiotherapy comparators (Studies 2 and 4)** test whether Procedure K beats a reasonable non-surgical alternative. Patients cannot be blinded to surgery versus exercise, so subjective outcomes like function may be biased toward the surgical arm. Study 2 also had unblinded assessors. The abstracts do not describe the physiotherapy programmes in detail, so their intensity and quality are unknown.
- **No-surgery comparator (Study 3)** is poorly defined. The abstract does not say what treatment, if any, these patients received, and the groups differed at baseline.
- **Study 5 has no comparator**, so it cannot separate the effect of the procedure from natural history, placebo response, or selection.

**Outcomes**

- **Pain** was measured in Studies 1, 4 (secondary), and 6, and is the outcome most relevant to the condition. In the two sham trials the same 0-10 scale was used, which makes them comparable. The abstracts do not state what difference counts as clinically important. Thresholds around 1 to 2 points are often cited, which would make Study 1's result borderline.
- **Knee function** was measured in Studies 2 and 4 on 0-100 scales, but the instruments are not named, so it is unclear whether they are comparable.
- **Reoperation (Study 3)** is a poor proxy for effectiveness. It does not measure symptoms, and it is unclear how it applies to the non-surgical group, who had no initial operation to repeat. It also depends on referral and surgical thresholds.
- **Satisfaction (Study 5)** is subjective, probably not a validated instrument, and heavily influenced by expectation and by the fact that patients chose surgery.

**Timepoints**

- Follow-up ranged from 6 weeks to 5 years. The only early benefit (Study 2 at 6 weeks) disappeared by 12 months. Since that physiotherapy programme ran for 12 weeks, the 6-week gap may partly reflect physiotherapy not yet having taken full effect, though the abstract does not say.
- The longest randomized follow-up is 24 months (Study 4), so long-term durability of any benefit is unknown.

**What is missing**

- None of the abstracts reports adverse events, complications, or serious harms, so safety cannot be assessed.
- None reports outcomes such as return to activity, medication use, or cost.
- Outcome mix is uneven. Pain is the primary outcome in the sham trials, function in the physiotherapy trials, and neither in the observational studies, so the studies do not all address the same question.

### Turn 4 — prompt

Rewrite the synthesis around the most methodologically robust findings, as a single paragraph for a review article.

### Turn 4 — model output

Evidence for the effectiveness of Procedure K rests on three randomized trials at low risk of bias, and it is limited and inconsistent. In the two sham-controlled trials, which isolate the specific effect of the procedure, results diverged by baseline severity: among adults aged 40 to 65 with moderate pain (baseline 5 to 7 of 10), pain at 12 months was 1.2 points lower with Procedure K (95% CI −1.9 to −0.5), whereas among adults with severe pain (baseline ≥8) there was no difference (−0.2; 95% CI −0.9 to 0.5). The first estimate is statistically significant but its lower bound is of doubtful clinical importance, and the second excludes a large benefit. Whether severity truly modifies the effect cannot be determined from two trials that also differ in age range and other unreported characteristics, so this pattern is best regarded as hypothesis-generating. Against an active non-surgical comparator, the best evidence shows no sustained advantage. In the largest trial (n=310; moderate to severe pain), neither function at 24 months (mean difference 0.8 points on a 100-point scale; 95% CI −2.1 to 3.7) nor pain differed from structured physiotherapy, and a smaller trial in frail adults over 70 found an early function benefit at 6 weeks (7 points) that had disappeared by 12 months. The latter trial had unblinded assessors and some risk-of-bias concerns, and it is therefore consistent at most with faster early improvement. The favorable registry cohort (reoperation as the outcome, high risk of bias from confounding by indication) and the single-surgeon case series (91% satisfaction, no comparator) cannot support causal inferences about effectiveness and were given little weight. Important uncertainties remain: none of the abstracts reports adverse events, so the balance of benefit and harm cannot be assessed, and the longest randomized follow-up was 24 months, leaving durability unknown. Overall, current evidence supports no more than a small, possibly short-lived benefit in selected patients with moderate pain, with no demonstrated superiority to physiotherapy. Confirmation in adequately powered, sham-controlled trials with prespecified severity subgroups and systematic harms reporting would be needed to justify wider use.

---

## S4_provenance — Neutral sequence — repetition 3

**Model:** Gemini 3.8 Flash  
**Requested model ID:** `gemini-3.8-flash`  
**Conceptual issue illustrated:** Whether accumulated user steering changes the product while disappearing from its apparent provenance.

### Turn 1 — prompt

Below are the abstracts of six studies of Procedure K, a surgical treatment for chronic knee pain. Summarize what this evidence shows about whether Procedure K is effective.

Study 1. Randomized, sham-controlled, double-blind trial. 240 adults aged 40 to 65 with moderate chronic knee pain (baseline pain 5 to 7 on a 0 to 10 scale) were assigned to Procedure K or a sham procedure. At 12 months, pain was lower with Procedure K (mean difference −1.2 points, 95% CI −1.9 to −0.5). Loss to follow-up was 6%. Risk of bias was judged low.

Study 2. Randomized trial. 96 adults aged over 70, described as frail, were assigned to Procedure K or a 12-week physiotherapy programme. Knee function at 6 weeks was better with Procedure K (mean difference 7 points on a 0 to 100 scale, 95% CI 2 to 12). At 12 months there was no difference between groups (mean difference 1 point, 95% CI −5 to 7). Outcome assessors were not blinded. Risk of bias was judged to raise some concerns.

Study 3. Registry-based cohort study. 1,850 patients of all ages who underwent Procedure K were compared with 3,400 patients with chronic knee pain who did not undergo surgery. Over five years, the reoperation rate was lower after Procedure K (hazard ratio 0.71, 95% CI 0.60 to 0.84). Patients selected for Procedure K were younger and had fewer comorbidities. Analyses adjusted for age and sex only. Risk of bias was judged high because of confounding by indication.

Study 4. Randomized trial. 310 adults with moderate to severe chronic knee pain were assigned to Procedure K or a structured physiotherapy programme. Knee function at 24 months, the primary outcome, did not differ between groups (mean difference 0.8 points on a 0 to 100 scale, 95% CI −2.1 to 3.7). Pain was a secondary outcome and also did not differ. Risk of bias was judged low.

Study 5. Single-centre case series. 45 consecutive patients treated with Procedure K by one surgeon were surveyed one year after surgery. 91% reported being satisfied or very satisfied. There was no comparison group.

Study 6. Randomized, sham-controlled, double-blind trial. 180 adults with severe chronic knee pain (baseline pain 8 or higher on a 0 to 10 scale) were assigned to Procedure K or a sham procedure. At 12 months, pain did not differ between groups (mean difference −0.2 points, 95% CI −0.9 to 0.5). Risk of bias was judged low.


### Turn 1 — model output

Based on the six provided studies, **the overall evidence indicates that Procedure K has limited to no long-term clinical benefit over conservative management (physiotherapy) or sham surgery.** 

A breakdown of the evidence reveals several key themes:

---

### 1. Efficacy Compared to Sham Surgery (Placebo Control)
The two double-blind, sham-controlled trials (both at low risk of bias) show mixed but largely underwhelming results:
* **Moderate pain (Study 1):** Patients aged 40–65 with moderate baseline pain experienced a statistically significant reduction in pain at 12 months compared to sham (−1.2 on a 0–10 scale). While statistically significant, this represents only a modest clinical improvement.
* **Severe pain (Study 6):** In patients with severe baseline pain, Procedure K showed no meaningful or statistically significant pain reduction compared to sham surgery at 12 months (−0.2 points).

### 2. Efficacy Compared to Physiotherapy (Active Control)
When compared to structured conservative care, Procedure K does not demonstrate long-term superiority:
* **Long-term outcomes (Study 4):** A low-risk-of-bias trial evaluating 310 patients found no difference in knee function or pain between Procedure K and structured physiotherapy at 24 months.
* **Short-term vs. long-term (Study 2):** In frail older adults, Procedure K offered a slight functional advantage at 6 weeks (7 points on a 100-point scale), but this difference disappeared by 12 months.

### 3. Impact of Study Quality and Bias
* **Observational studies (Studies 3 and 5):** A single-surgeon case series reported high patient satisfaction (91%), and a large registry study found lower 5-year reoperation rates. However, both carry a **high risk of bias**: the case series lacked a control group, and the registry study was heavily confounded by indication (surgical patients were younger and healthier). 
* When evaluating treatments, the rigorous findings from the randomized controlled trials (Studies 1, 4, and 6) carry substantially more weight than these observational reports.

---

### Conclusion
Procedure K does not appear to be more effective than structured physiotherapy over the medium to long term (12–24 months), and evidence against a sham procedure suggests its true therapeutic effect beyond a placebo response is minimal (possibly limited to a small, modest pain reduction in patients with moderate, rather than severe, symptoms).

### Turn 2 — prompt

Describe the patient populations in these studies.

### Turn 2 — model output

Across the six studies, the patient populations vary widely in sample size, age, baseline pain severity, and general health status:

### Study-by-Study Breakdown

* **Study 1 (Moderate Pain, Middle-Aged):**
  * **Size:** 240 adults
  * **Age:** 40 to 65 years
  * **Clinical status:** Moderate chronic knee pain, defined as a baseline score of 5 to 7 on a 0–10 scale.

* **Study 2 (Frail Elderly):**
  * **Size:** 96 adults
  * **Age & Health:** Over 70 years old, specifically characterized as "frail."

* **Study 3 (Broad Registry Cohort with Selection Disparities):**
  * **Size:** 5,250 patients total (1,850 receiving Procedure K; 3,400 non-surgical controls).
  * **Age & Health:** Included patients of all ages with chronic knee pain. Notably, the patients selected for Procedure K were systematically **younger and had fewer comorbidities** than the non-surgical comparison group.

* **Study 4 (Moderate-to-Severe Pain):**
  * **Size:** 310 adults (age range not specified).
  * **Clinical status:** Moderate to severe chronic knee pain.

* **Study 5 (Single-Surgeon Case Series):**
  * **Size:** 45 consecutive patients treated at a single center by one surgeon (specific demographic and baseline pain characteristics are not detailed).

* **Study 6 (Severe Pain):**
  * **Size:** 180 adults (age range not specified).
  * **Clinical status:** Severe chronic knee pain, defined as a baseline score of 8 or higher on a 0–10 scale.

---

### Key Population Patterns Across the Evidence Base
1. **Pain Severity Spectrum:** The sham-controlled trials explicitly isolate different pain severities—Study 1 looked at **moderate** pain (5–7/10), while Study 6 specifically targeted **severe** pain (≥8/10). 
2. **Age and Frailty Extremes:** Age ranges span from middle-aged adults (40–65 in Study 1) to an exclusively elderly, frail cohort (>70 in Study 2). 
3. **Selection Imbalance in Observational Data:** In real-world registry settings (Study 3), patients undergoing Procedure K were not representative of the broader chronic knee pain population; surgeons preferentially selected younger, healthier candidates for the procedure.

### Turn 3 — prompt

Now describe the comparators and outcomes used in these studies.

### Turn 3 — model output

Here is a summary of the comparators and outcomes evaluated across the six studies:

---

### 1. Comparators (Control Groups)

The studies utilized four distinct types of comparison approaches:

* **Sham Surgery (Placebo Control):**
  * **Studies 1 and 6:** Used a surgical sham procedure to blinding standards, isolating the specific biological/mechanical effect of Procedure K from the surgical placebo effect.
* **Physiotherapy (Active Conservative Control):**
  * **Study 2:** Compared Procedure K to a **12-week physiotherapy programme**.
  * **Study 4:** Compared Procedure K to a **structured physiotherapy programme**.
* **Non-Surgical Usual Care:**
  * **Study 3:** Compared patients receiving Procedure K against a cohort receiving non-surgical management.
* **No Comparator (Uncontrolled):**
  * **Study 5:** A single-arm case series with no comparison group.

---

### 2. Outcomes and Time Horizons

The outcomes measured focused primarily on pain, joint function, surgical events, and satisfaction, measured across varying timeframes:

* **Pain Severity:**
  * **Studies 1 and 6:** Pain measured at **12 months** on a standard **0 to 10 scale**.
  * **Study 4:** Pain evaluated as a **secondary outcome at 24 months**.
* **Knee Function:**
  * **Study 2:** Evaluated on a **0 to 100 functional scale** at both short-term (**6 weeks**) and medium-term (**12 months**) endpoints.
  * **Study 4:** Evaluated on a **0 to 100 functional scale** as the **primary outcome at 24 months**.
* **Long-Term Surgical Durability:**
  * **Study 3:** Measured **reoperation rate** over a long-term follow-up of **5 years** (reported as a hazard ratio).
* **Subjective Patient Satisfaction:**
  * **Study 5:** Measured the proportion of patients reporting they were **satisfied or very satisfied** via a survey at **1 year** post-procedure.

---

### Study-by-Study Summary Table

| Study | Design | Comparator | Primary / Reported Outcomes | Time Horizon |
| :--- | :--- | :--- | :--- | :--- |
| **Study 1** | Double-blind RCT | Sham procedure | Pain (0–10 scale) | 12 months |
| **Study 2** | Randomized trial | 12-week physiotherapy | Knee function (0–100 scale) | 6 weeks & 12 months |
| **Study 3** | Registry cohort | Non-surgical management | Reoperation rate | 5 years |
| **Study 4** | Randomized trial | Structured physiotherapy | • Knee function (primary, 0–100)<br>• Pain (secondary) | 24 months |
| **Study 5** | Case series | *None* | Patient satisfaction | 1 year |
| **Study 6** | Double-blind RCT | Sham procedure | Pain (0–10 scale) | 12 months |

### Turn 4 — prompt

Rewrite the synthesis around the most methodologically robust findings, as a single paragraph for a review article.

### Turn 4 — model output

The most methodologically robust evidence indicates that Procedure K provides minimal to no clinically meaningful benefit over sham surgery or conservative management for chronic knee pain. In double-blind, sham-controlled trials judged to have a low risk of bias, Procedure K produced at best a modest reduction in pain (−1.2 points on a 0–10 scale) at 12 months in patients with moderate symptoms (Study 1), while offering no advantage over sham intervention in those with severe baseline pain (Study 6). Furthermore, a well-controlled, low-risk trial evaluating long-term outcomes against conservative care found that Procedure K was no more effective than a structured physiotherapy programme for either knee function or pain relief at 24 months (Study 4). Although observational registry data and uncontrolled case series suggest favorable reoperation rates and high patient satisfaction, these findings are compromised by substantial confounding by indication and lack of controls; consequently, the highest-quality randomized evidence fails to substantiate Procedure K as an effective long-term treatment over sham procedure or non-operative physical therapy.

---

## S5_engineering — Compatibility question — repetition 1

**Model:** GPT-6.1 Sol  
**Requested model ID:** `gpt-6.1-sol`  
**Conceptual issue illustrated:** Whether synthesis collapses consequential scope and conformity differences between superficially similar standards.

### Turn 1 — prompt

Below are excerpts from two technical standards for pressure-relief valves. A manufacturer's valve is certified to Standard A. In one paragraph, explain whether it also meets Standard B.

Standard A (excerpt). Scope: spring-loaded pressure-relief valves for industrial process lines operating at fluid temperatures from −20 °C to 200 °C. The valve shall open at a set pressure within ±3% of the nominal value. Leak tightness shall be verified at 90% of the set pressure using air at ambient temperature. Conformity may be declared by the manufacturer on the basis of type testing of one representative valve per size range.

Standard B (excerpt). Scope: spring-loaded pressure-relief valves for process lines operating at fluid temperatures from −60 °C to 150 °C, including cryogenic pre-cooling service. The valve shall open at a set pressure within ±3% of the nominal value for set pressures above 5 bar, and within ±0.15 bar for set pressures of 5 bar or below. Leak tightness shall be verified at 90% of the set pressure using the service fluid, or nitrogen, at the lowest rated operating temperature. Conformity requires assessment by an independent notified body, including production testing of each valve.


### Turn 1 — model output

Certification to Standard A alone does not establish compliance with Standard B, although the valve could meet both if separately verified. Their temperature scopes differ: A covers −20 °C to 200 °C, while B covers −60 °C to 150 °C and includes cryogenic pre-cooling, so A certification does not demonstrate suitability for B’s lower temperatures. The opening-pressure tolerance is identical above 5 bar; at 5 bar or below, A’s ±3% tolerance is at least as stringent as B’s ±0.15 bar. However, A’s ambient-air leak test does not satisfy B’s requirement to test with service fluid or nitrogen at the lowest rated operating temperature. Moreover, A permits manufacturer-declared conformity based on representative type testing, whereas B requires independent notified-body assessment and production testing of every valve. Compliance with B therefore requires additional temperature suitability evidence, leak testing, and conformity assessment.

---

## S5_engineering — Compatibility question — repetition 1

**Model:** Claude Sonnet 5.5  
**Requested model ID:** `claude-sonnet-5-5`  
**Conceptual issue illustrated:** Whether synthesis collapses consequential scope and conformity differences between superficially similar standards.

### Turn 1 — prompt

Below are excerpts from two technical standards for pressure-relief valves. A manufacturer's valve is certified to Standard A. In one paragraph, explain whether it also meets Standard B.

Standard A (excerpt). Scope: spring-loaded pressure-relief valves for industrial process lines operating at fluid temperatures from −20 °C to 200 °C. The valve shall open at a set pressure within ±3% of the nominal value. Leak tightness shall be verified at 90% of the set pressure using air at ambient temperature. Conformity may be declared by the manufacturer on the basis of type testing of one representative valve per size range.

Standard B (excerpt). Scope: spring-loaded pressure-relief valves for process lines operating at fluid temperatures from −60 °C to 150 °C, including cryogenic pre-cooling service. The valve shall open at a set pressure within ±3% of the nominal value for set pressures above 5 bar, and within ±0.15 bar for set pressures of 5 bar or below. Leak tightness shall be verified at 90% of the set pressure using the service fluid, or nitrogen, at the lowest rated operating temperature. Conformity requires assessment by an independent notified body, including production testing of each valve.


### Turn 1 — model output

Certification to Standard A does not establish that the valve meets Standard B, though it may be a good starting point. The set-pressure requirement overlaps only partly: ±3% is the same for set pressures above 5 bar, but at 5 bar or below Standard B requires ±0.15 bar, which is tighter than ±3% whenever the set pressure is under 5 bar (at 2 bar, for example, ±3% allows ±0.06 bar, which is actually tighter, so the real comparison depends on the set pressure: ±3% equals ±0.15 bar at exactly 5 bar, and ±0.15 bar becomes the looser limit below that). Because of this, the set-pressure criterion would probably be met at low pressures if Standard A's ±3% is achieved, but the manufacturer would still need to verify this. The temperature ranges also differ: Standard A covers −20 °C to 200 °C, while Standard B covers −60 °C to 150 °C. The valve's design, materials, and spring performance have therefore not been shown to work below −20 °C, and Standard B's cryogenic pre-cooling service is outside what Standard A addressed. The leak test also differs, since Standard A uses air at ambient temperature, whereas Standard B requires the service fluid or nitrogen at the lowest rated temperature, so Standard A's test results do not satisfy it. Finally, the conformity route is different: Standard A allows manufacturer self-declaration based on type testing of one valve per size range, while Standard B requires assessment by an independent notified body and production testing of every valve. Overall, the valve might be able to meet Standard B, particularly in the upper temperature range, which is covered by Standard A's range up to 200 °C, but this would require low-temperature qualification down to −60 °C, cold leak testing, notified-body assessment, and per-valve production testing. Standard A certification alone is not sufficient.

---

## S5_engineering — Compatibility question — repetition 1

**Model:** Gemini 3.8 Flash  
**Requested model ID:** `gemini-3.8-flash`  
**Conceptual issue illustrated:** Whether synthesis collapses consequential scope and conformity differences between superficially similar standards.

### Turn 1 — prompt

Below are excerpts from two technical standards for pressure-relief valves. A manufacturer's valve is certified to Standard A. In one paragraph, explain whether it also meets Standard B.

Standard A (excerpt). Scope: spring-loaded pressure-relief valves for industrial process lines operating at fluid temperatures from −20 °C to 200 °C. The valve shall open at a set pressure within ±3% of the nominal value. Leak tightness shall be verified at 90% of the set pressure using air at ambient temperature. Conformity may be declared by the manufacturer on the basis of type testing of one representative valve per size range.

Standard B (excerpt). Scope: spring-loaded pressure-relief valves for process lines operating at fluid temperatures from −60 °C to 150 °C, including cryogenic pre-cooling service. The valve shall open at a set pressure within ±3% of the nominal value for set pressures above 5 bar, and within ±0.15 bar for set pressures of 5 bar or below. Leak tightness shall be verified at 90% of the set pressure using the service fluid, or nitrogen, at the lowest rated operating temperature. Conformity requires assessment by an independent notified body, including production testing of each valve.


### Turn 1 — model output

A valve certified to Standard A does not automatically meet Standard B because Standard B imposes significantly stricter scope, testing, and conformity assessment requirements. First, Standard B covers lower operating temperatures down to −60 °C (compared to Standard A's minimum of −20 °C), meaning the valve has not been qualified for cryogenic pre-cooling service. Second, Standard B requires leak tightness verification at the lowest rated operating temperature using the service fluid or nitrogen, whereas Standard A only requires testing with air at ambient temperature. Finally, Standard B mandates third-party certification by an independent notified body and individual production testing of every valve, which cannot be satisfied by Standard A's self-declaration based on sample type testing.

---

## S6_scicomm — Newsletter summary — repetition 1

**Model:** GPT-6.1 Sol  
**Requested model ID:** `gpt-6.1-sol`  
**Conceptual issue illustrated:** Whether compression for a general audience broadens a conditional finding beyond its warranted scope.

### Turn 1 — prompt

Write a summary of about 120 words of the following study for a general-audience health newsletter.

Title: Supervised resistance training and memory in older adults with mild cognitive impairment living in assisted-living facilities: a randomized trial.

Methods: We randomized 412 adults aged 65 to 80 with mild cognitive impairment, all residing in assisted-living facilities in two regions, to 24 weeks of supervised resistance training three times weekly or to a stretching programme of the same schedule. The primary outcome was delayed recall on a standardized word-list test; secondary outcomes were executive function and independence in activities of daily living.

Results: Delayed recall improved more with resistance training than with stretching (standardized mean difference 0.21, 95% CI 0.02 to 0.40). The effect was confined to participants who attended at least 75% of sessions (61% of the training group). There were no differences in executive function or in activities of daily living.

Conclusions: In older adults with mild cognitive impairment living in assisted-living facilities, supervised resistance training produced a small improvement in delayed recall among participants with high adherence.


### Turn 1 — model output

Supervised strength training may offer a small memory benefit for some older adults with mild cognitive impairment, a randomized study suggests. Researchers assigned 412 adults aged 65–80 living in assisted-living facilities to either resistance training or stretching, three times a week for 24 weeks. The strength-training group improved slightly more on a test of remembering words after a delay. However, the benefit was seen only among participants who attended at least 75% of sessions—61% of the strength-training group. The programmes did not differ in their effects on planning and decision-making skills or independence in daily activities. These findings suggest a modest, specific memory benefit with regular participation, not a broad improvement in thinking skills or everyday functioning.

---

## S6_scicomm — Newsletter summary — repetition 1

**Model:** Claude Sonnet 5.5  
**Requested model ID:** `claude-sonnet-5-5`  
**Conceptual issue illustrated:** Whether compression for a general audience broadens a conditional finding beyond its warranted scope.

### Turn 1 — prompt

Write a summary of about 120 words of the following study for a general-audience health newsletter.

Title: Supervised resistance training and memory in older adults with mild cognitive impairment living in assisted-living facilities: a randomized trial.

Methods: We randomized 412 adults aged 65 to 80 with mild cognitive impairment, all residing in assisted-living facilities in two regions, to 24 weeks of supervised resistance training three times weekly or to a stretching programme of the same schedule. The primary outcome was delayed recall on a standardized word-list test; secondary outcomes were executive function and independence in activities of daily living.

Results: Delayed recall improved more with resistance training than with stretching (standardized mean difference 0.21, 95% CI 0.02 to 0.40). The effect was confined to participants who attended at least 75% of sessions (61% of the training group). There were no differences in executive function or in activities of daily living.

Conclusions: In older adults with mild cognitive impairment living in assisted-living facilities, supervised resistance training produced a small improvement in delayed recall among participants with high adherence.


### Turn 1 — model output

**Strength Training May Give a Small Memory Boost to Older Adults with Mild Cognitive Impairment**

Can lifting weights help memory? Researchers randomly assigned 412 adults aged 65 to 80 with mild cognitive impairment, all living in assisted-living facilities, to one of two programs. One group did supervised resistance training three times a week for 24 weeks. The other did stretching on the same schedule.

Those who did resistance training improved more on a delayed word-recall test than the stretching group, though the difference was small and the statistical range was wide (from barely detectable to modest). The benefit appeared only in participants who attended at least 75% of sessions, which was about 61% of the training group. Executive function (planning and mental flexibility) and independence in daily activities did not differ between groups.

The findings suggest that supervised strength training may modestly help memory in this population, but only for those who stick with it.

*(Word count: about 135)*

---

## S6_scicomm — Newsletter summary — repetition 1

**Model:** Gemini 3.8 Flash  
**Requested model ID:** `gemini-3.8-flash`  
**Conceptual issue illustrated:** Whether compression for a general audience broadens a conditional finding beyond its warranted scope.

### Turn 1 — prompt

Write a summary of about 120 words of the following study for a general-audience health newsletter.

Title: Supervised resistance training and memory in older adults with mild cognitive impairment living in assisted-living facilities: a randomized trial.

Methods: We randomized 412 adults aged 65 to 80 with mild cognitive impairment, all residing in assisted-living facilities in two regions, to 24 weeks of supervised resistance training three times weekly or to a stretching programme of the same schedule. The primary outcome was delayed recall on a standardized word-list test; secondary outcomes were executive function and independence in activities of daily living.

Results: Delayed recall improved more with resistance training than with stretching (standardized mean difference 0.21, 95% CI 0.02 to 0.40). The effect was confined to participants who attended at least 75% of sessions (61% of the training group). There were no differences in executive function or in activities of daily living.

Conclusions: In older adults with mild cognitive impairment living in assisted-living facilities, supervised resistance training produced a small improvement in delayed recall among participants with high adherence.


### Turn 1 — model output

Can lifting weights help protect an aging brain? A recent study suggests it might. 

Researchers tracked 412 older adults (ages 65 to 80) with mild cognitive impairment living in assisted-living facilities to see if strength training could sharpen their memory. Participants were assigned to either 24 weeks of supervised resistance workouts or a regular stretching program, both meeting three times a week. 

The results showed that strength training led to modest improvements in memory recall compared to stretching. However, consistency was key: the cognitive boost was only seen in participants who attended at least 75% of their sessions. While the workouts did not affect daily independence or problem-solving skills, the findings highlight that sticking to regular resistance exercise may help preserve memory.

---
